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Abstract
Interventions to treat premature ejaculation: a systematic
review short report
Katy Cooper,* Marrissa Martyn-St James, Eva Kaltenthaler,
Kath Dickinson and Anna Cantrell
School of Health and Related Research (ScHARR) Technology Assessment Group,
The University of Sheffield, Sheffield, UK
*Corresponding author k.l.cooper@sheffield.ac.uk
Background: Premature ejaculation (PE) is commonly defined as ejaculation with minimal sexual
stimulation before, on or shortly after penetration and before the person wishes it. PE can be either
lifelong and present since first sexual experiences (primary), or acquired (secondary), beginning
later (Godpodinoff ML. Premature ejaculation: clinical subgroups and etiology. J Sex Marital Ther
1989;15:130–4). Treatments include behavioural and pharmacological interventions.
Objective: To systematically review evidence for clinical effectiveness of behavioural, topical and systemic
treatments for PE.
Data sources: The following databases were searched from inception to 6 August 2013 for published
and unpublished research evidence: MEDLINE; EMBASE; Cumulative Index to Nursing and Allied Health
Literature; The Cochrane Library including the Cochrane Systematic Reviews Database, Cochrane
Controlled Trials Register, Database of Abstracts of Reviews of Effects and the Health Technology
Assessment database; ISI Web of Science, including Science Citation Index, and the Conference
Proceedings Citation Index-Science. The US Food and Drug Administration website and the European
Medicines Agency (EMA) website were also searched.
Methods: Randomised controlled trials (RCTs) in adult men with PE were eligible (or non-RCTs in the
absence of RCTs). RCT data were extrapolated from review articles when available. The primary outcome
was intravaginal ejaculatory latency time (IELT). Data were meta-analysed when possible. Other outcomes
included sexual satisfaction, control over ejaculation, relationship satisfaction, self-esteem, quality of life,
treatment acceptability and adverse events (AEs).
Results: A total of 103 studies (102 RCTs, 65 from reviews) were included. RCTs were available for all
interventions except yoga. The following interventions demonstrated significant improvements (p< 0.05)
in arithmetic mean difference in IELT compared with placebo: topical anaesthetics – eutectic mixture of
local anaesthetics (EMLA®, AstraZeneca), topical eutectic mixture for PE (Plethora Solutions Ltd) spray;
selective serotonin reuptake inhibitors (SSRIs) – citalopram (Cipramil®, Lundbeck), escitalopram
(Cipralex®, Lundbeck), fluoxetine, paroxetine, sertraline, dapoxetine (Priligy®, Menarini), 30mg or
60mg; serotonin–noradrenaline reuptake inhibitors – duloxetine (Cymbalta®, Eli Lilly & Co Ltd); tricyclic
antidepressants – inhaled clomipramine 4mg; phosphodiesterase-5 (PDE5) inhibitors – vardenafil (Levitra®,
Bayer), tadalafil (Cialis®, Eli Lilly & Co Ltd); opioid analgesics – tramadol (Zydol SR®, Grünenthal).
Improvements in sexual satisfaction and other outcomes compared with placebo were evident for SSRIs,
PDE5 inhibitors and tramadol. Outcomes for interventions not compared with placebo were as follows:
behavioural therapies – improvements over wait list control in IELT and other outcomes, behavioural
therapy plus pharmacotherapy better than either therapy alone; alpha blockers – terazosin (Hytrin®, AMCO)
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not significantly different to antidepressants in ejaculation control; acupuncture – improvements over
sham acupuncture in IELT, conflicting results for comparisons with SSRIs; Chinese medicine – improvements
over treatment as usual; delay device – improvements in IELT when added to stop–start technique;
yoga – improved IELT over baseline, fluoxetine better than yoga. Treatment-related AEs were evident
with most pharmacological interventions.
Limitations: Although data extraction from reviews was optimised when more than one review reported
data for the same RCT, the reliability of the data extraction within these reviews cannot be guaranteed
by this assessment report.
Conclusions: Several interventions significantly improved IELT. Many interventions also improved
sexual satisfaction and other outcomes. However, assessment of longer-term safety and effectiveness is
required to evaluate whether or not initial treatment effects are maintained long term, whether or not dose
escalation is required, how soon treatment effects end following treatment cessation and whether or not
treatments can be stopped and resumed at a later time. In addition, assessment of the AEs associated with
long-term treatment and whether or not different doses have differing AE profiles is required.
Study registration: This study is registered as PROSPERO CRD42013005289.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Anejaculation Inability to ejaculate.
Bibliotherapy Expressive therapy that uses an individual’s relationship to the content of books.
Hypoaesthesia Diminished sensitivity to pain.
Intravaginal ejaculatory latency time Time taken by a man to ejaculate during vaginal penetration.
Libido Sexual drive or desire for sexual activity.
Sensate focus A focus on the patient’s own varied sense experience, rather than viewing orgasm as the
sole goal of sex.
Somnolence Strong desire for sleep.
Squeeze technique Application of firm pressure with thumb and forefinger below head of penis.
Stop–start/pause technique Pausing action when approaching ‘point of no return’.
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Plain English summary
P remature ejaculation (PE) is ejaculation with minimal sexual stimulation before, on or shortly afterpenetration and before the person wishes it, and can cause distress for a man and his partner.
Evidence from randomised controlled trials suggests that several treatments provide improvements of
between 1 and 6 minutes in time to ejaculation, including drug treatments [selective serotonin inhibitors
and other antidepressants, phosphodiesterase-5 inhibitors and tramadol (Zydol SR®, Grünenthal)],
anaesthetic creams and behavioural therapies. Many treatments also improve sexual satisfaction and other
measures. However, drug treatments and anaesthetic creams are associated with side effects. Behavioural
therapy combined with drug treatment is better than behavioural therapy or drug treatment alone. Most
studies of treatments for PE last 12 weeks [some that we found, e.g. for dapoxetine (Priligy®, Menarini)
and tramadol, lasted 24 weeks]. Patients may have different treatment preferences related to differences in
treatment administration, clinical effectiveness and side effects (e.g. drug or behavioural treatments). For
this reason, maintaining a range of treatment options is a useful approach. Future research should aim to
investigate the long-term safety and effectiveness of treatments (> 6 months), whether or not higher doses
are required in the longer term, the effects of treatment cessation and whether or not treatments can be
stopped and restarted later. This research could be undertaken by reviewing the literature for these
treatments used in other conditions, in addition to further, longer-duration studies in men with PE.
DOI: 10.3310/hta19210 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 21
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Cooper et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xvii

Scientific summary
Background
Premature ejaculation (PE) is commonly defined as ejaculation with minimal sexual stimulation before, on
or shortly after penetration and before the person wishes it. PE can be either lifelong and present since
first sexual experiences (primary), or acquired (secondary), beginning later. Prevalence rates internationally
are 20–30%. Treatments include behavioural techniques, anaesthetic creams and sprays, tricyclic
antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), phosphodiesterase-5 (PDE5)
inhibitors, analgesics such as tramadol (Zydol SR®, Grünenthal) and other interventions. Dapoxetine
(Priligy®, Menarini) (a SSRI) is the only drug to have received approval for the treatment of PE in the UK.
Objectives
The objective was to systematically review the evidence for the clinical effectiveness of behavioural, topical
and systemic treatments for PE in the form of a Health Technology Assessment (HTA) short report.
Data sources
The following electronic databases were searched from inception to 6 August 2013 for published and
unpublished research evidence: MEDLINE; EMBASE; Cumulative Index to Nursing and Allied Health
Literature; The Cochrane Library including the Cochrane Systematic Reviews Database, Cochrane
Controlled Trials Register, Database of Abstracts of Reviews of Effects and the HTA database; ISI Web of
Science, including Science Citation Index, and the Conference Proceedings Citation Index-Science. The US
Food and Drug Administration website and the European Medicines Agency website were also searched.
Methods
The systematic review included randomised controlled trials (RCTs) evaluating any intervention relevant to
the UK in men with primary and/or secondary PE. Comparators included other interventions, waiting list
control, placebo, or no treatment. RCTs were identified through literature searching of databases from
inception to August 2013 and from existing reviews. Quality assessment was conducted for existing
reviews and for further RCTs not captured in a review. For RCTs within existing reviews, data were
extracted from the review and not from the original RCT publication. When no RCT evidence was
identified for an intervention, other study types were considered. Outcomes included intravaginal
ejaculatory latency time (IELT), sexual satisfaction, control over ejaculation, relationship satisfaction,
self-esteem, quality of life, treatment acceptability and adverse events (AEs).
Results
A total of 103 studies (102 RCTs) were included (65 from reviews). The majority of RCTs not already in
reviews (n= 37) were of unclear methodological quality.
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Behavioural interventions
Twelve RCTs were identified. Behavioural therapies improved IELT and sexual satisfaction compared with
waiting list control, and behavioural therapies combined with pharmacological therapies were better than
either intervention alone in improving IELT, sexual satisfaction, sexual anxiety and ejaculation control.
When reported, no AEs were associated with behavioural interventions alone.
Topical anaesthetics
Nine RCTs assessed treatment over 4–12 weeks. Both eutectic mixture of local anaesthetics cream and
topical eutectic mixture for PE spray were significantly more effective than placebo in increasing IELT
[mean difference (MD) 6.44 minutes, 95% confidence interval (CI) 6.01 to 6.87 minutes] and 3.30 minutes
(95% CI 1.33 to 5.27 minutes); both p< 0.00001. AEs include loss of sensation and irritation (men and
women) and loss of erection with applications ≥ 20 minutes.
Selective serotonin reuptake inhibitors other than dapoxetine
Forty-two RCTs assessed SSRIs, mostly taken daily, and treatment duration was 4–12 weeks.
Citalopram (Cipramil®, Lundbeck) significantly increased IELT compared with placebo or no treatment
[MD 0.25 minutes (95% CI –0.06 to 0.56 minutes) to 4.62 minutes (95% CI 4.21 to 5.03 minutes);
p< 0.00001] and improved sexual satisfaction. Escitalopram (Cipralex®, Lundbeck) significantly increased
IELT compared with placebo (MD 1.2 minutes, 95% CI 0.79 to 1.61 minutes; p< 0.00001). Fluoxetine
significantly increased IELT compared with placebo (MD 2.41 minutes, 95% CI 2.10 to 2.73 minutes;
p< 0.00001). Fluvoxamine did not significantly increase IELT compared with placebo. Paroxetine
significantly increased IELT compared with placebo (MD 5.34 minutes, 95% CI 3.79 to 6.89 minutes;
p< 0.00001) and improved sexual satisfaction. Sertraline significantly increased IELT compared with
placebo (MD 2.72 minutes, 95% CI 1.77 to 3.67 minutes; p< 0.00001) and improved ejaculation control.
AEs included nausea, headache, insomnia, dry mouth, diarrhoea, drowsiness, dizziness, somnolence,
decreased libido and anejaculation.
Selective serotonin reuptake inhibitors: dapoxetine
Eight RCT reports assessed licensed doses of dapoxetine, generally taken on demand prior to intercourse.
Treatment duration was 2–24 weeks. Dapoxetine 30mg and 60mg significantly increased IELT compared
with placebo [MD 1.16 minutes (95% CI 0.94 to 1.39 minutes) and 1.66 minutes (95% CI 1.46 to
1.87 minutes); p< 0.00001] and dapoxetine 60mg was more effective than 30mg (MD 0.46 minutes,
95% CI 0.19 to 0.74 minutes; p= 0.0009). Similar effects are evident for ejaculatory control, sexual
satisfaction, global impression of change and clinical benefit. AEs included nausea, diarrhoea, headache
and dizziness and appearing to be dose dependent.
Serotonin–noradrenaline reuptake inhibitors
Three RCTs were identified. One 12-week trial indicated that duloxetine (Cymbalta®, Eli Lilly & Co Ltd) is
better than placebo in increasing IELT (MD 1.52 minutes, 95% CI 0.08 to 2.24 minutes; p< 0.00001).
Evidence from two RCTs suggests venlafaxine is not effective at increasing IELT compared with placebo.
Duloxetine side effects included dry mouth and nausea. Venlafaxine caused significantly more side effects
than placebo.
Tricyclic antidepressants
Thirteen RCTs were identified all evaluating clomipramine (oral or nasal). RCT evidence summarised from
reviews suggests a significant increase in IELT with clomipramine compared with placebo; however, data
were poorly reported. Inhaled clomipramine 4mg appears effective at increasing IELT when compared with
placebo (1.68 minutes, 95% CI 1.06 to 2.29 minutes; p< 0.00001). AEs were not well reported but
included dry mouth and constipation. Inhaled clomipramine may cause some local irritation.
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Phosphodiesterase-5 inhibitors
Twelve RCTs were identified, but IELT was poorly reported. Vardenafil (Levitra®, Bayer) and tadalafil
(Cialis®, Eli Lilly & Co Ltd) significantly increased IELT compared with placebo [based on one RCT each; MD
3.80 minutes (95% CI 3.30 to 4.30 minutes) and 2.59 minutes (95% CI 1.28 to 3.90 minutes); p= 0.006
and p< 0.00001, respectively], but there was no significant difference in one RCT between sildenafil and
placebo. Sexual satisfaction favoured PDE5 inhibitors over placebo. Sildenafil plus sertraline or behavioural
therapy was better than sildenafil alone. AEs included flushing, headache and palpitations.
Alpha-blockers
Two RCTs were identified, neither assessing IELT. Evidence from one 8-week RCT showed improvements
for terazosin (Hytrin®, AMCO) compared with placebo in ejaculation control. The current evidence base for
alpha-blockers in the treatment of PE is limited.
Tramadol
Seven RCTs were identified. Treatment duration was 6–24 weeks. Tramadol significantly increased IELT
compared with placebo (MD 1.35 minutes, 95% CI 0.63 to 2.07 minutes; p= 0.0002) and improved
sexual satisfaction. Tramadol plus behavioural therapy improved IELT over behavioural therapy alone
(MD 1.65 minutes, 95% CI 0.30 to 3.00 minutes; p= 0.02). There was no significant difference between
tramadol and paroxetine. AEs included erectile dysfunction, constipation, nausea, headache, somnolence,
dry mouth, dizziness, pruritus and vomiting. Addiction potential was not assessed.
Acupuncture
Two 4-week RCTs were identified. Acupuncture significantly increased IELT compared with sham
acupuncture but comparisons with SSRIs were inconsistent. AEs were not well reported.
Chinese medicine
Five RCTs were identified. In one 2-week trial, Chinese medicine was more effective than treatment as
usual (1.57 minutes, 95% CI 1.11 to 2.03 minutes; p< 0.00001). In one 4-week trial, fluoxetine improved
IELT compared with Chinese medicine (0.60 minutes, 95% CI 0.19 to 1.01 minutes; p< 0.00001). AEs
were not well reported.
Delay devices
One RCT compared a desensitising band plus stop–start technique compared with behavioural therapy plus
stop–start technique (treatment duration unclear). IELT appeared improved with the desensitising band.
AEs (soreness with overuse) were minimal when used as directed.
Yoga
No RCTs were identified. In one non-RCT comparing yoga with fluoxetine over 12 weeks, both yoga and
fluoxetine significantly improved IELT from baseline, but fluoxetine significantly increased IELT compared
with yoga. A high proportion of partners reported a good sexual satisfaction with yoga. AEs were
not reported.
Discussion
Strengths
This report systematically reviews the evidence for PE treatments relevant to the UK. In contrast to many
existing reviews, this review meta-analysed data across RCTs where appropriate, used appropriate outcome
measures (MD) to summarise IELT, avoided double-counting of participants and considered pairwise and
crossover RCT data separately. An assessment of methodological quality is also included.
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Limitations and uncertainties
Owing to the large volume of evidence, data for RCTs reported in reviews were extracted from the review
article and not the original RCT publication. Thus, the reliability of these data cannot be guaranteed.
Similarly, the methodological quality of individual RCTs reported in existing reviews was not assessed by
this assessment report.
Generalisability of findings
Most trials involved men with primary PE without a concomitant condition such as erectile dysfunction,
mainly recruited from specialist sexual health settings. The effectiveness of treatments for men with
secondary PE, PE concomitant to another condition, or not attending specialised clinics, is less certain.
Included trials were undertaken in various European Union (EU) and non-EU countries. Variability in
trial populations, PE definitions and IELT entry criteria, cultural attitudes towards PE and acceptability
of treatments also limits generalisability of findings. Treatment duration among trials ranged from 2 to
24 weeks. The long-term effectiveness and safety for patients either continuing or withdrawing from
treatment are unknown. Furthermore, patient adherence to and acceptability of treatments have not been
fully evaluated. The improvements in IELT ranged from 1 to 6 minutes. While these effects were statistically
significant, it is difficult to quantify how acceptable and meaningful these changes are for men with PE
without being able to evaluate the relationship between IELT, ejaculation control, and sexual satisfaction.
There is currently no consensus on what constitutes a clinically significant threshold response to
interventions for PE.
Conclusions
Implications for service provision
Several interventions provided statistically significant improvements of between 1 and 6 minutes in
time to ejaculation (IELT), including pharmacological interventions (SSRIs and other antidepressants,
PDE5 inhibitors, tramadol), topical anaesthetics and behavioural therapies. Many interventions also
demonstrated improvements in sexual satisfaction and other outcomes. Behavioural therapy combined
with pharmacotherapy was better than behavioural therapy or pharmacotherapy alone. Pharmacological
and topical therapies are associated with some AEs. Trial duration was a maximum of 12 weeks for most
interventions (24 weeks for dapoxetine and tramadol). Different interventions have different modes of
action and individual patients may have a preference for pharmacological or behavioural interventions, so
maintaining a range of options (to be used individually or in combination) may remain a useful approach in
the treatment of PE.
Suggested research priorities
Assessment of long-term safety and effectiveness of interventions (> 6 months) is required and should
assess whether or not initial treatment effects are maintained long term, whether or not the effects end
with treatment cessation, whether or not treatments require dose escalation to maintain initial treatment
effects and whether or not treatments can be stopped and resumed, as well as AEs associated with
long-term treatment. This could be addressed by reviewing the literature for these treatments in other
conditions, supplemented by longer-term studies in PE, possibly observational studies or longer-term
follow-up of RCT participants.
The current evidence base does not include sufficient direct comparisons to inform a judgement
regarding the ‘best treatment’ in terms of either efficacy or safety as active treatments are compared with
placebo/no treatment by the majority of RCTs. Future research could consider head-to-head trials or a
mixed treatment comparison/network meta-analysis, as well as assessment of cost-effectiveness of the
different interventions. As dapoxetine has been specifically developed for PE and has been extensively
evaluation for this indication, head-to-head comparisons between this and other treatments might be
informative. The effect of treatments used sequentially or in combination should also be further assessed.
For behavioural therapies, further research is required to determine the components, intensity and delivery
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of interventions that are most effective. However, patients may have preferences for different types of
treatment (e.g. pharmacological or behavioural) and, therefore, maintaining a range of options may be a
useful approach.
Future research should also consider an evaluation of clinically meaningful increases in IELT, including
evaluation of the relationship between increases in IELT, ejaculatory control and sexual satisfaction, and
whether or not increases of a few minutes in IELT are more meaningful to some patients than others.
The trade-off between an improvement in IELT and other effectiveness outcomes compared with AEs and
inconvenience should also be further evaluated.
Funding
Funding for this study was provided by the HTA programme of the National Institute for Health Research.
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Chapter 1 Background
Description of health problem
Premature ejaculation (PE) is a form of male sexual dysfunction. It is also referred to as early ejaculation,
rapid ejaculation, rapid climax, premature climax and (historically) ejaculation praecox. Official definitions of
PE have been set out in the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text
Revision (DSM-IV-TR)1 and in the World Health Organization’s (WHO’s) International Classification of
Diseases, Tenth Edition (ICD-10).2 The DSM-IV-TR defines the condition as persistent or recurrent
ejaculation with minimal sexual stimulation before, on or shortly after penetration and before the person
wishes it.1 Other definitions have also been proposed by the Second International Consultation on Sexual
and Erectile Dysfunction3 and the International Society for Sexual Medicine (ISSM).4 All four definitions
consider time to ejaculation, inability to control or delay ejaculation and negative consequences of PE.
However, there is no current consensus on quantification of the time to ejaculation, which is usually
described by intravaginal ejaculatory latency time (IELT), i.e. the time taken by a man to ejaculate during
vaginal penetration.5
Aetiology, pathology and prognosis
According to the European Association of Urology (EAU), the aetiology of PE is unknown, with few data to
support suggested biological and psychological hypotheses, including anxiety, penile hypersensitivity and
5-hydroxytryptamine (5-HT) receptor dysfunction, and the pathophysiology of PE is largely unknown.6
PE can be either lifelong (primary) or acquired (secondary).7 Lifelong PE is that which has been present
since the person’s first sexual experiences, while acquired PE is that which begins later following normal
ejaculation experiences. PE can occur secondary to another condition such as erectile dysfunction or
prostatitis, in which case guidelines recommend treating the underlying condition first or concomitantly.6,8
PE cannot be cured, but can be managed with behavioural and/or pharmacological treatment.
Epidemiology and prevalence
Epidemiological surveys in the USA and other countries suggest that PE as defined in the Diagnostic and
Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV)9 is the most common male sexual
dysfunction, with prevalence rates of 20–30%.3,10,11 The highest prevalence, 31% (among men aged
18–59 years), was found by the USA National Health and Social Life Survey study.11 In a five-country
European observational study, which included the UK, the prevalence of PE was 18%.12
Impact of health problem
Men with PE are more likely to report lower levels of sexual functioning and satisfaction, and higher levels
of personal distress and interpersonal difficulty, than men without PE.5 They may also rate their overall
quality of life lower than that of men without PE.5 In addition, the partner’s satisfaction with the sexual
relationship has been reported to decrease with increasing severity of the condition.13
Measurement of disease
Diagnosis of PE is based on the patient’s medical and sexual history.14,15 IELT can be either self-assessed or
stopwatch measured. The EAU 2013 Guidelines on Male Sexual Dysfunction6 state that the use of IELT
alone is not sufficient to define PE, and the need to assess PE objectively has led to the development of
several questionnaires, including two questionnaires that can discriminate between patients who have PE
and those who do not. These are the Premature Ejaculation Diagnostic Tool (PEDT)16,17 and the Arabic
Index of Premature Ejaculation (AIPE).18 Other questionnaires used to characterise PE and determine
treatment effects include the Premature Ejaculation Profile (PEP),19 the Index of Premature Ejaculation
(IPE)20 and the Male Sexual Health Questionnaire Ejaculatory Dysfunction.21
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Current service provision
Relevant national guidelines
Guidelines on PE include the EAU 2013 Guidelines on Male Sexual Dysfunction6 and the British
Recommendations for the Management of Premature Ejaculation, 2006.8
Management of the condition
The treatment of PE should attempt to alleviate concern about the condition as well as increase sexual
satisfaction for the patient and the partner.8 Descriptions of a recommended treatment pathway for the
condition are varied. The British Association of Urological Surgeons suggest that counselling may help men
with less troublesome PE but, for most men, the mainstay of long-term treatment is drugs.22 The British
Association for Sexual Health and HIV, Special Interest Group for Sexual Dysfunction, suggests that
management of patients should be decided on a case-by-case basis that considers behavioural, local and
systemic pharmacological treatments.8 The EAU presents a definitive treatment pathway based on clinical
diagnosis of the condition and treatment of PE based on whether or not the condition is either lifelong
or acquired. There is currently no published literature that identifies a clinically significant threshold
response to interventions for PE.23
Description of technology under assessment
Summary of interventions
Treatments include behavioural techniques, anaesthetic creams and sprays, tricyclic antidepressants (TCAs),
selective serotonin reuptake inhibitors (SSRIs), phosphodiesterase-5 (PDE5) inhibitors such as sildenafil,
analgesics such as tramadol (Zydol SR®, Grünenthal) and other drug and non-drug interventions.6,8
One antidepressant [dapoxetine (Priligy®, Menarini), a SSRI] has received approval for the treatment of
PE in the UK.24 To date, no other drug has been approved for PE in Europe or the USA and other
medical treatments prescribed for PE are ‘off-label’ (the practice of prescribing treatments for an
unapproved indication).
BACKGROUND
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Chapter 2 Definition of the decision problem
Decision problem
Population and subgroups
The relevant population comprised all men aged ≥ 18 years with PE, both lifelong and acquired PE.
Studies focusing specifically on men with PE secondary to another condition (such as erectile dysfunction
or prostate conditions) were excluded if possible; however, this information was often not reported.
Interventions assessed
Treatment modalities included behavioural techniques, topical therapies, systemic therapies and
other therapies.
Relevant comparators
Comparators included other interventions, waiting list control, placebo or no treatment.
Key outcomes
The key outcomes for this review were IELT, sexual satisfaction, control over ejaculation, relationship
satisfaction, self-esteem and quality of life. As these outcomes in PE are assessed in the literature using
different methods, and there is a lack of core validated outcome measures, any assessment methods were
permitted for these outcomes.
Overall aim and objective of assessment
The aim and objective of this assessment were to systematically review the evidence for the clinical
effectiveness of interventions for management of PE, in the form of a Health Technology Assessment
(HTA) short report.
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Chapter 3 Assessment of clinical effectiveness
A systematic review of the literature was undertaken to evaluate the clinical effectiveness ofinterventions for men with PE. A review of the evidence was undertaken in accordance with the
general principles recommended in the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement.25 The completed PRISMA checklist is presented in Appendix 1.
Methods for reviewing effectiveness
Identification of studies
The following electronic databases were searched from inception to 6 August 2013 for published and
unpublished research evidence: MEDLINE; EMBASE; Cumulative Index to Nursing and Allied Health
Literature (CINAHL); The Cochrane Library including the Cochrane Systematic Reviews Database; Cochrane
Controlled Trials Register (CCRT); Database of Abstracts of Reviews of Effects and the HTA database; ISI
Web of Science, including Science Citation Index, and the Conference Proceedings Citation Index-Science;
The US Food and Drug Administration website and the European Medicines Agency website were also
searched. All citations were imported into Reference Manager Software (version 12, Thomson ResearchSoft,
Carlsbad, CA, USA) and any duplicates deleted.
Search terms were included a combination of medical subject headings (MeSHs) and free-text searches for
terms around ‘premature ejaculation’. These included:
l MeSHs: Ejaculation; Premature ejaculation.
l Free-text search terms: premature$adj3 ejaculat$; early adj3 ejaculat$; rapid adj3 ejaculat$; rapid adj3
climax$; premature$adj3 climax$; ejaculat$adj3 pr?ecox.
Search filters (study design filters) were used to restrict the searches to randomised controlled trials (RCTs),
reviews and guidelines. These were:
l the RCT filter available from the Scottish Intercollegiate Guidelines Network26
l the reviews filter available from the York Centre for Reviews and Dissemination27
l the filter for guidelines available from the Health Evidence Bulletins Wales resource.28
Details of the MEDLINE strategy are presented in Appendix 2. Existing reviews identified by the searches
were obtained and examined for relevant RCT data. However, all bibliographic data sources were searched
from inception; thus, existing reviews were not relied upon as the only source for identifying relevant RCTs.
Inclusion and exclusion criteria
Population
The relevant population included all men aged ≥ 18 years with PE, including both lifelong and acquired PE.
Studies focusing specifically on men with PE secondary to another condition (such as erectile dysfunction
or prostate conditions) were excluded; however, this information was often not reported.
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As some formal definitions of PE have only recently been developed, studies were included whether or not
they used a standard definition and all definitions used were recorded. Common definitions of PE include
the following:
l DSM-IV-TR1
l WHO’s ICD-102
l the Second International Consultation on Sexual and Erectile Dysfunction4
l ISSM.29
Included interventions
Behavioural interventions included psychological or psychosocial interventions to develop sexual management
strategies that were either validated or described by investigators as being a treatment for PE treatment.
Examples include:
l ‘Stop–start’ programme developed by Semans:16 the man or his partner stimulates the penis until he
feels the urge to ejaculate, then stops until the sensation passes; this is repeated a few times before
allowing ejaculation to occur. The aim is to learn to recognise the feelings of arousal in order to
improve control over ejaculation.
l ‘Squeeze’ technique, proposed by Masters and Johnson:17 the man’s partner stimulates the penis until
he feels the urge to ejaculate, then squeezes the glans of the penis until the sensation passes; this is
repeated before allowing ejaculation to occur.
l Sensate focus or sensate focusing:4 the man and his partner begin by focusing on touch which
excludes breasts, genitals and intercourse, to encourage body awareness while reducing performance
anxiety; this is followed by gradual reintroduction of genital touching and then full intercourse.
Topical treatments included:
l Lidocaine–prilocaine, eutectic mixture of local anaesthetics (EMLA®, AstraZeneca), topical eutectic
mixture for PE [(TEMPE), a combination of two medicines – lidocaine and prilocaine], dyclonine or
lidocaine. These can be in the form of either a cream or an aerosol vehicle or a gel containing a local
anaesthetic (Instillagel®, CliniMed).
Systemic treatments included:
l SSRIs [e.g. fluoxetine, sertraline, citalopram (Cipramil®, Lundbeck), paroxetine, fluvoxamine and
dapoxetine]. Dapoxetine is a short-acting SSRI that can be taken a few hours preintercourse rather than
as a daily dose and is the only drug currently licensed for PE in the UK.
l Serotonin–noradrenaline reuptake inhibitors (SNRIs) [e.g. duloxetine (Cymbalta®, Eli Lilly & Co Ltd),
venlafaxine].
l TCAs (e.g. clomipramine).
l PDE5 inhibitors [e.g. sildenafil (Viagra), vardenafil (Levitra®, Bayer), tadalafil (Cialis®, Eli Lilly & Co Ltd)].
l Alpha-blockers [e.g. terazosin (Hytrin®, AMCO), alfuzosin].
l Opioid analgesics (e.g. tramadol).
Other therapies included:
l acupuncture
l Chinese medicine
l delay device/desensitising band: a small device which the man can use together with stop–start and
squeeze techniques to gradually improve control over ejaculation
l yoga.
Combinations of therapies included drug plus behavioural therapies or combinations of drug therapies.
ASSESSMENT OF CLINICAL EFFECTIVENESS
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Excluded interventions
The following interventions not considered relevant to the UK setting were excluded:
l Severance Secret cream (SS cream: a topical plant-based preparation comprising extracts of nine
plants). Not currently available within the UK (Professor Kevan Wylie, Porterbrook Clinic, 2013,
personal communication).
l Antiepileptic drugs (e.g. gabapentin). Not currently included in the UK30 or European6 guidelines and
not currently used in clinical practice in the UK (Professor Kevan Wylie, personal communication).
l Antipsychotics [e.g. thioridazine (Melleril, Novartis, withdrawn worldwide in 2005), perphenazine
(Trilafon, Merck Sharp & Dohme), levosulpiride]. Not currently included in the UK30 or European6
guidelines and not currently used in clinical practice in the UK (Professor Kevan Wylie,
personal communication).
l Antiemetics (e.g. metoclopramide). Not currently included in the UK30 or European6 guidelines and
not currently used in clinical practice in the UK (Professor Kevan Wylie, personal communication).
l Barbiturates (e.g. Atrium 300). Not currently included in the UK30 or European6 guidelines and not
currently used in clinical practice in the UK (Professor Kevan Wylie, personal communication).
l Beta-blockers (e.g. propranolol). Not currently included in the UK30 or European6 guidelines and not
currently used in clinical practice in the UK (Professor Kevan Wylie, personal communication).
Comparators
Comparators included other interventions, waiting list control, placebo or no treatment.
Outcomes
The key outcomes for this review were:
l IELT: studies that do not report this outcome objectively, but assess the outcome via another subjective
measure such as a questionnaire, were included. Studies that assess ejaculation latency time in a
laboratory setting, i.e. not intravaginally, were excluded.
l Sexual satisfaction.
l Control over ejaculation.
l Relationship satisfaction.
l Self-esteem.
Other outcomes included:
l Quality of life.
l Treatment acceptability.
l Adverse events (AEs).
Included study types
Included study designs were restricted to RCTs, if available. If no RCT evidence was identified for a
particular intervention, other study types (non-RCT) were considered. Owing to the time constraints of this
short report, if RCTs were included in existing reviews, data were extracted from the review and not from
the original RCT publication. RCTs not captured by existing reviews and those published subsequently to
existing reviews were identified via the literature search and data were extracted directly from the RCT
publication. RCTs reported in abstract form only were eligible for inclusion, provided adequate information
was presented in the abstract. Studies using quasi-randomisation were excluded, providing other RCT
evidence for the treatment of interest was available.
Non-English-language studies were excluded unless sufficient data could be extracted (from English-
language abstracts and/or tables). Dissertations and theses were excluded.
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Data abstraction strategy
Titles and abstracts of citations identified by the searches were screened for potentially relevant studies by
one reviewer and a subset checked by a second reviewer (and a check for consistency undertaken). Full
texts were screened by two reviewers. Details of studies identified for inclusion were extracted using a data
extraction sheet. One reviewer performed data extraction of each included study. All numerical data were
then checked against the original article by a second reviewer. Any disagreements were resolved by a third
reviewer. When studies comprised duplicate reports (parallel publications), all associated reports were used
to extract information.
Methods of data synthesis
When possible, data were pooled in a meta-analysis from RCTs reported in the existing reviews along with
data extracted from additional RCTs not captured by the existing reviews. Meta-analysis of outcome data
from all RCTs was then undertaken using Cochrane RevMan software (version 5.2, The Cochrane
Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark). Outcomes reported as continuous
data were estimated using a mean difference (MD) with 95% confidence interval (CI). Outcomes reported
as dichotomous were estimated as relative risks (RRs) with associated 95% CI. When RCTs reported AEs in
sufficient detail (e.g. the number of participants who experienced at least one AE), these were analysed as
dichotomous data. Data from single-arm randomised crossover design studies were considered separately
in the analysis to avoid a unit-of-analysis error.31
Clinical heterogeneity across RCTs (the degree to which RCTs appear different in terms of participants,
intervention type and duration and outcome type) and statistical heterogeneity were considered prior to
data pooling. Statistical heterogeneity was assessed using the chi-squared test (p-value< 0.10 was
considered to indicate statistically significant heterogeneity) in conjunction with the I-squared statistic.32
For comparisons in which there was little apparent clinical heterogeneity and the I2-value was ≤ 40%,
a fixed-effects model was applied. When there was little apparent clinical heterogeneity and the I2-value
was > 40%, a random-effects model was applied. Effect estimates (estimated in RevMan as z-values) were
considered significant at p< 0.05. Data were not pooled across RCTs for which heterogeneity was very
high (I2-values of ≥ 75%).
Quality assessment of included studies
The methodological quality of systematic reviews used as a source of RCT data were assessed using the
Assessing Methodological Quality of Systematic Reviews (AMSTAR) checklist.33 This checklist consists
of 11 items and has good face and content validity for measuring the methodological quality of systematic
reviews.33 Domain items with a ‘yes’ response are scored one point. ‘No’, ‘not applicable’ and ‘unclear’
responses score a zero. An overall score was estimated for each review by summing the total number of
points. It was not possible to undertake quality assessment for RCTs for which data were extracted from
existing reviews. Methodological quality of further RCTs identified from the literature search was assessed
using the Cochrane Collaboration risk of bias assessment criteria. This tool addresses specific domains,
namely sequence generation, allocation concealment, blinding of participants and personnel, blinding
of outcome assessment, incomplete outcome data and selective outcome reporting.34 We classified RCTs
as being at overall ‘low risk’ of bias if they were rated as ‘low’ for each of three key domains – allocation
concealment, blinding of outcome assessment and completeness of outcome data. RCTs judged as being
at ‘high risk’ of bias for any of these domains were judged at overall ‘high risk’. Similarly, RCTs judged as
being at ‘unclear risk’ of bias for any of these domains were judged at overall ‘unclear risk’.
ASSESSMENT OF CLINICAL EFFECTIVENESS
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Results
Quantity and quality of research available
The searches identified 2283 citations. Of these, 2181 citations were excluded, 2174 based on title and/or
abstract information and seven that we were unable to obtain. One hundred and three (103) full-text
articles were obtained as potentially relevant. Of these, 24 were excluded: eight were non-systematic
reviews or treatment overviews, two were laboratory-based assessments, two were pharmacokinetic
assessment studies and 12 were studies evaluating treatments not relevant to the UK setting. Details of the
24 excluded studies are presented in Appendix 3. In total, 78 articles from the searches were included in
this assessment report comprising: 28 reviews, 47 primary study articles (relating to 38 studies) and
three guideline articles (relating to two guidelines) (Figure 1).
From these publications, a total of 103 primary studies (102 RCTs) are summarised in this review (Table 1).
Sixty-five RCTs were extracted from existing reviews and 38 further studies from the literature search
(see Table 1). All 65 RCTs reported in existing reviews were also captured by the searches for this
Records identified
through database
searching
(n = 2283)
Sc
re
en
in
g
In
cl
u
d
ed
El
ig
ib
ili
ty
Id
en
ti
fi
ca
ti
o
n Additional records
identified through
other sources
(n = 0)
Records screened – title
and/or abstract
(n = 2283)
Records excluded at title/abstract stage
(n = 2181)
•  Not relevant, n = 2072
•  Dissertation, n = 1
•  Summarised in a review – primary study, n = 68
•  Summarised in a review – parallel publication, n = 30
•  New parallel publication to study already in a
    review, n = 3
•  Unable to obtain, n = 7
Full-text articles assessed
for eligibility
(n = 102)
Full-text articles excluded, with
reasons 
(n = 24)
Articles included in narrative synthesis
(n = 78)
Included in the data synthesis 103 primary studies
(102 RCTs, 1 non-RCT)
•  Non-systematic review, n = 8
•  Laboratory study, n = 2
•  Pharmacokinetic study, n = 2
•  Treatment not relevant to UK, n = 12
•  28 reviews yielding 65 relevant RCTS
•  47 additional articles yielding 38 further primary
    studies (37 RCTs and 1 observational study)
•  3 articles reporting guidelines on the treatment of PE
FIGURE 1 Study selection process: PRISMA flow diagram.
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assessment report. RCT evidence was available for all of the treatments of interest for this review, bar
yoga. For yoga, one observational study was included (a non-RCT). Details of the AMSTAR33 quality
assessment of included reviews and Cochrane risk of bias assessment34 for the RCTs not included by
reviews are presented in Appendix 4.
As titles and abstracts were screened for inclusion by one reviewer, a check for consistency was
undertaken. A second reviewer screened approximately 10% of the references (n= 250) during the initial
screening stage. At this stage, references tagged as potentially relevant by reviewer 1 included 5 out of
194 (3%) references excluded by reviewer 2, and references tagged as potentially relevant by reviewer
2 included 22 out of 211 (10%) references excluded by reviewer 1. This gave a kappa statistic of 0.65,
generally classed as good agreement. The discrepancies appeared to be due to the very broad inclusion
criteria (in terms of study type and intervention type) that were applied at the time of initial screening.
The references for which there was a discrepancy related to article types such as comment articles, news
articles and uncontrolled studies that were initially tagged as potentially relevant. However, later
examination revealed that none of these articles were relevant for inclusion in the final review.
TABLE 1 Summary of reviews and RCTs by intervention
Intervention type No. of reviews
No. of RCTs (extracted
from reviews)
Further RCTs (not in
reviews) RCTs (total)
Behavioural therapies 435–38 939–47 348–50 12
Topical anaesthetics 451–54 755–61 262,63 9
SSRIs other than
dapoxetine
7: 26: 16: 42:
l SSRIs: 464–67 l Citalopram: 470–73 l Citalopram: 592–96 l Citalopram: 9
l Various
treatments:
352,68,69
l Escitalopram
(Cipralex®,
Lundbeck): 0
l Escitalopram
(Cipralex®,
Lundbeck): 494,97–99
l Escitalopram
(Cipralex®,
Lundbeck): 4
l Fluoxetine: 1141,74–83 l Fluoxetine:
595,97,100–102
l Fluoxetine: 16
l Fluvoxamine: 181 l Fluvoxamine: 0 l Fluvoxamine: 1
l Paroxetine:
939,73,81,82,84–88
l Paroxetine:
497,103–105
l Paroxetine: 13
l Sertraline:
939,76,78,81,82,84,89–91
l Sertraline:
492,102,106,107
l Sertraline: 13
Dapoxetine 8: 885,113–119 (one non-licensed
doses; data not included
here115)
1120 9 (8 for licensed
doses)
l Dapoxetine:
668,108–112
l Various
SSRIs: 265,67
SNRIs 168 1 (duloxetine)121 2 (venlafaxine)122,123 3
TCAs (clomipramine) 352,68,69 1039,76,124–131 3107,132,133 13
PDE5 537,134–137 1039,55,138–145 2101,120 12
Alpha-blockers 2 (various
treatments)52,69
1146 1107 2
Opioid analgesics
(tramadol)
3147–149 546,150–153 2154,155 7
Acupuncture 0 0 2156,157 2
Chinese medicine 0 0 5158–162 5
Delay device 0 0 1163 1
Yoga 0 0 1164 (non-RCT) 1 (non-RCT)
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Assessment of effectiveness
Overall summary of results
An overall results summary from this assessment report for outcomes of IELT, sexual satisfaction, control
over ejaculation and other secondary outcomes, plus AEs, following treatment with behavioural techniques
anaesthetic creams and sprays, TCAs, SSRIs including dapoxetine, PDE5 inhibitors, analgesics (tramadol)
and other interventions in the management of PE is provided in Table 2. A detailed assessment of the
effectiveness for each treatment type then follows.
TABLE 2 Summary of overall results from RCT pairwise non-crossover comparisons
Treatment Better than On outcomes of
Between-group
difference
significant AEs with treatment
Behavioural therapies
Behavioural therapy Waiting list control Duration of intercourse,
sexual satisfaction,
desire, self-confidence
Yes No AE data available for
behavioural therapies
Behavioural therapy
plus pharmacotherapy
Pharmacotherapy
alone
IELT, ejaculatory control,
sexual satisfaction,
sexual anxiety
Yes
Behavioural therapy
plus pharmacotherapy
Behavioural therapy
alone
IELT, ejaculatory control,
sexual satisfaction,
sexual anxiety
Yes
Pharmacotherapy
alone
Behavioural therapy
alone
IELT, sexual satisfaction Yes Various AEs associated with
pharmacotherapy (nausea,
vomiting, dry mouth,
dizziness, flushing, diarrhoea)
Topical anaesthetics
EMLA cream Placebo IELT Yes Loss of sensation, irritation
and loss of erection
(application ≥ 20 minutes)TEMPE spray Placebo IELT ejaculatory control,
sexual satisfaction and
distress
Yes
SSRIs currently not licensed for PE
Citalopram Placebo or no
therapy
IELT, sexual satisfaction
and measures of clinical
improvement
Yes
Escitalopram (Cipralex®,
Lundbeck)
Placebo IELT, sexual satisfaction Yes Nausea, headache, insomnia,
dry mouth, diarrhoea,
drowsiness, dizziness,
somnolence, decreased libido
and anejaculation
Fluoxetine
Paroxetine
Sertraline Placebo IELT, ejaculation control Yes
Clomipramine Paroxetine IELT Yes Similar to SSRIs
Fluvoxamine Placebo IELT No Not significant between
fluvoxamine, fluoxetine,
paroxetine and sertraline
SSRIs licensed for PE (dapoxetine)
Dapoxetine 30mg or
60mg
Placebo IELT, ejaculatory control,
sexual satisfaction,
patients reporting
change
Yes Similar to other SSRIs
Dapoxetine 60mg Dapoxetine 30mg Yes
continued
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TABLE 2 Summary of overall results from RCT pairwise non-crossover comparisons (continued )
Treatment Better than On outcomes of
Between-group
difference
significant AEs with treatment
SNRIs
Duloxetine Placebo IELT Yes Dry mouth and nausea; more
AEs with venlafaxine than
placebo
Venlafaxine Placebo IELT No Significantly more treatment-
related side effects than
placebo
TCAs
Clomipramine: oral Placebo IELT Yes More AEs with clomipramine
than fluoxetine or sertraline
Clomipramine: nasal
(4mg)
Yes Local irritation associated with
nasal administration
PDE5 inhibitors
PDE5 inhibitors Placebo IELT Vardenafil or
tadalafil, yes;
sildenafil, no
Flushing, headache and
palpitations
PDE5 inhibitors SSRIs Sertraline, yes;
fluoxetine, no
PDE5 inhibitors plus
SSRIs
SSRIs alone Yes
PDE5 inhibitors Behavioural therapy Yes
Alpha-blockers
Terazosin Placebo Ejaculation control Yes Headache, hypotension,
drowsiness, ejaculation
disorder
Opioid analgesics
Tramadol Placebo IELT, various patient-
reported outcomes,
including sexual
satisfaction
Yes Erectile dysfunction,
constipation, nausea,
headache, somnolence, dry
mouth, dizziness, pruritus,
vomiting
Tramadol plus
behavioural therapy
Behavioural therapy Yes
Paroxetine Tramadol IELT No
Other therapies
Acupuncture Sham acupuncture IELT Yes No AE, data available for
acupuncture, Chinese
medicine or yogaChinese medicine Treatment as usual Yes
Yoga (observational
study)
Baseline IELT Yes
Fluoxetine Yoga Yes
Desensitising band
plus stop–start
technique
Stop–start
technique
IELT Yes Appear minimal when device
used as directed
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Behavioural therapies
Characteristics of included studies: behavioural therapies
Behavioural therapies were evaluated by one Cochrane review35 and two further systematic reviews of
behavioural therapies.36,38 Nine RCTs evaluating behavioural therapies were identified from these and other
reviews of pharmacological therapies.39–47 A further three RCTs of behavioural therapy were identified by
the literature search:48–50 one evaluated pelvic floor exercises compared with dapoxetine,48 one evaluated a
multicomponent behavioural therapy intervention compared with paroxetine alone or in combination with
the behavioural intervention49 and one evaluated an internet-based behavioural intervention compared
with waiting list control.50
Reviews The Cochrane review by Melnik et al.35 and the systematic review by Melnik et al.38 were
conducted in Brazil. The review by Berner and Gunzler36 was undertaken in Germany. The Cochrane
review by Melnik et al.35 was awarded an overall AMSTAR quality score 7 out of 11. The systematic
reviews by Berner and Gunzler36 and Melnik et al.38 were awarded 6 and 3 out of 11, respectively. Details
of the review type, the databases searched and dates, relevant included RCTs and the AMSTAR points
awarded to these reviews is presented in Table 3. Full details of the AMSTAR assessment for these and all
other include reviews are presented in Appendix 4.
Randomised controlled trials included in reviews All reviews varied in terms of which RCTs they
included. In total, nine RCTs of behavioural therapies39–47 (total n= 505) were included in at least one
systematic review. The method of IELT assessment (stopwatch) was reported for only five RCTs.39,40,44,46,48
The duration of the RCTs included in the reviews ranged from 2 to 12 weeks. The behavioural therapies
that were evaluated included the squeeze technique,39 functional–sexological treatment involving
movement of the body, speed of sexual activity and education regarding sensuality,40 the stop–start
technique plus squeeze technique,40 behavioural psychotherapy,42 stop–start technique alone,43 behavioural
psychotherapy,44 ‘Bibliotherapy’ (consisting of introduction to PE, descriptions of squeeze technique, pause
technique and sensate focusing), and sexual therapy for couples (sensate focus, stop–start technique and
communication exercises).45 The type of behavioural intervention was not specified for one RCT.47
In addition to the RCTs captured in reviews of behavioural therapy, one RCT evaluating the stop–start
technique compared with fluoxetine or placebo41 was captured in reviews of SSRIs (see Selective serotonin
reuptake inhibitors currently not licensed for premature ejaculation) and one RCT evaluating a behavioural
therapy that intervention was not specified compared with tramadol46 was captured in another review of
pharmacological agents (see Opioid analgesics). Details of the RCTs extracted from reviews are presented
in Table 4. All RCTs in reviews were captured by the search strategy for this assessment report.
Randomised controlled trials not included in reviews The RCT by Pastore et al.48 was conducted in
Italy. Forty patients were randomised to pelvic floor muscle physiokinesitherapy (awareness of muscle
contraction), comprising electrical stimulation of perineal floor, three 60-minute sessions per week, or to
dapoxetine (30mg or 60mg on demand). IELT was assessed with a stopwatch. The duration was 12 weeks.
The authors reported that 34 out of 40 (85%) patients completed the trial and IELT was stopwatch
assessed. The RCT by Shao and Li49 was conducted in China. A total of 120 patients were randomised to
paroxetine 10mg per day (for the first 4 weeks) combined with behavioural therapy comprising the Masters
and Johnson squeeze technique,17 sensate focus and Chinese traditional Qigong treatment (penis swinging
and acupoint tapping), to paroxetine 20mg per day, or to behavioural therapy only. The duration was
8 weeks. No objective assessment of IELT was reported. All patients (100%) were reported as completing
the intervention. In the RCT by van Lankveld et al.,50 an internet-based sex therapy based on the Masters
and Johnson sensate focus technique was compared with waiting list control and 40 patients were
randomised. The number and frequency of therapeutic contacts was left to the judgement of the therapist
and the participant. No objective assessment of IELT was reported. The authors reported that 37 out of
40 (93%) patients completed the 3-month treatment programme. All three RCTs107,132,133 were considered to
be at overall unclear risk of bias.34
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TABLE 3 Behavioural therapies: details of reviews and AMSTAR quality score
Author (country)
review type Databases searched and dates
Included RCTs relevant to
this section
AMSTAR review quality
assessment
Berner and
Gunzler, 201236
(Germany)
systematic review
CENTRAL, MEDLINE, CINAHL,
Academic Search Premier,
PsycINFO, PubMed and
PSYNDEX between 1985 and
2009
de Carufel and Trudel 2006,40
Oguzhanoglu et al. 2005,43
Trudel and Proulx 198745
AMSTAR score, 6/11:
l a priori design reported
l duplicate study selection
and data extraction
l comprehensive
literature search
l characteristics of included
studies reported
l study quality assessed,
study quality used to
informed conclusions
l conflict of interest
statement reported
Melnik et al.
200938 (Brazil)
systematic review
MEDLINE by PubMed
(1966–2009), PsycINFO
(1974–2009), EMBASE
(1980–2009), Latin America
and Caribbean Health Sciences
Literature (1982–2009) and
CENTRAL (The Cochrane Library,
2009, issue 1)
Abdel-Hamid et al. 2001,39
de Carufel and Trudel 2006,40
Li et al. 2006,42 Tang et al.
2004,44 Trudel and Proulx
1987,45 Yuan et al. 200847
AMSTAR score, 3/11:
l comprehensive
literature search
l studies included
regardless of
publication type
l study quality assessed
Melnik et al.
201135 (Brazil)
Cochrane review
MEDLINE, 1966–2010; PsycINFO,
1974–2010; EMBASE,
1980–2010; Latin America and
Caribbean Health Sciences
Literature, 1982–2010; and The
Cochrane Library, 2010
Abdel-Hamid et al. 2001,39
de Carufel and Trudel 2006,40
Li et al. 2006,42 Yuan et al.
200847
AMSTAR score, 7/11:
l a priori design reported
l comprehensive
literature search
l studies included
regardless of
publication type
l characteristics of included
studies reported
l study quality assessed
l study quality used to
informed conclusions
l appropriate methods
used to pool data
l conflict of interest
statement reported
CENTRAL, Cochrane Central Register of Controlled Trials.
AMSTAR review quality criteria: a priori design, duplicate study selection and data extraction; comprehensive literature
search of databases and other supplementary sources; studies included regardless of publication type; list of studies
(included and excluded); characteristics of included studies reported; study quality assessed; study quality used to informed
conclusions; appropriate methods used to pool data; publication bias assessed; and conflict of interest statement included.
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Details of the treatments evaluated, definition of PE, IELT assessment method, other outcomes assessed,
study duration, along with the study country for the further RCTs not in reviews and the overall study
quality assessment (AMSTAR33 for reviews and Cochrane risk of bias assessment34 for the RCTs not
included by reviews) are presented in Table 4.
Assessment of effectiveness: behavioural therapies – intravaginal ejaculatory
latency time outcomes
The reporting of IELT outcomes for RCTs included in the reviews was varied in terms of the treatment
comparisons, the reporting of the assessment method, the outcome metric that was reported and the
reporting of variance estimates and p-values. With the exception of the crossover study by Abdel-Hamid
et al.39 and the RCT by Xiong et al.,46 no data were suitable to either estimate between-group differences
for individual trial or pool data across studies in RevMan for this assessment report.
Intravaginal ejaculatory latency time: behavioural therapy compared with waiting
list control
Duration of intercourse: functional sexological treatment or behavioural therapy compared with
waiting list control No variance estimates were reported for this outcome in the review by Berner and
Gunzler.36 Melnik et al.35 reported that both functional sexological treatment and behavioural therapy
significantly increased duration of intercourse compared with waiting list controls (functional sexological
therapy: MD 6.87 minutes, 95% CI 5.10 to 8.64 minutes; behavioural therapy: MD 6.80 minutes, 95% CI
5.04 to 8.56 minutes) for one RCT.40 p-values for the between-group differences were not reported.
Summary results for these and across all other behavioural intervention trials are presented in Table 5.
Intravaginal ejaculatory latency time: bibliotherapy with/without therapist contact, sexual
therapy, waiting list control Mean ejaculatory latency (minutes) post treatment in one trial45 was
reported by Berner and Gunzler36 as follows: bibliotherapy without therapist contact, 11.05 minutes
(change from baseline, p< 0.01); bibliotherapy with therapist contact by phone, 9.23 minutes (change
from baseline, p< 0.01); sexual therapy for couples, 10.78 minutes (change from baseline, p< 0.01); and
waiting list control, 1.94 minutes (improvement not significant, p-value not reported).
Golombok Rust Inventory of Sexual Satisfaction premature ejaculation subscale score:
internet-based behavioural therapy compared with waiting list control The between-group MD in
the Golombok Rust Inventory of Sexual Satisfaction (GRISS) PE subscale score at 3 months based on
one RCT50 (n= 37) was –0.20 minutes (fixed effect; 95% CI –1.75 to 1.35 minutes; p= 0.80) (Figure 2).
Intravaginal ejaculatory latency time: behavioural therapy with pharmacotherapy
compared with pharmacotherapy alone
Intravaginal ejaculatory latency time: behavioural therapy plus chlorpromazine compared with
chlorpromazine Melnik et al.35 reported that behavioural therapy plus chlorpromazine was superior to
chlorpromazine alone in increasing IELT (minutes) after treatment in one RCT42 (MD 1.11 minutes, 95% CI
0.82 to 1.40 minutes). A p-value for the between-group difference was not reported.
Intravaginal ejaculatory latency time: behavioural therapy plus citalopram compared with
citalopram Melnik et al.35 reported that, in one trial,47 citalopram combined with behavioural therapy
compared with citalopram alone favoured the combined approach therapy (no data reported). p-values
were not reported.
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Chinese Index of Premature Ejaculation 5 premature ejaculation-related items ejaculatory latency
score: behavioural therapy plus paroxetine compared with paroxetine The between-group
difference in the Chinese Index of Premature Ejaculation 5 PE-related items (CIPE5) ejaculatory latency
score at 8 weeks based on one RCT49 (n= 80) was 0.40 minutes in favour of behavioural therapy
combined with paroxetine 20mg compared with paroxetine 20mg alone [MD (fixed effect), 95% CI 0.18
to 0.62 minutes; p= 0.0003] (see Figure 2).
Intravaginal ejaculatory latency time: behavioural therapy with pharmacotherapy
compared with behavioural therapy alone
Intravaginal ejaculatory latency time: behavioural therapy plus sildenafil compared with
behavioural therapy Mean values (minutes) at week 6 for one trial44 were reported as 3.63 minutes for
cognitive–behavioural therapy (CBT) plus sildenafil compared with 1.82 minutes for behavioural therapy
alone. The p-value for between-group difference was reported as p< 0.001 in favour of behavioural
therapy with sildenafil.
Intravaginal ejaculatory latency time: behavioural therapy plus tramadol vs. behavioural
therapy The between-group difference in mean IELT (minutes) at 12 weeks, based on one RCT46 (n= 72),
was 1.65 minutes, significantly favouring tramadol with behavioural therapy compared with behavioural
therapy alone (95% CI 0.30 to 3.00 minutes; p= 0.02). The forest plot for this analysis is presented as
Figure 18 in the Opioid analgesics section of this assessment report.
Chinese Index of Premature Ejaculation 5 premature ejaculation-related items ejaculatory
latency score – behavioural therapy plus paroxetine compared with behavioural therapy The
between-group difference in the CIPE5 ejaculatory latency score at 8 weeks based on one RCT49 (n= 80)
was 0.60 minutes in favour of behavioural therapy combined with paroxetine 20mg compared with
behavioural therapy alone [MD (fixed effect), 95% CI 0.40 to 0.80 minutes; p< 0.00001] (see Figure 2).
Intravaginal ejaculatory latency time: behavioural therapy compared
with pharmacotherapy
Intravaginal ejaculatory latency time: pelvic floor rehabilitation compared with dapoxetine The
between-group difference in geometric mean IELT (minutes) at 12 weeks based on one RCT48 (n= 32) was
1.22 minutes in favour of dapoxetine 30mg or 60mg compared with pelvic floor rehabilitation [MD (fixed
effect) 95% CI 0.79 to 1.65 minutes; p< 0.0001] (see Figure 2).
Intravaginal ejaculatory latency time: behavioural therapy compared with citalopram Melnik
et al.35 reported that, in one trial,47 citalopram significantly improved IELT compared with behavioural
therapy (RR 0.52, 95% CI 0.34 to 0.78). p-values were not reported.
Intravaginal ejaculatory latency time: stop–start technique compared with fluoxetine The review
by Berner and Gunzler36 reported that no outcome data were available for the one RCT evaluating this
treatment comparison.43
Intravaginal ejaculatory latency time: squeeze technique compared with selective serotonin
reuptake inhibitors or tricyclic antidepressants The between-group difference in mean IELT change
(minutes) following a 4-week randomised crossover comparison39 was 12.00 minutes in favour of sildenafil
compared with squeeze technique [MD (fixed effect) 95% CI 8.06 to 15.94 minutes; p< 0.00001].
Comparisons of squeeze technique with clomipramine, sertraline and paroxetine were not significant
(Figure 3). A paired analysis could not be undertaken for approximation purposes for this study. Data from
this trial were not pooled with other RCTs in any meta-analysis in this assessment report.
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Chinese Index of Premature Ejaculation 5 premature ejaculation-related items ejaculatory latency
score: behavioural therapy compared with paroxetine The between-group difference in the CIPE5
ejaculatory latency score at 8 weeks based on one RCT49 (n= 80) was 0.20 in favour of paroxetine 20mg
compared with behavioural therapy [MD (fixed effect), 95% CI 0.00 to 0.40 minutes; p= 0.05]
(see Figure 2).
Assessment of effectiveness – behavioural therapies: other outcomes
With the exception of the RCTs by Pastore et al.48 and Trudel and Proulx45 all of the included trials were
reported as evaluating one or more other outcomes. However, these were diverse across the included trials
and were often not reported in sufficient detail to permit any pooling across trials (Table 6).
Other outcomes: behavioural therapy compared with waiting list control Male perceptions of the
duration of intercourse and couples’ sexual satisfaction were significantly improved with either functional
sexological treatment (sensual education) or behavioural therapy (stop–start technique and squeeze
technique) compared with waiting list control in one RCT.40 One RCT50 reported a significant increase
from baseline in International Index of Erectile Function (IIEF) measures of sexual satisfaction and desire,
and on a measure of self-confidence associated with internet-based sex therapy based on a sensate focus
technique compared with waiting list control. No difference was evident on an improvement/impairment
of sexual functioning measure.
Other outcomes: behavioural therapy with pharmacotherapy compared with pharmacotherapy
alone Behavioural psychotherapy combined with chlorpromazine was reported by one RCT as being more
effective than chlorpromazine alone on a self-rated measure of anxiety and Chinese Index of Premature
Ejaculation (CIPE) measures of sexual anxiety, sexual satisfaction and ejaculatory control.42 Shao et al.49
reported that CIPE measures of ejaculation control, patient/partner satisfaction and sexual anxiety were all
significantly improved following treatment with behavioural therapy comprising squeeze technique,
sensate focus and Chinese traditional treatment plus paroxetine compared with paroxetine alone.
Yuan et al.47 reported that behavioural therapy combined with citalopram was more effective at improving
sexual satisfaction than citalopram alone.
Other outcomes: behavioural therapy with pharmacotherapy compared with behavioural therapy
alone Shao et al.49 reported that CIPE measures of ejaculation control, patient/partner satisfaction and
sexual anxiety were all significantly improved following treatment with behavioural therapy comprising
squeeze technique, sensate focus and Chinese traditional treatment plus paroxetine compared with
behavioural therapy alone. In one RCT,44 more patients receiving behavioural therapy plus sildenafil than
patients receiving behavioural therapy alone reported ‘satisfied’ on a measure of sexual satisfaction.
Xiong et al.46 reported a between-group difference at 8 weeks of p< 0.05 on the IIEF favouring the
tramadol plus behavioural therapy group compared with behavioural therapy alone.
Other outcomes: behavioural therapy compared with pharmacotherapy Shao et al.49 reported
that paroxetine was significantly better than behavioural therapy on CIPE assessed ejaculation control.
However, patient/partner satisfaction was significantly better following behavioural therapy than following
paroxetine. No significant between-group difference was observed for sexual anxiety. Yuan et al.47
reported that citalopram significantly increased the number of couples satisfied with their sex life
compared with behavioural therapy alone. Oguzhanoglu et al.43 reported no statistically significant
between-group difference in satisfaction with treatment for stop–start technique compared
with fluoxetine.
Assessment of safety: behavioural therapies – adverse events
Adverse event data were available for only 4 of the 12 included RCTs. Abdel-Hamid et al.39 reported that
the incidence of side effects was similar among groups and included headache, flushing and nasal
congestion in 18% of the patients who received sildenafil. Pastore et al.48 reported that dapoxetine was
associated with nausea and diarrhoea whereas no AEs were reported for the pelvic floor rehabilitation group.
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In the RCT by Shao et al.,49 the incidence of AEs was reported in the paroxetine group and the behavioural
therapy combined with paroxetine group. However, the types of AEs were not reported. AEs for the
behavioural therapy-only group were not reported. For one RCT,46 the between-group difference in relative
risk (RR) at 12 weeks was 21.00 experiencing AEs [RR (random effects), 95% CI 1.28 to 345.41; p= 0.03] in
favour of behavioural therapy alone compared with tramadol (lower risk). The forest plot for this analysis is
presented as Figure 20 in the Opioid analgesics section of this assessment report.
Assessment of effectiveness: behavioural therapies – evidence summary
The current evidence base for behavioural therapy in the treatment of PE comprises 12 RCTs,
nine captured in three low to good methodological quality systematic reviews and three further RCTs
which are at overall unclear risk of bias. The quality of IELT outcome reporting across these trials is limited
and does not facilitate any meaningful pooling across trials to be undertaken. However, individual trial
results suggest that behavioural therapies are better than waiting list control in improving IELT, that
behavioural therapies combined with pharmacological therapies are better than pharmacological agents
alone (chlorpromazine, citalopram or paroxetine) and that behavioural therapies combined with
pharmacological therapies (sildenafil, paroxetine or tramadol) are better than behavioural therapy alone in
improving IELT in men with PE.
Various assessment methods in terms of ejaculation control, patients’/partners’ sexual satisfaction,
anxiety and other patient-reported outcomes have been used across RCTs to measure the effectiveness of
behavioural therapies. There is, however, some evidence to suggest that behavioural therapies combined
with pharmacological therapies (paroxetine or tramadol) are better than behavioural therapy alone and
that behavioural therapies combined with pharmacological therapies are better than pharmacotherapy
alone (paroxetine, chlorpromazine, sildenafil or citalopram) in improving outcomes other than IELT. AE
reporting across RCTs evaluating behavioural interventions is limited and AEs are often reported only for
an adjuvant pharmacological agent or a pharmacological comparator. Adjuvant therapies to behavioural
interventions that include SSRIs (dapoxetine, paroxetine) and PDE5 inhibitors (sildenafil) are reported to be
associated with headache, flushing, nausea and diarrhoea.
Behavioural therapy alone appears to be more effective than no treatment in the treatment of PE.
Behavioural therapy combined with pharmacological therapy appears more effective than behavioural
therapy or pharmacological therapy alone. Comparisons between behavioural therapy and pharmacological
therapies generally favour the pharmacological intervention for improvement in IELT, but are uncertain
for other outcomes. AEs may be associated with adjuvant pharmacotherapy. The long-term efficacy
of behavioural therapy in the treatment of PE is not evaluated in the current evidence base.
Topical anaesthetics
Characteristics of included studies: topical anaesthetics
Topical anaesthetics were evaluated by two systematic reviews51,53 and one ‘mini review’.54 Two of these
systematic reviews pooled data in a meta-analysis.51,53 Trials of topical treatments were also included in one
other review of pharmacological therapies.52 A further two RCTs were identified, one of which evaluated
EMLA (lidocaine and prilocaine) cream compared with electrical stimulation or placebo,62 while the other
evaluated a lidocaine spray (Premjact, Boots Pharmaceuticals) compared with paroxetine.63
Reviews One of the reviews of topical anaesthetics was conducted in the USA.54 The two systematic
reviews that pooled data in a meta-analysis were both undertaken in China.51,53 The overall AMSTAR
quality score of one of the reviews was 1 out of 11.54 The two systematic reviews with a meta-analysis
were scored as 4 out of 1151 and 5 out of 11.53 Details of the review type, the databases searched and
dates, relevant included RCTs and the AMSTAR points awarded to these reviews are presented in Table 7.
Full details of the AMSTAR assessment for these and all other include reviews are presented in Appendix 4.
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The search methodology and inclusion criteria varied across these reviews. Pu et al.51 pooled secondary
outcome data from different domains of the same instrument in an overall summary effect estimate,
in effect counting participants twice in the analysis. In the review by Xia et al.,53 the authors pooled IELT
effect estimates across studies using a standardised MD.
Randomised controlled trials included in reviews The reviews above varied in terms of which RCTs
they included. In total, seven RCTs (total n= 675) were included in at least one of these reviews.55–61 IELT
was reported as being assessed using a stopwatch in four RCTs57–60 and by patient self-report in one RCT.56
The method of IELT assessment was not reported for two RCTs.55,61 With the exception of the RCTs by
Atikeler et al.56 that evaluated the effects after more than five applications of treatment, and one trial
reported as a crossover RCT,61 duration across trials ranged from 4 to 12 weeks. The topical anaesthetics
evaluated included EMLA cream, TEMPE spray (containing lidocaine and prilocaine) and other topical
anaesthetic creams (dyclonine cream and alprostadil cream). All of the RCTs compared topical anaesthetics
with placebo. In addition, one RCT was identified that compared EMLA cream with sildenafil or EMLA
cream combined with sildenafil.55 This RCT is also evaluated in the section Phosphodiesterase-5 inhibitors of
this assessment report. All RCTs in reviews were captured by the search strategy for this assessment report.
Randomised controlled trials not included in reviews The RCT by Mallat et al.62 was conducted in
Tunisia. Patients were randomised, 30 per group, to EMLA, electrical stimulation or placebo. The trial was
reported in abstract form only and the full details each treatment were not reported. The authors reported
that 90 out of 90 (100%) patients completed the 12-week follow-up. The assessment method of IELT was
TABLE 7 Topical anaesthetics: details of reviews and AMSTAR quality score
Author (country),
review type
Databases searched
and dates
Included RCTs relevant to this
section
AMSTAR review quality
assessment
Morales et al. 200754
(USA), mini-review
MEDLINE 1966 to
January 2004
Atan et al. 2006,55 Atikeler et al.
2002,56 Busato and Galindo
2004,57 Dinsmore et al. 2007,59
Gittelman et al. 200661
AMSTAR score, 1/11:
l conflict of interest
statement reported
Pu et al. 201351
(China), systematic
and meta-analysis
Cochrane Central
Register of Controlled
Trials, PubMed (from
1980 to June 2012), and
EMBASE (from 1980 to
June 2012)
Atan et al. 2006,55 Atikeler et al.
2002,56 Busato and Galindo
2004,57 Carson et al. 2010,58
Dinsmore et al. 2007,59 Dinsmore
and Wyllie 200960
AMSTAR score, 4/11:
l comprehensive
literature search
l studies included regardless
of publication type
l characteristics of included
studies reported
l study quality assessed
Xia et al. 201353
(China), systematic
and meta-analysis
The Cochrane Library,
PubMed and EMBASE to
October 2012
Atikeler et al. 2002,56 Busato and
Galindo 2004,57 Carson et al.
2010,58 Dinsmore et al. 2007,59
Dinsmore and Wyllie 200960
AMSTAR score, 5/11:
l duplicate study
selection extraction
l characteristics of included
studies reported
l study quality assessed
l appropriate methods used
to pool data
l conflict of interest
statement reported
AMSTAR review quality criteria: a priori design, duplicate study selection and data extraction; comprehensive literature
search of databases and other supplementary sources; studies included regardless of publication type; list of studies
(included and excluded); characteristics of included studies reported; study quality assessed; study quality used to informed
conclusions; appropriate methods used to pool data; publication bias assessed; and conflict of interest statement included.
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not reported. The RCT by Steggall et al.63 was conducted in the UK. Sixty patients were recruited to the
trial and were randomised to either a lidocaine spray (Premjact) 10 minutes preintercourse or paroxetine
20mg daily. Treatment duration was 2 months and the authors reported that 44 out of 60 (70%) patients
completed the intervention. Both of these trials were considered to be at overall unclear risk of bias.
Details of the treatments evaluated, definition of PE, IELT assessment method, other outcomes assessed,
study duration, along with the study country for the further RCTs not in reviews, and the overall study
quality assessment (AMSTAR33 for reviews and Cochrane risk of bias assessment34 for the RCTs not
included by reviews) are presented in Table 8.
Assessment of effectiveness: topical anaesthetics – intravaginal ejaculatory latency
time outcomes
With the exception of the RCT by Atan et al.,55 IELT outcomes were reported for all of the RCTs identified
from existing reviews. The review by Morales et al.54 reported that there was no statistical advantage in
adding sildenafil to topical prilocaine-lidocaine treatment in the RCT by Atan et al.55 No data or p-value
were reported. The two further RCTs identified for inclusion in this assessment report both reported IELT
outcomes, but without any variance estimates. Mallat et al.62 reported a p-value for IELT of p< 0.001,
but it was unclear if this was across or between groups, or whether this was for end of study values or
change from baseline. Steggall et al.63 reported a p-value for median IELT change from baseline of
p= 0.038 for lidocaine spray and p< 0.0005 for paroxetine. These trials were therefore not included in
any IELT meta-analysis in this assessment report.
Intravaginal ejaculatory latency time: EMLA cream compared with placebo Meta-analysis of mean
IELT (minutes) following an application of EMLA cream< 20 minutes preintercourse, based on two RCT
study group comparisons (n= 49), displayed low heterogeneity (I2= 0%). The pooled MD in IELT was
6.44 minutes, significantly favouring EMLA [MD (fixed effect); 95% CI 6.01 to 6.87 minutes; p< 0.00001].
The forest plot for this analysis is presented in Figure 4. Summary results for these and all other
meta-analyses are presented in Table 9.
Intravaginal ejaculatory latency time: TEMPE spray compared with placebo The between-group
difference in mean IELT (minutes) based on one RCT (n= 54) was 3.30 minutes, significantly favouring
TEMPE spray [MD (fixed effect); 95% CI 1.33 to 5.27 minutes; p= 0.001]. Meta-analysis of geometric
mean IELT (minutes), based on two RCT study group comparisons (n= 49), displayed low heterogeneity
(I2= 0%). The pooled MD in IELT was 2.10 minutes, significantly favouring TEMPE spray [MD (fixed effect);
95% CI 1.27 to 2.93 minutes; p< 0.00001]. The forest plot for this analysis is presented in Figure 4.
Intravaginal ejaculatory latency time: other topical anaesthetics compared with placebo
One single-arm randomised crossover trial (n= 30) evaluated three different topical anaesthetics.61
The between-group differences in mean IELT (minutes) were 0.87 minutes in favour of dyclonine cream
compared with placebo (95% CI 0.71 to 1.03 minutes; p< 0.00001); 1.41 minutes in favour of alprostadil
cream compared with placebo (95% CI 1.24 to 1.58 minutes; p< 0.00001); and 1.74 minutes in favour
of dyclonine/alprostadil cream compared with placebo (95% CI 1.58 to 1.90 minutes; p< 0.00001).
The forest plot for this analysis is presented in Figure 5. A paired analysis could not be undertaken for
approximation purposes for this study. Data from this trial were not pooled with other RCTs in any
meta-analysis in this assessment report.
Assessment of effectiveness: topical anaesthetics – other outcomes
Three RCTs did not report any effectiveness outcomes other than IELT.55,56,63 Amongst the other RCTs,
outcomes other than IELT were diverse across the included trials (Table 10).
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Other outcomes: EMLA cream compared with placebo A statistically significant between-group
difference in sexual satisfaction in favour of EMLA cream after 2 months was reported by Busato
and Galindo.57 There appeared to be no difference between EMLA cream and placebo on the IIEF.
Number of coitus per week and sexual satisfaction values were reported by one RCT.62
Other outcomes: TEMPE spray compared with placebo The between-group differences on the Index
of Ejaculatory Control and Sexual Quality of Life for both men and women were reported as being not
statistically significant at 4 weeks in one RCT.59 However, two RCTs reported that TEMPE spray was
significantly more effective than placebo at 12 weeks on the IPE measures including ejaculatory control,
sexual satisfaction and distress and on the PEP.58,60
Other outcomes: other topical creams compared with placebo In one crossover RCT, > 70% of
patients allocated to receive a cream containing either dyclonine, alprostadil or both agents reported ‘yes’
for sexual satisfaction.61 However, 66.7% in the placebo group also reported ‘yes’. A p-value for
between-group difference was not reported.
Assessment of safety: topical anaesthetics – adverse events
Adverse events were not reported for one RCT.63 When reported, AEs associated with topical anaesthetics
included erectile dysfunction/loss of erection, loss of sensitivity/numbness (men and women) and irritation/
burning (men and women).
Adverse events: topical anaesthetics compared with placebo Meta-analysis of patient numbers
experiencing AEs following treatment with topical anaesthetics displayed low heterogeneity (I2= 0%).
The between-group difference in EMLA cream applied for ≥ 20 minutes compared with placebo was not
statistically significant [RR 9.06 (fixed effect), 95% CI 0.55 to 150.06; p= 0.12]. However, Atikeler et al.56
reported that EMLA cream caused 6 out of 10 men in the 30-minute application group and 10 out of
10 men in the 45-minute application group to report erection loss or numbness.
The pooled RR across three trials comparing TEMPE spray with placebo (593 participants) was 3.25
[RR (fixed effect); 95% CI 1.50 to 7.02; p= 0.003] in favour of placebo (lower risk). The forest plot for this
analysis is presented in Figure 6. Results for these and all other meta-analyses are presented in Table 10.
Assessment of effectiveness: topical anaesthetics – evidence summary
The current evidence base for topical anaesthetics in the treatment of PE comprises nine RCTs,54–63
seven55–61 captured in three low methodological quality systematic reviews51,53,54 and two further RCTs62,63
which are at overall unclear risk of bias. The pooled evidence across two RCTs56,57 comprising 49
participants suggests that EMLA cream is effective in significantly increasing IELT in men with PE compared
with placebo (MD 6.44 minutes, 95% CI 6.01 to 6.87 minutes; p< 0.00001). Evidence from one RCT59
(54 participants) suggests that TEMPE spray is effective in significantly increasing IELT in men with PE
compared with placebo (MD 3.30 minutes, 95% CI 1.33 to 5.27 minutes; p< 0.00001). Evidence from
one crossover RCT61 suggests that creams containing dyclonine, alprostadil or both agents are more
significantly more effective than placebo.
Various assessment methods in terms patient/partners sexual satisfaction and other outcomes have been
used across RCTs to measure the effectiveness of topical anaesthetics. Evidence from three RCTs58–60
suggests significant improvements in sexual satisfaction with topical anaesthetics compared with placebo.
However, two other RCTs that assessed the effects of topical anaesthetics or placebo suggests there is no
difference in sexual satisfaction or intercourse frequency,57 or ejaculatory control and sexual quality of life.58
Pooled evidence across trials suggests that topical anaesthetics are associated with significantly more AEs
than placebo. AEs associated with topical anaesthetics include loss of sensitivity/numbness and irritation/
burning for both men and women. Erectile dysfunction and loss of erection are also reported by men and
appear to be related to treatment applications ≥ 20 minutes preintercourse.
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Topical anaesthetics appear more effective than placebo in the treatment of PE. Loss of sensation and
irritation are common AEs in both men and women, and there is more reporting of AEs associated with
TEMPE spray than EMLA cream. Application of topical anaesthetics ≥ 20 minutes preintercourse is
associated with erection loss. However, these findings should be interpreted with caution given the
methodological quality of the available evidence. In addition, patient acceptability of this treatment
modality (topical application) for PE has not been evaluated in the current evidence base.
Selective serotonin reuptake inhibitors currently not licensed for
premature ejaculation
Characteristics of included studies: selective serotonin reuptake inhibitors
Selective serotonin reuptake inhibitors were evaluated by seven systematic reviews.52,64–69 Four reviews
focused specifically on SSRIs,64–67 while the others evaluated various treatments for PE including SSRIs.
One review of SSRIs pooled data from RCTs comparing fluoxetine with placebo in a meta-analysis,64
and one pooled data from RCTs comparing citalopram, dapoxetine, fluoxetine, fluvoxamine and sertraline
with placebo in a meta-analysis.65 Details of the review type, the databases searched and dates,
relevant included RCTs and the AMSTAR points awarded to these reviews is presented in Table 11.
Reviews Three of the systematic reviews were conducted in China.64,65,67 One review was conducted in
Australia,68 one in the Netherlands,52 one in the USA66 and one in the UK.69 The overall AMSTAR quality
score was 1 out of 11 in three of the reviews,52,65,69 2 out of 11 in one review68 and 3 out of 11 in one
review.64 Two reviews scored 0 out of 11.66,67 The review by Huang et al.65 was the most comprehensive in
terms of included RCTs evaluating SSRIs. However, the reviewers pooled data from single-arm crossover
studies with separate treatment arm studies in a meta-analysis. Full details of the AMSTAR assessment for
these and all other included reviews are presented in Appendix 4. The search methodology and inclusion
criteria for studies were varied across these reviews. All RCTs in reviews were captured by the search
strategy for this assessment report.
Randomised controlled trials (included in reviews and further randomised controlled
trials) Twenty-six RCTs of SSRIs were evaluated across the seven reviews.39,41,70–91,141,166 A further 16 RCTs
additional to those already included reviews were identified for inclusion,92–107 resulting in a total of 42
RCTs that evaluated SSRIs. Fourteen of the 16 additional RCTs identified by the literature search were
considered to be at overall unclear risk of bias.92–94,96–102,104–107 Two were considered to be at overall high
risk of bias.95,103 The 16 additional RCTs were undertaken in China, Egypt, Georgia, Italy, the Islamic
Republic of Iran, the Republic of Korea, the Netherlands, Saudi Arabia and Turkey. Across the 42
included RCTs:
l Citalopram was assessed in nine RCTs.70–73,92–96 Four RCTs were identified from reviews70–73 and five
from the literature search.92–96 Across these RCTS treatment doses ranged from 20mg to 60mg.
Comparators included placebo, no therapy and other SSRIs. Duration ranged from 4 to 12 weeks.
l Escitalopram (Cipralex®, Lundbeck) was evaluated in four RCTs, all identified from the literature
search.94,97–98 All prescribed daily dose of 10mg. Comparators included placebo and other SSRIs.
Duration ranged from 4 to 12 weeks.
l Fluoxetine was assessed in 16 RCTs.41,74–81,83,95,97,100–102,141 Eleven RCTs were identified from reviews41,74–83
and five from the literature search.95,97,100–102 The doses evaluated were 10, 20 or 40mg per day or
90mg once weekly. Comparators included placebo, other SSRIs, clomipramine, fluoxetine plus tadalafil,
and behavioural therapies (stop–start/squeeze technique). Duration ranged from 4 to 12 weeks.
l Fluvoxamine was assessed in one RCT at a dose of 20mg for 6 weeks, compared with placebo and
other SSRIs (Waldinger et al.,81 identified from a review).
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TABLE 11 Selective serotonin reuptake inhibitors currently not licensed for PE: details of reviews and AMSTAR
quality score
Author
(country),
review type
Databases searched and
dates Included RCTs relevant to this section
AMSTAR review
quality assessment
Cong et al.
2012,64 (China),
systematic review
and meta-analysis
MEDLINE, EMBASE, PubMed,
Ovid, CENTRAL, CBM and
CNKI database July 1996 to
May 2012
Kara et al. 1996,75 Kim and Seo 1998,76
Mattos et al. 2008,141 Panshou and
Xie 2004,80 Waldinger et al. 1998,81
Yilmaz et al. 199983
AMSTAR score, 3/11:
l comprehensive
literature search
l study quality
assessed
l publication
bias assessed
Huang et al.
200965 (China),
systematic review
and meta-analysis
MEDLINE, January 1950 to
March 2008; EMBASE,
January 1950 to March
2008; The Cochrane Library,
Issue I 2008; and CNKI,
January 1979 to March 2008
Atmaca et al. 2002,70 Atmaca et al.
2003,71 Biri et al. 1998,89 Kara et al.
1996,75 Kim and Seo 1998,76 Mattos et al.
2008,141 McMahon and Touma 1999,84
Mendels et al. 1995,90 Novaretti et al.
2002,79 Panshou and Xie 2004,80
Safarinejad and Hosseini 2006,72
Safarinejad 2006,85 Waldinger et al.
1998,81 Yilmaz et al. 1999,83 Zhou 200791
AMSTAR score, 1/11:
l study quality
assessed
McMahon and
Porst 201168
(Australia),
systematic review
PubMed 2004 Atmaca et al. 2002,70 Kara et al. 1996,75
Mattos et al. 2008,141 Novaretti et al.
2002,79 Waldinger et al. 1998,81
Waldinger et al. 200182
AMSTAR score, 2/11:
l characteristics of
included studies
reported
l conflict of interest
statement reported
Moreland and
Makela 200566
(USA), described
as a ‘mini review’
NR Atmaca et al. 2002,70 Biri et al. 1998,89
Kim and Seo 1998,76 Manasia et al.
2003,77 McMahon and Touma 1999,84
Mendels et al. 1995,90 Waldinger et al.
1997,87 Waldinger et al. 1998,81 Waldinger
et al. 2001,73 Waldinger et al. 200182
AMSTAR score, 0/11
Richardson
et al. 200569 (UK),
systematic review
MEDLINE, 1966 to January
2003 and PsycINFO, 1872 to
January 2003
Abdel-Hamid et al. 2001,39 Kara et al.
1996,75 Kim and Seo 1998,76 McMahon
and Touma 1999,84 Waldinger et al.
1997,87 Waldinger et al. 1998,81
Waldinger et al. 2001,82 Waldinger et al.
2001,73 Yilmaz et al. 199983
AMSTAR score, 1/11:
l characteristics of
included studies
reported
Waldinger et al.
200452 (the
Netherlands),
systematic review
MEDLINE (1966–2002),
Web of Science, PICA,
a and EMBASE (1980–2002)
Biri et al. 1998,89 Abdel-Hamid et al.
2001,39 Atmaca et al. 2002,70 Haensel
et al. 1998,74 Kara et al. 1996,75 Kim and
Seo 1998,76 Kolomaznik et al. 2002,41
McMahon and Touma 1999,84 Novaretti
et al. 2002,79 Waldinger et al. 1994,86
Waldinger et al. 1997,87 Waldinger et al.
1998,81 Waldinger et al. 2001,73
Waldinger et al. 2001,82 Waldinger et al.
2003,88 Yilmaz et al. 199983
AMSTAR score, 1/11:
l characteristics of
included studies
reported
Wang et al.
200767 (China),
systematic review
MEDLINE 1 January 1996 to
1 August 2006
Atmaca et al. 2003,71 McMahon 1998,166
McMahon and Touma 1999,84 Murat
Basar et al. 1999,78 Safarinejad and
Hosseini 2006,72 Waldinger et al. 2001,82
Waldinger et al. 2001,73 Waldinger et al.
2003,88 Yilmaz et al. 199983
AMSTAR score, 0/11
CBM, Chinese Biomedical Literature database; CENTRAL, Cochrane Central Register of Controlled Trials; CNKI, China
National Knowledge Infrastructure; NR, not reported.
a Acronym not defined in original study.
AMSTAR review quality criteria: a priori design, duplicate study selection and data extraction; comprehensive literature
search of databases and other supplementary sources; studies included regardless of publication type; list of studies
(included and excluded); characteristics of included studies reported; study quality assessed; study quality used to informed
conclusions; appropriate methods used to pool data; publication bias assessed; and conflict of interest statement included.
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l Paroxetine was assessed in 13 RCTs.39,73,81,82,84–88,97,103,104,105 Nine RCTs were identified from
reviews39,73,81,82,84–88 and four from the literature search.97,103,104,105 Doses were 20mg or 40mg
(usually 20mg as a daily dose). Comparators included placebo, other SSRIs, clomipramine, sildenafil,
mirtazapine, nefazodone (Serzone, Bristol-Myers Squibb, discontinued 2005) and the squeeze
technique. Duration ranged from 4 to 12 weeks.
l Sertraline was assessed in 13 RCTs.39,76,78,81,82,89–92,102,106,107,166 Nine RCTs were identified from
reviews39,76,78,81,82,89–91,166 and four from the literature search.92,102,106,107 Doses ranged from 50mg to
200mg (usually 50mg as a daily dose). Comparators included placebo, other SSRIs, clomipramine,
sildenafil, terazosin, mirtazapine, PDE5 inhibitors and behavioural therapies.
Details of the treatments evaluated, definition of PE, IELT assessment method, other outcomes assessed,
study duration, along with the study country for the further RCTs not in reviews, and the overall study
quality assessment (AMSTAR for reviews and Cochrane risk of bias assessment34 for the RCTs not included
by reviews) are presented in Table 12.
Assessment of effectiveness: selective serotonin reuptake inhibitors – intravaginal
ejaculatory latency time outcomes
Previous reviews have pooled data from single-arm crossover studies with separate treatment arm studies
in a meta-analysis.64,65 Data from these trials39,74,76,79,84 have not been included in any meta-analysis of SSRIs
in this assessment report.
Intravaginal ejaculatory latency time – selective serotonin reuptake inhibitors compared
with placebo or no treatment
Intravaginal ejaculatory latency time: citalopram compared with placebo or no treatment Mean
IELT data with variance estimates were available for four RCTs.70–72,96 A high level of heterogeneity was
observed across these trials (I2= 99%, meta-analysis not undertaken). Three of the four trials70,72,96
demonstrated a significant improvement in IELT for citalopram compared with placebo after 8–12 weeks
(all p< 0.00001). The p-value for the between-group difference for one trial comparing citalopram with no
therapy71 was p< 0.00001 (Figure 7). Summary results for these, and all other meta-analyses, are
presented in Table 13.
Intravaginal ejaculatory latency time: escitalopram compared with placebo The between-group
difference in IELT in favour of escitalopram compared with placebo was significant for one RCT reporting
end of study mean values98 and one reporting geometric mean fold increase99 (both p< 0.0001)
(see Figure 7).
Intravaginal ejaculatory latency time: fluoxetine compared with placebo Meta-analysis of mean IELT
(minutes) at 3–12 weeks’ follow-up, based on six RCT comparisons of fluoxetine at 20mg or 40mg daily,
or 90mg weekly (n= 170), displayed low heterogeneity (I2= 0%). The pooled MD in IELT was 2.41 minutes,
significantly favouring fluoxetine [MD (fixed effect); 95% CI 2.10 to 2.73 minutes; p< 0.00001] (Figure 8).
Fluoxetine at 90mg weekly was compared with 20mg daily in one RCT.77 IELT outcomes were reported
without variance estimates or p-values. The between-group difference was reported as non-significant.
For the comparison of fluoxetine alone compared with fluoxetine plus PDE inhibitor (tadalafil) reported in
one RCT,141 refer to the section Phosphodiesterase-5 inhibitors.
Intravaginal ejaculatory latency time: fluvoxamine compared with placebo The between-group
difference in change from baseline values after 6 weeks of treatment for one RCT comparing fluvoxamine
with placebo81 was not significant (p= 0.98) (see Figure 7).
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Study or subgroup
Citalopram vs. placebo – end of study values
Citalopram vs. no therapy – change from baseline
Escitalopram vs. placebo – end of study values
Escitalopram vs. placebo – geometric mean fold increase
Fluvoxamine vs. placebo – change from baseline
Paroxetine vs. placebo – change from baseline (fixed effect)
Sertraline vs. placebo – end of study values
– 10 – 5
Favours
comparator
Favours
treatment
0 5 10
WeightMean SD Total
Treatment
Mean SD Total
Comparator MD
IV, random, 95% Cl
Atmaca 200270 20–60 mg 8 weeks
Farnia 200893 20 mg 8 weeks
Safarinejad 2006a72 20 mg 12 weeks
Shang 200796 20 mg 2 weeks
Subtotal (95% Cl)
24.8%
25.2%
24.8%
25.1%
100.0%
4.17
1.35
3.93
5.64
1.22
0.72
1.76
1.31
13
42
26
40
121
0.09
1.1
0.32
1.02
0.24
0.57
0.32
0.24
13
25
25
40
103
4.08 (3.40 to 4.76)
0.25 (–0.06 to 0.56)
3.61 (2.92 to 4.30)
4.62 (4.21 to 5.03)
3.13 (0.63 to 5.63)
Atmaca 200371 20–60 mg 8 weeks
Subtotal (95% Cl)
100.0%
100.0%
3.49 1.85 15
15
0.08 0.25 15
15
3.41 (2.47 to 4.35)
3.41 (2.47 to 4.35)
Nada 200998 10 mg 4 weeks
Subtotal (95% Cl)
100.0%
100.0%
6.8 0.4 15
15
5.6 0.7 15
15
1.20 (0.79 to 1.61)
1.20 (0.79 to 1.61)
Safarinejad 200799 10 mg 12 weeks
Subtotal (95% Cl)
100.0%
100.0%
4.9 8.6 128
128
1.4 2.34 126
126
3.50 (1.96 to 5.04)
3.50 (1.96 to 5.04)
Waldinger 199881 100 mg 6 weeks
Subtotal (95% Cl)
100.0%
100.0%
0.18 1.09 10
10
0.17 0.36 9
9
0.01 (–0.71 to 0.73)
0.01 (–0.71 to 0.73)
Safarinejad 2006b85 20 mg 12 weeks
Waldinger 199881 20 mg 6 weeks
Subtotal (95% Cl)
98.3%
1.7%
100.0%
5.65
7.67
8.11
19.02
105
10
115
0.35
0.17
1.07
0.36
100
9
109
5.30 (3.73 to 6.87)
7.50 (–4.29 to 19.29)
5.34 (3.79 to 6.89)
Biri 199889 50 mg 4 weeks
McMahon 199884 50 mg 4 weeks
Mendels 199590 50–200 mg 8 weeks
Waldinger 199881 50 mg 6 weeks
Zhou 200791 4 weeks
Subtotal (95% Cl)
14.2%
17.8%
9.9%
27.5%
30.6%
100.0%
4.74
3.1
4.45
1.6
3.15
4.26
3.42
5.14
1.36
1.33
22
19
22
12
24
99
1.18
0.2
0.75
0.17
0.09
1.42
0.52
3.22
0.36
0.31
15
18
22
12
22
89
3.56 (1.64 to 5.48)
2.90 (1.34 to 4.46)
3.70 (1.17 to 6.23)
1.43 (0.63 to 2.23)
3.06 (2.51 to 3.61)
2.72 (1.77 to 3.67)
MD
IV, random, 95% Cl
Test for subgroup differences: χ2 = 71.62, df = 6 (p < 0.00001), I 2 = 91.6%
Heterogeneity: τ2 = 0.69, χ2 = 12.80, df = 4 (p = 0.01); I 2 = 69%
Test for overall effect: z = 5.62 (p < 0.00001)
Heterogeneity: τ2 = 0.00, χ2 = 0.13, df = 1 (p = 0.72); I 2 = 0%
Test for overall effect: z = 6.74 (p < 0.00001)
Heterogeneity: τ2 = 6.43, χ2 = 327.69, df = 3 (p < 0.00001); I 2 = 99%
Test for overall effect: z = 2.46 (p = 0.01)
Heterogeneity: not applicable
Test for overall effect: z = 7.07 (p < 0.00001)
Heterogeneity: not applicable
Test for overall effect: z = 4.44 (p < 0.00001)
Heterogeneity: not applicable
Test for overall effect: z = 5.76 (p < 0.00001)
Heterogeneity: not applicable
Test for overall effect: z = 0.03 (p = 0.89)
FIGURE 7 Selective serotonin reuptake inhibitors compared with placebo or no treatment: forest plot of IELT
outcomes. df, degrees of freedom; IV, inverse variance; M–H, Mantel–Haenzel; SD, standard deviation.
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Intravaginal ejaculatory latency time: paroxetine compared with placebo Meta-analysis of mean
change from baseline IELT (minutes) at 6 or 12 weeks’ follow-up, based on two RCT comparisons of
paroxetine at 20mg (n= 70), displayed low heterogeneity (I2= 0%). The pooled MD in IELT was
5.34 minutes, significantly favouring paroxetine [MD (fixed effect); 95% CI 3.79 to 6.89 minutes;
p< 0.00001] (see Figure 7).
Intravaginal ejaculatory latency time: sertraline compared with placebo Meta-analysis of mean IELT
(minutes) at 4, 6 or 8 weeks’ follow-up, based on five RCT comparisons of sertraline at 50mg to 200mg
(n= 164), displayed moderate heterogeneity (I2= 64%). The pooled MD in IELT was 2.72 minutes
[MD (random effects); 95% CI 1.77 to 3.67 minutes; p< 0.00001] (see Figure 7).
Intravaginal ejaculatory latency time: selective serotonin reuptake inhibitors compared
with other selective serotonin reuptake inhibitors or other treatments
Intravaginal ejaculatory latency time: paroxetine compared with citalopram Waldinger et al.73
reported a fold increase in IELT for paroxetine 20mg of 8.9-fold and for citalopram 20mg of 1.8-fold. The
fold was reported to be statistically significant increase for paroxetine (p< 0.001), but not for citalopram
(p= 0.07). No variance estimates were reported.
Intravaginal ejaculatory latency time: paroxetine compared with clomipramine The p-value for the
between-group difference for one trial comparing a geometric mean fold increase between paroxetine and
clomipramine105 was 2.29-fold [MD (random effects); 95% CI 1.61 to 2.97; p< 0.00001] in favour of
clomipramine (figure not presented).
Assessment of effectiveness: selective serotonin reuptake inhibitors – other outcomes
Outcomes other than IELT were reported across the RCTs using a diversity of instruments (which were
sometimes not reported) and outcome data. In a large proportion of the RCTs, a variance estimate for the
outcome was not reported. Either p-values were not available or it was unclear if reported p-values were
for between- or across-group comparisons (Table 14).
Citalopram Sexual satisfaction and intercourse satisfaction appeared improved in two RCTs compared
with placebo.92,96 The number of intercourse episodes per week also improved after treatment with
citalopram in one RCT.72 The proportion of patients reported as ‘much improved’ and ‘very much
improved’ on a subjective measure of clinical improvement was greater with citalopram than placebo in
one RCT.70 One trial reported a significant between-group difference in favour of citalopram compared
with placebo on the CIPE93 (see Table 14).
Escitalopram There was no between-group difference in escitalopram compared with placebo on the
CIPE overall score at weeks 2, 4 or 6 in one RCT.98 Intercourse satisfaction was reported as significantly
improved at 3 and 6 months with escitalopram in one RCT99 (see Table 14).
Fluoxetine The number of thrusts before ejaculation appeared greater with fluoxetine than placebo in
one RCT.100 Sexual satisfaction appeared improved with fluoxetine in two crossover RCTs compared with
placebo.78,79 There was no apparent between-group difference in sexual satisfaction between fluoxetine
20mg daily or 90mg weekly.77 One RCT suggested an improvement in sexual satisfaction with fluoxetine
30mg, compared with 20mg, sertraline at 50mg or 100mg, or the squeeze technique.102 One RCT
suggested that there is no difference in change on the AIPE between fluoxetine and escitalopram97
(see Table 14).
Fluvoxamine No data were available.
Paroxetine Sexual satisfaction and IIEF satisfaction scores appeared improved with paroxetine when
compared with placebo in two RCTs85,104 (see Table 14).
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TABLE 14 Selective serotonin reuptake inhibitors currently not licensed for PE: outcomes other than IELT
RCT, duration Treatment Outcome measure Results
Between-group
difference
significant
Citalopram vs. placebo or no therapy
Atmaca et al. 2002,70
8 weeks
Citalopram
20–60mg/day
(n= 13)
CGI-I Citalopram ‘much
improved’, 4/13; (30.8%);
’very much improved’, 5/13
(38.5%). Placebo ‘much
improved’, 1/13 (7.7%)
Unclear
Placebo (n= 13) YSFI-II Improved significantly with
citalopram, compared with
placebo (p-value NR)
Yes
Sexual satisfaction n/N ‘yes’: citalopram 9/13,
placebo 1/13
Unclear
Farnia et al. 2008,93
4 weeks
Citalopram 20mg
4 hours precoitus
(n= 49)
CIPE CIPE between-group
difference in IELT change
from baseline at week 4,
p= 0.002
Yes
Placebo (n= 43)
Safarinejad and
Hosseini 2006,72
12 weeks
Citalopram 20mg
(n= 26)
IIEF: intercourse
satisfaction domain
n/N ‘yes’: citalopram 23/26
(88.4%), placebo 10/25
(40.0%)
Yes
Placebo (n= 25) Intercourse episodes
per week
Significantly improved,
citalopram (no p-value)
Shang et al. 2012,96
duration NR
Citalopram
20mg/day (n= 40)
Sexual satisfaction Mean (assume SD):
citalopram – week 2,
p< 0.01; week 4, p< 0.01
Yes
Placebo (n= 40) Placebo – week 2, p-value
NR; week 4, p> 0.05
Escitalopram vs. placebo
Nada et al. 2012,94
2, 4 and 6 weeks’
treatment
Escitalopram 10mg
(n= 30)
CIPE overall score Between-group difference:
week 2, p= 0.51; week 4,
p= 0.27; week 6, p= 0.32;
3-month post-treatment
follow-up, p= 0.10
No
Citalopram 20mg
(n= 30)
Safarinejad 2007,99
12 weeks
Escitalopram
10mg/day (n= 138)
Weekly coitus
episodes
NR
Placebo (n= 138) IIEF intercourse
satisfaction
Escitalopram: 12 weeks
p= 0.01; 3 months
p= 0.01; 6 months
p= 0.01. Placebo:
12 weeks p=NS; 3 months
p=NS; 6 months p=NS
Yes
Sexual satisfaction Between-groups: ‘satisfied’,
p≤ 0.001; ‘moderately
satisfied’, p=NS;
‘dissatisfied’, p≤ 0.001
Yes
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TABLE 14 Selective serotonin reuptake inhibitors currently not licensed for PE: outcomes other
than IELT (continued )
RCT, duration Treatment Outcome measure Results
Between-group
difference
significant
Fluoxetine vs. placebo
Ahn et al. 1996,100
6 weeks
Fluoxetine
40mg/day (n= 12)
Questionnaire
assessing number of
thrusts before
ejaculation, frequency
of coitus, libido and
side effects of
treatment
Number of patients with
< 30/≥ 30 thrusts before
ejaculation: fluoxetine,
from baseline at 3 and at
6 weeks p< 0.05. Placebo
change from baseline at
3 and at 6 weeks p> 0.05
Yes
Placebo (n= 11)
Novaretti et al.
2002,79 crossover
8 weeks
Fluoxetine 20mg
once daily
Sexual satisfaction n/N ‘yes’: fluoxetine 34/50
(68%), placebo 5/50 (10%)
Unclear
Placebo once daily Hamilton Anxiety and
Depression Scale;
Beck Depression
Inventory
p-value between groups
NR
Total n= 50 NR
Fluoxetine vs. other treatments
Arafa and Shamloul
2007,97 4 weeks
Fluoxetine 20mg
(n= 33)
AIPE AIPE domains with change
from baseline p< 0.05 all
groups
Unclear
Escitalopram 10mg
(n= 37)
Frequency of
intercourse
NR
Paroxetine 20mg
(n= 30)
Culba et al. 2008,101
10 weeks
Fluoxetine
20mg/day
IIEC Patients who were treated
with fluoxetine+ tadalafil
had better scores with both
questionnaires
Unclear
Tadalafil+ fluoxetine PE question of
CMASH
questionnaire
Difference was NS
compared with fluoxetine
group. No data reportedTadalafil 20mg
2/weeks
Placebo
(Total n= 180)
Kim and Seo 1998,76
each agent for
4 weeks, with 1-week
washout
Fluoxetine 40mg Patient and partner
sexual satisfaction:
patient self-reported
questionnaire
n/N ‘yes’: fluoxetine 23/36
(88.4%); sertraline 28/36
(77.7%); placebo 17/36
(47.2%); greater with
clomipramine (NR)
Unclear
Sertraline 100mg p-value between groups
NR
Clomipramine
50mg
Placebo
Total n= 36
Murat Basar 1999,78
4 and 8 weeks
Fluoxetine 40mg
(n= 26)
The results were
classified as
unsuccessful,
improvement and
cure
Fluoxetine and sertraline,
had the same efficacy. No
data or p-value reported
Unclear
Sertraline 50mg
(n= 31)
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TABLE 14 Selective serotonin reuptake inhibitors currently not licensed for PE: outcomes other
than IELT (continued )
RCT, duration Treatment Outcome measure Results
Between-group
difference
significant
Weixing et al.
2012,102 6 and
12 weeks
Fluoxetine 20 or
30mg
Sexual satisfaction Sexual satisfaction was
increased significantly in
fluoxetine 30mg. p-value
NR
Unclear
Sertraline 50 or
100mg
Squeeze technique
Total n= 104
Fluoxetine different doses
Manasia et al. 2003,77
Duration NR
Fluoxetine 90mg
weekly (n= 40)
Sexual satisfaction
ratings
Sexual satisfaction ratings
did not significantly differ
between the two groups.
No data or p-value
reported
Unclear
Fluoxetine 20mg
daily (n= 40)
Paroxetine vs. placebo
Khelaia et al. 2012,104
4 weeks
Paroxetine
20mg/day (n= 26)
IIEF, intercourse
satisfaction, overall
satisfaction
Mean IIEF intercourse
satisfaction scores
Unclear
Paroxetine 20mg
2–3 hours precoitus
(n= 28)
Mean IIEF overall
satisfaction scores:
p< 0.001, but unclear if
change from baseline or
for which group
comparison
Placebo (n= 24)
Safarinejad 2006,85
12 weeks
Paroxetine 20mg
(n= 113)
Sexual satisfaction Sexual satisfaction assume
n/N ‘yes’: paroxetine
97/105, placebo 30/100
Unclear
Placebo (n= 112) p-value for between-group
difference NR
Dapoxetine 60mg
(n= 115)
Sertraline vs. placebo
Arafa and Shamloul
2007,106 crossover
4 weeks per
treatment
Sertraline 50mg/day AIPE Sertraline vs. baseline or
placebo, p< 0.05
Yes
Placebo Frequency of
intercourse –
assessment method
NR
Between-group (sertraline
vs. placebo) difference in
overall AIPE score,
p< 0.001
Yes
Total n= 77 Between-group (sertraline
vs. placebo), change from
other study phases,
p> 0.05
Mendels et al.
1995,90 8 weeks
Sertraline
50–200mg (n= 22)
Patient and partner
satisfaction measured
using a numbered
scale
Improved during the
treatment period in the
sertraline group. No data
or p-value reported
Unclear
Placebo (n= 22)
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TABLE 14 Selective serotonin reuptake inhibitors currently not licensed for PE: outcomes other
than IELT (continued )
RCT, duration Treatment Outcome measure Results
Between-group
difference
significant
Sertraline vs. other treatments
Abdel-Hamid et al.
2001,39 4 weeks
Sertraline 50mg EDITS (scale 0–5):
sexual satisfaction
score
Unclear if reported values
are means or medians.
No variance estimates or
p-values reported
Unclear
Paroxetine 20mg Arabic Anxiety
Inventory (scale 0–30)
Unclear if reported values
are means or medians.
No variance estimates or
p-values reported
Clomipramine
25mg
Sildenafil 50mg
Squeeze technique
Total n= 31
Akgül et al. 200892 Sertraline 50mg/day
(n= 40)
IPE Between-group difference
at 8 weeks: p= 0.50
No
Citalopram
20mg/day (n= 40)
Tuncel et al. 2008,107
treatment was for
2 months
Sertraline 50mg/day
(n= 23)
Clinical responses
(assume control
of ejaculation),
self-assessed
Patients reporting ‘no
change’, ‘improvement’,
‘under control’. All three
treatments ‘superior to
placebo’: p= 0.001
Yes compared
with placebo
Clomipramine
25mg/day (n= 20)
No significant difference in
efficacy between ‘medical
treatments’: p= 0.537
Terazosin 5 mg/day
(n= 25)
Placebo (n= 22)
Studies with no data on other outcomes reported
RCT Treatments
Citalopram
Atmaca et al. 200371 Citalopram, no therapy
Escitalopram
Nada et al. 200998 Escitalopram, placebo
Fluoxetine
Haensel et al. 199874 Fluoxetine, placebo
Kara et al. 1996,75 Panshou and Xie 2004,80 Yilmaz et al. 199983 Fluoxetine, stop–start, placebo
Kolomaznik et al. 200241 Fluoxetine, tadalafil, fluoxetine+ tadalafil,
placebo
Mattos et al. 2008141 Fluoxetine, citalopram
Fluvoxamine
Rezakhaniha et al. 201095 Fluvoxamine, fluoxetine, paroxetine, sertraline,
placebo
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
62
Sertraline A significant between-group difference between sertraline and placebo on the AIPE and the
frequency of intercourse was reported in one crossover study.106 Patient and partner satisfaction improved
during the treatment period in the sertraline group in one RCT.90 A significant difference between
sertraline and placebo on ejaculation control was reported by one RCT.107 The same RCT reported that
sertraline was comparable to both clomipramine and terazosin on this outcome. One RCT reported no
significant between-group difference in sertraline or citalopram on the IPE92 (see Table 14).
Assessment of safety: selective serotonin reuptake inhibitors – adverse events
summarised by existing reviews
The systematic review by Huang et al.65 reported a summary table of the incidence of AEs for citalopram,
fluoxetine, paroxetine and sertraline across the included studies. These data are adapted in Table 15. From
these data, AEs affecting > 5% of patients appear to be:
l citalopram: insomnia and nausea
l fluoxetine: headache, insomnia, nausea, somnolence, erectile dysfunction, libido decrease
l paroxetine: nausea and diarrhoea
l sertraline: headache, dry mouth, dizziness, insomnia, nausea, somnolence, diarrhoea, anejaculation.
However, these data were reported by Huang et al.65 as the overall number of incidents across included
studies by AE as opposed to being reported for each included study. Therefore, it is unclear which of the
included RCTs and single-arm randomised crossover trials contribute to the numbers in each AE. Thus, the
differences in event rates may reflect the differences across the studies included by Huang et al.65
Assessment of safety: selective serotonin reuptake inhibitors – adverse events for
individual randomised controlled trials
Adverse event data were not available for 1441,71,72,74,84–88,90,91,94,96,98 out of the 4239,41,70–107,141,166 included
RCTs evaluating SSRIs (Table 16). When AE data were reported, it was often unclear how many patients
suffered AEs, what the AEs were or which group the AEs related to. Reporting of how many patients
withdrew owing to AEs was limited across trials.
TABLE 14 Selective serotonin reuptake inhibitors currently not licensed for PE: outcomes other
than IELT (continued )
RCT, duration Treatment Outcome measure Results
Between-group
difference
significant
Paroxetine
Waldinger et al. 199787 Paroxetine 20mg, paroxetine 40mg
Waldinger et al. 199881 Paroxetine, placebo
McMahon and Touma 1999,84 Waldinger et al. 199486 Paroxetine, clomipramine
Waldinger et al. 2004105 Paroxetine, citalopram
Waldinger et al. 200173 Paroxetine, sertraline, nefazodone, placebo
Waldinger et al. 200182 Paroxetine, mirtazapine
Waldinger et al. 200386 Paroxetine different doses
Sertraline
Giammusso et al. 1997,103 Waldinger et al. 1997,87 Biri et al. 1998,89
McMahon 1998,166 Zhou 200791
Sertraline, placebo
CGI-I, Clinical Global Impression – Improvement; CMASH, Center for Marital and Sexual Health; IIEC, International Index of
Ejaculatory Control; NR, not reported; NS, not significant; SD, standard deviation; YSFI-II, Yonsei Sexual Function Inventory-II.
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TABLE 16 Selective serotonin reuptake inhibitors currently not licensed for PE: AE data from
individual studies
RCT, duration Treatment AEs
Citalopram vs. placebo or no therapy
Atmaca et al. 2002,70
8 weeks
Citalopram 20–60mg (n= 13) Nausea and headache were reported in three subjects.
Unclear which group
Placebo (n= 13)
Atmaca et al. 2003,71
8 weeks
Citalopram 20–60mg (n= 15) NR
No therapy (n= 15)
Farnia et al. 2008,93
4 weeks
Citalopram 20mg (n= 49) Twelve patients overall left the study (seven citalopram, five
placebo). Five owing to headache and nausea (n by group
NR). No other AE data reportedPlacebo (n= 43)
Safarinejad and Hosseini
200672
Citalopram vs. placebo NR
Shang et al. 201296 Citalopram vs. placebo Treatment duration NR
Escitalopram vs. placebo
Nada et al. 2009,98
1 month
Escitalopram 10mg (n= 15) NR
Placebo (n= 15)
Nada et al. 2012,94
2, 4 and 6 weeks’
treatment
Escitalopram 10mg (n= 30) NR
Citalopram 20mg (n= 30)
Safarinejad 2007,99
12 weeks
Escitalopram 10mg (n= 138) Escitalopram – 12/128 (9.4%) treatment-related AEs: nausea,
6/128 (4.7%); headache, 5/128 (3.9%); dry mouth, 4/128
(3.1%); diarrhoea, 4/128 (3.1%). Insomnia, drowsiness and
dizziness were reported by < 1%. Four patients (3.1%)
withdrew because of AEs (nausea, two; diarrhoea, one;
headache, one)
Placebo (n= 138) Placebo – 7/128 (5.5%) treatment-related AEs. Erectile
dysfunction, 3/126 (2%). Two (1.6%) withdrew
More AEs with escitalopram (p= 0.04)
Fluoxetine vs. placebo
Ahn et al. 1996,100
6 weeks
Fluoxetine 40mg (n=12) n/N (%) patients experiencing AEs: mild fatigue or yawning,
3/12 (25%); severe fatigue, 2/12 (16.7%); gastrointestinal
discomfort, 0/12 (0%)
Placebo (n= 11) n/N (%) patients experiencing AEs: mild fatigue or yawning,
0/11 (0%); severe fatigue, 1/11 (9.1%); gastrointestinal
discomfort, 1/11 (9.1%)
Haensel et al. 1998,74
4-week periods
Fluoxetine 10mg NR
Placebo (total n= 15)
Kara et al. 1996,75
4 weeks
Fluoxetine 40mg (n= 9) Two patients stopped because of side effects. Side effects
were not described and it was unclear to which group these
patients belongedPlacebo (n= 8)
Novaretti et al. 2002,79
crossover 8 weeks
Fluoxetine 20mg once daily Drowsiness (30%), headache (14%), insomnia (6%),
decreased libido (4%), dry mouth (2%), dizziness (2%).
Unclear if number of events or patients. Significant
differences from placebo were noted
Placebo once daily
(total n= 50)
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TABLE 16 Selective serotonin reuptake inhibitors currently not licensed for PE: AE data from
individual studies (continued )
RCT, duration Treatment AEs
Panshou and Xie 2004,80
12 weeks
Fluoxetine 20mg (n= 24) n/N experiencing AEs: fluoxetine, 7/24 (29%); placebo, 0/20
(0%)
Placebo (n= 20)
Yilmaz et al. 1999,83 Fluoxetine 20mg d (n= 20) n/N experiencing AEs: fluoxetine, 10/20 (50%); placebo, 1/20
(5%)
Placebo (n= 20)
Fluoxetine vs. other treatments
Arafa and Shamloul
2007,97 4 weeks
Fluoxetine 20mg (n= 33) Drowsiness, anorexia and insomnia occurred in three patients
on fluoxetine and three patients on escitalopram. Five
patients on paroxetine complained of somnolenceEscitalopram 10mg (n= 37)
Paroxetine 20mg (n= 30)
Culba et al. 2008,101
10 weeks
Fluoxetine Minor side effects due to tadalafil and fluoxetine were
temporary. No data reported
Tadalafil+ fluoxetine
Tadalafil
Placebo (total n= 180)
Kim and Seo 1998,76
each agent 4 weeks,
1-week washout
Fluoxetine 40mg Percentage experiencing AEs: fluoxetine 40mg, 13%;
sertraline 100mg, 12%; clomipramine 50mg, 23%; placebo,
NR. p-value for clomipramine compared with sertraline and
fluoxetine, p< 0.05. No other p-values reported
Sertraline 100mg
Clomipramine 50mg
Placebo (total n= 36)
Fluoxetine vs. other treatments
Kolomaznik et al.
2002,41 8 weeks
Fluoxetine NR
Stop–start technique
Placebo (total n= 93)
Mattos et al. 2008,141
4 weeks
Fluoxetine 90mg/week
(n= 15)
Fluoxetine: yawning and somnolence (three patients),
asthenia (three patients), nausea (one patient)
Tadalafil 20mg
daily+ fluoxetine 90mg
(n= 15)
Fluoxetine+ tadalafil: yawning and somnolence (three
patients), nausea (two patients) palpitation (one patient),
muscle soreness (one patient)
Tadalafil (n= 15) Tadalafil: headache (three patients), facial redness
(two patients), palpitations (two patients)
Placebo (n= 15)
Murat Basar et al.
1999,78 4 and 8 weeks
Fluoxetine 40mg (n= 26) Sertraline, fluoxetine had the same side effects. No data or
p-value reported
Sertraline 50mg (n= 31)
Rezakhaniha and
Sirosbakht 2010,95
4 weeks
Fluoxetine 40mg Five patients withdrew owing to drug side effects such as
headache, dizziness, insomnia and diarrhoea (NR which
group)Citalopram 40mg d
Weixing et al. 2012,102
6 and 12 weeks
Fluoxetine 20mg AEs with fluoxetine and sertraline were drowsiness,
headache, insomnia and diarrhoea. No data or p-values
reportedFluoxetine 30mg
Sertraline 50mg
Sertraline 100mg
Squeeze technique
(total n= 104)
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TABLE 16 Selective serotonin reuptake inhibitors currently not licensed for PE: AE data from
individual studies (continued )
RCT, duration Treatment AEs
Fluoxetine different doses
Manasia et al. 2003,77
duration NR
Fluoxetine 90mg weekly
(n= 40)
The occurrence of AEs did not significantly differ between the
two groups. No data or p-value reported
Fluoxetine 20mg daily
(n= 40)
Mattos et al. 2008,141
4 weeks
Fluoxetine 90 mg/week
(n= 15)
Fluoxetine: yawning and somnolence (three patients),
asthenia (three patients), nausea (one patient)
Tadalafil 20mg
daily+ fluoxetine 90mg
(n= 15)
Fluoxetine+ tadalafil: yawning and somnolence
(three patients), nausea (two patients) palpitation
(one patient), muscle soreness (one patient)
Tadalafil (n= 15) Tadalafil: headache (three patients), facial redness
(two patients), palpitations (two patients)
Placebo (n= 15)
Fluvoxamine vs. other treatments
Waldinger et al. 199881 Fluoxetine 20mg (n= 12) There were no statistically significant differences between the
active treatment groups and the placebo group with respect
to non-sexual side effects, including nausea and headache.
No data or p-value reported
Fluvoxamine 100mg (n= 12)
Paroxetine 20mg (n= 12)
Sertraline 50mg (n= 12)
Placebo (n= 12)
(all once daily)
Paroxetine vs. placebo
Khelaia et al. 2012,104
4 weeks
Paroxetine 20mg (n= 26) ‘Drug related side effects’ were headache, drowsiness,
nausea and dry mouth, but were mild an self-limited – n by
group NR. Decreased libido was reported by
four patients in the paroxetine daily group
Paroxetine on demand 20mg
(n= 28)
Placebo (n= 24)
McMahon and Touma
1999,84 crossover
(single-arm), duration
unclear
Study I: paroxetine 20mg vs.
placebo (total n= 26)
No AEs reported with paroxetine
Study II: paroxetine 20mg vs.
placebo (total n= 42)
Safarinejad 200685 Paroxetine vs. dapoxetine vs.
placebo
NR
Waldinger et al. 199486 Paroxetine vs. placebo NR
Paroxetine vs. other treatments
Waldinger et al. 200173 Paroxetine 20mg (n= 15) AEs were not significantly different between the treatment
groups. No data or p-value reported
Citalopram 20mg (n= 15) One patient discontinued on each treatment (two in total)
Waldinger et al. 200182 Paroxetine 20mg (n= 12) There were no statistically significant differences between the
active treatment groups and the placebo group with respect
to non-sexual side effects. No data or p-value reported
Sertraline 50mg (n= 12) Five did not complete because of side effects (paroxetine,
three; sertraline, one; nefazodone, one)
Nefazodone 400mg (n= 12)
Placebo (n= 12)
continued
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TABLE 16 Selective serotonin reuptake inhibitors currently not licensed for PE: AE data from
individual studies (continued )
RCT, duration Treatment AEs
Paroxetine vs. other treatments
Waldinger et al. 200388 Paroxetine (n= 12) NR
Mirtazapine (n= 12)
Waldinger et al. 2004,105
4 weeks
Paroxetine 20mg (n= 15) Difficulty concentrating, fatigue, sleepiness, restless, yawning,
tremor, dry mouth, nausea, vomiting, loose stools, constipation,
dizziness, perspiration, headache, decreased libido, difficulty
attaining and maintaining erection. Six (20%) did not complete
study: three owing to side effects (one on paroxetine, two on
clomipramine) and three for non-medical/logistic reasons.
Two drop-outs in first week, four in second week. Significant
between-group differences in non-sexual side effects of
treatment: day 1 sleepiness (more with paroxetine), p<0.005;
day one yawning (more with paroxetine), p<0.05; day 2
nausea (more with clomipramine), p<0.05
Clomipramine 25mg (n= 15)
Paroxetine different doses
Giammusso et al.
1997,103 3, 6 and
9 months
Paroxetine 20mg (n= 28) Paroxetine 20mg – one patient withdrew from study owing
to AEs (reported as ‘asentia’, unclear)
Paroxetine 20mg 10mg
(n= 34)
Paroxetine 10mg – non-serious AEs: nausea, sweating,
reduced libido, drowsiness (n NR)
Waldinger et al. 199787 Paroxetine 20mg vs. 40mg NR
Sertraline vs. placebo
Arafa and Shamloul
2007,106 crossover
4 weeks per treatment
Sertraline 50mg The authors report that sertraline was generally well
tolerated. Most side effects were minor and none prompted
withdrawal from the study. Drowsiness and anorexia occurred
in one patient out of 47 (0.7%) patient. Two patients (1.4%)
experienced minor gastrointestinal upset
Placebo (total n= 77)
Biri et al. 1998,89
8 weeks
Sertraline 50mg (n= 22) AEs not significantly different between groups. No data or
p-value reported. After treatment with sertraline was
discontinued, PE returned in 86.36% of patientsPlacebo (n= 15)
McMahon and Touma
199984
Sertraline vs. placebo NR
Mendels et al. 199590 Sertraline vs. placebo NR
Zhou 200791 Sertraline vs. placebo NR
Sertraline vs. other treatments
Abdel-Hamid et al.
2001,39 4 weeks
Sertraline 50mg Headache, flushing and nasal congestion: 18% of
participants in the sildenafil group (n NR). The incidence of
side effects was similar among groupsParoxetine 20mg
Clomipramine 25mg
Sildenafil 50mg
Squeeze technique
(total n= 31)
Akgül et al. 2008,92
8 weeks
Sertraline 50mg (n= 40) No serious AEs were detected in any of the patients. 3/40
patients (7.5%) in the citalopram group and 2/40 (5.0%)
in the sertraline group had mild nausea at the beginning of
the treatment
Citalopram 20mg (n= 40)
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Citalopram Nausea and headache were reported in two RCTs evaluating citalopram.70,91 However,
between-group differences with placebo groups were unclear.
Escitalopram One RCT reported that escitalopram was associated with nausea, headache, dry mouth,
diarrhoea, insomnia, drowsiness and dizziness and that significantly more AEs were experienced with
escitalopram than with placebo.99
Fluoxetine A significant between-group difference compared with placebo in drowsiness, headache,
insomnia, decreased libido, dry mouth and dizziness were reported by one crossover trial.79 In one RCT,100
more patients treated with fluoxetine than with placebo experienced mild/severe fatigue and yawning.
One crossover RCT reported that significantly more AEs were experienced with clomipramine than
fluoxetine,76 and one RCT reported that both fluoxetine and sertraline caused the same type of AEs.78
Fluvoxamine One trial reported that there were no statistically significant differences between
fluvoxamine, fluoxetine, paroxetine and sertraline in non-sexual side effects, including nausea
and headache.81
Paroxetine One RCT reported paroxetine-associated AEs of headache, drowsiness, nausea and dry
mouth,104 one reported that AEs were not significantly different between paroxetine and citalopram,73 one
reported that AEs were not significantly different between paroxetine and sertraline,82 and one reported
patients on paroxetine experiencing sleepiness and yawning early in treatment, whereas more patients on
clomipramine experienced nausea.105
Sertraline One RCT reported that sertraline was well tolerated and that drowsiness and anorexia were
minor.106 Tuncel et al.107 reported no significant differences between sertraline, clomipramine or terazosin
in the occurrence of headache, hypotension, drowsiness and ejaculation disorder.
Assessment of effectiveness: selective serotonin reuptake inhibitors – evidence summary
The current evidence base for SSRIs in the treatment of PE comprises 26 RCTs39,41,70–91,141,166 captured in
seven52,64–69 low methodological quality systematic reviews and 16 further RCTs,92–107 two95,103 of which are
at high risk of bias and 1492–94,96–102,104–107 care onsidered at unclear risk of bias.
Citalopram Evidence from three70,72,96 out of four70,72,93,96 separate RCTs suggests that citalopram is
significantly more effective than placebo in increasing IELT [MD 0.25 minutes (95% CI –0.06 to
0.56 minutes) to 4.62 minutes (95% CI 4.21 to 5.03 minutes); p< 0.00001]. However, a high level of
heterogeneity is evident across these four trials. Citalopram is significantly more effective than no therapy
(one RCT,71 30 participants). Evidence from four separate RCTs suggests that sexual satisfaction and
TABLE 16 Selective serotonin reuptake inhibitors currently not licensed for PE: AE data from
individual studies (continued )
RCT, duration Treatment AEs
Tuncel et al. 2008,107
2 months
Sertraline 50mg (n=23) n/N (%) reporting AEs were as follows. Clomipramine –
headache, 8/23 (34.8%); hypotension, 1/23 (4%); drowsiness,
2/23 (8.6%); ejaculation disorder, 0/23 (0%). Sertraline –
headache, 5/20 (25%); hypotension, 0/20 (0%); drowsiness,
3/20 (15%); ejaculation disorder, 0/20 (0%). Terazosin –
headache, 5/25 (20%); hypotension, 3/25 (12%); drowsiness,
0/25 (0%); ejaculation disorder, 2/25 (8%). Placebo –
headache, 2/22 (9.1%); hypotension, 0/22 (0%); drowsiness,
0/22 (0%); ejaculation disorder, 0/22 (0%). No significant
differences between the ‘medical treatment groups’ in
AEs – p=0.204
Clomipramine 25mg (n=20)
Terazosin 5mg (n= 25)
Placebo (n= 22)
NR, not reported.
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measures of clinical improvement are improved with citalopram.70,72,93,96 AEs with citalopram appear to be
nausea, headache, insomnia and dry mouth although the magnitude and severity are unclear.
Escitalopram Evidence from one RCT98 reporting end of study mean values (30 participants) and one
RCT99 reporting fold increase (i.e. by how many ‘fold’ the value in minutes at baseline had increased)
(254 participants) indicates that escitalopram is significantly more effective than placebo in increasing IELT
[MD 1.20 minutes (95% CI 0.79 to 1.61 minutes), p< 0.00001; geometric mean 3.50 minutes (95% CI
1.96 to 5.04 minutes), p< 0.00001]. Evidence from one RCT99 suggests that sexual satisfaction is improved
with escitalopram. Evidence from one RCT suggests that there is no significant between-group difference
for escitalopram compared with placebo on the Chinese Index of Sexual Function for PE scores.94 Evidence
from one RCT99 indicates that nausea, headache, dry mouth, diarrhoea, insomnia, drowsiness and dizziness
are reported more with escitalopram than with placebo.
Fluoxetine Pooled effects across six RCTs75,80,81,83,100,141 (170 participants) demonstrates that fluoxetine
daily or weekly is significantly more effective than placebo at increasing IELT over 4–12 weeks [MD
2.41 minutes (95% CI 2.10 to 2.73 minutes); p< 0.00001]. Evidence from one RCT suggests that sexual
satisfaction is improved with fluoxetine compared with placebo.79 One RCT102 suggests that sexual
satisfaction is improved with fluoxetine 30mg compared with either fluoxetine 20mg, sertraline at 50mg
or 100mg, or the squeeze technique. There is evidence from one RCT77 that there is no apparent
between-group difference in sexual satisfaction between fluoxetine 20mg daily and 90mg weekly.
Evidence from one crossover79 indicates that fluoxetine is associated with more drowsiness, headache,
insomnia, decreased libido, dry mouth and dizziness than placebo. Another crossover RCT78 indicates that
both fluoxetine and sertraline cause the same AEs, and a further crossover RCT indicates that more AEs are
experienced with clomipramine than with fluoxetine76 but that satisfaction ratings are greater with
clomipramine. Evidence summarised by one systematic review65 suggests that > 5% patients treated with
fluoxetine report headache, insomnia, nausea, somnolence, erectile dysfunction and libido decrease.
However, the review is of overall low methodological quality.
Fluvoxamine Evidence from one RCT95 (19 participants) indicates that there is no significant difference
between fluvoxamine and placebo in increase in IELT and that there is no significant differences between
fluvoxamine, fluoxetine, paroxetine and sertraline in non-sexual side effects, including nausea and headache.
Paroxetine Pooled evidence across two RCTs81,85 (70 participants) demonstrates that paroxetine 20mg is
significantly more effective than placebo at increasing IELT over 6–12 weeks [MD 5.34 minutes (95% CI
3.79 to 6.89 minutes); p< 0.00001]. However, evidence from one RCT105 (30 participants) indicates that
clomipramine is significantly more effective than paroxetine [2.29 minutes (95% CI 1.61 to 2.97 minutes);
p< 0.00001]. Two RCTs85,104 indicate that sexual satisfaction and IIEF satisfaction scores appear improved
with paroxetine compared with placebo. Paroxetine-associated AEs include headache, drowsiness, nausea
and dry mouth. One RCT82 indicates that there is no significant difference in the occurrence of these
events between paroxetine and sertraline. One RCT105 suggests that more patients on clomipramine than
those on paroxetine experience nausea early in treatment.
Sertraline Pooled effects across five RCTs79,81,84,89,90 (188 participants) suggest that sertraline 50mg is
significantly more effective than placebo at increasing IELT over 4–8 weeks [MD 2.72 minutes (95% CI
1.77 to 3.67 minutes); p< 0.00001]. However, a moderate level of heterogeneity is evident across these
trials. Evidence from one RCT107 suggests a significant improvement in ejaculation control with sertraline
compared with placebo. Evidence from one RCT106 also suggests a significant improvement over placebo
on the AIPE. One RCT106 suggests that there is no significant difference between sertraline or citalopram
on the IPE. One RCT90 suggests that both patient and partner satisfaction improved are improved with
sertraline. One RCT107 indicates no significant differences between sertraline, clomipramine and terazosin in
AEs including headache, hypotension, drowsiness and ejaculation disorder. Evidence summarised by one
systematic review65 suggests that > 5% patients treated with sertraline report headache, dry mouth,
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insomnia, nausea, somnolence, diarrhoea and anejaculation. However, the review is of overall low
methodological quality.
Selective serotonin reuptake inhibitors: evidence summary
There is evidence which suggests that, with the exception of fluvoxamine, SSRIs are more effective than
placebo at increasing IELT in men with PE. Sexual satisfaction measures and other secondary outcomes also
appear improved. However, the current evidence base comprises studies captured in low methodological
quality reviews and further RCTs that are of unclear and high risk of bias. In addition, the evidence base is
limited in terms of assessing the benefits of one SSRI compared with another SSRI in treating PE. AE data
suggest that SSRIs are associated with a number of AEs. However, the choice of an appropriate SSRI for
the treatment of PE in terms of a safety profile is unclear. Furthermore, long-term treatment effects and AE
outcomes in the treatment of men with PE are not fully evaluated in the current literature. The RCTs
evaluating SSRIs identified for inclusion in this assessment report evaluated treatments over 4 to 12 weeks
and none reported a long-term follow-up or the effects when treatment with SSRIs is withdrawn. This,
coupled with the limited treatment comparisons evaluated by RCTs assessing SSRIs (mainly placebo),
prohibits any definitive conclusions regarding an appropriate choice of SSRI in terms of efficacy and safety
for the treatment of men with PE.
Selective serotonin reuptake inhibitors licensed for premature
ejaculation (dapoxetine)
Characteristics of included studies: dapoxetine
Dapoxetine as the primary treatment of investigation was evaluated by four systematic reviews of
effectiveness,108–110,169 two of which pooled data in a meta-analysis.108,110 One systematic review evaluated
the risk–benefit assessment of dapoxetine including withdrawal data from Phase III trials,111 one review
evaluated dapoxetine Phase II trials including pharmacokinetic and safety data112 and two further
effectiveness reviews of SSRIs included studies of dapoxetine and other SSRIs.65,67 One further RCT was
identified that evaluated dapoxetine and dapoxetine plus a PDE5 inhibitor (mirodenafil).120
Reviews Of four systematic reviews of effectiveness of dapoxetine, one was undertaken in Australia,169
one was undertaken in Ireland109 and two were undertaken in China.108,110 The overall AMSTAR quality
score was 1 out of 11 in one of the reviews,108 2 out of 11 in two of the reviews,109,110 and 4 out of 11 in
one review.167 Details of the review type, the databases searched and dates, included RCTs and the
AMSTAR points awarded to these reviews of effectiveness are presented in Table 17. The two reviews
of SRRIs that included some of the dapoxetine trials both scored 0 out of 11.65,67 Details of these reviews
are presented in Table 11 in the Characteristics of included studies: selective serotonin reuptake inhibitors
section of this assessment report. Full details of the AMSTAR assessment for these and all other include
reviews are presented in Appendix 4. The search methodology and inclusion criteria for studies varied
across these. The two reviews including a meta-analysis108,110 both included different dosing arms from
studies separately in the meta-analysis, but included the comparator arm (placebo) against each dosing
arm, in effect counting participants twice in the analysis.
Randomised controlled trials included in reviews The reviews above varied in terms of which RCTs
they included. In total, eight RCT85,113–116,118,119,170 reports (one118 integrating data from two RCTs)
(total n= 6968) were included in at least one review of effectiveness. Seven RCTs were reported as being
Phase III RCTs,85,113,116,118,119,170 (Pryor et al.118 is an integrated analysis of two RCTs) and two RCTs as Phase II
studies.114,115 The IELT assessment method within the RCTs was not reported by any of the reviews.
Duration of the RCTs included in these reviews was 2–4 weeks for the two Phase II trials and 9–24 weeks
for the Phase III trials. The majority of the RCTs included within the reviews evaluated one or more dose
level of dapoxetine compared with placebo. Only one RCT also evaluated paroxetine;85 however, no data
for this comparison were reported in any review. This trial is also evaluated in the section Characteristics
of included studies: selective serotonin reuptake inhibitors. Across the reviews, the dapoxetine doses
evaluated were 20mg, 30mg, 40mg, 60mg and 100mg on demand. As dapoxetine at 30mg and 60mg
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has received approval for the treatment of PE in the UK,24 these doses were used in the present review for
analysis. One Phase II RCT evaluated doses of 20mg and 40mg and is not discussed further here.115
Details of the RCTs extracted from these reviews are presented in Table 18. All RCTs in reviews were
captured by the search strategy for this assessment report.
Randomised controlled trials not included in reviews The RCT by Lee et al.120 was conducted in the
Republic of Korea. Patients were randomised to dapoxetine 30mg plus mirodenafil 50mg per day (n= 63)
or dapoxetine 30mg plus placebo (n= 57). The trial was considered to be at overall low risk of bias.
This trial is also evaluated in the section Characteristics of included studies: selective serotonin
reuptake inhibitors.
Details of the treatments evaluated, definition of PE, IELT assessment method, other outcomes assessed,
study duration, along with the study country for the further RCTs not in reviews, and the overall study
quality assessment (AMSTAR33 for reviews and Cochrane risk of bias assessment34 for the RCTs not
included by reviews) are presented in Table 18.
TABLE 17 Selective serotonin reuptake inhibitors licensed for PE (dapoxetine): details of reviews and AMSTAR
quality score
Author (country),
review type Databases searched and dates
Included RCTs relevant to
this section
AMSTAR review quality
assessment
Luo et al. 2012108
(China), systematic
and meta-analysis
PubMed, BIOSIS Previews (now part
of the Web of Knowledge), The
Cochrane Library, CNKI, Wangfang
Database searched to 2011
Buvat et al. 2009,113
Kaufman et al. 2009,116
McMahon et al. 2010,170
Pryor et al. 2006118
AMSTAR score, 1/11:
l study quality assessed
McCarty and
Dinsmore 2012109
(Ireland), systematic
review
PubMed, the Cochrane Database of
Systematic Reviews, NHS Evidence
and NICE to August 2011. Start
date not reported
Buvat et al. 2009,113
Kaufman et al. 2009,116
McMahon et al. 2010,170
Safarinejad 2008119
AMSTAR score, 2/11:
l characteristics of
included studies
reported
l conflict of interest
statement reported
McMahon 2012169
(Australia), systematic
review
MEDLINE, Web of Science, PICA
and EMBASE 1993 to April 2012
Phase II studies: Hellstrom
et al. 2004,114 Hellstrom
et al. 2005115 Phase III
studies: Buvat et al. 2009,113
Kaufman et al. 2009,116
McMahon et al. 2010,170
Pryor et al. 2006118
AMSTAR score, 4/11:
l comprehensive
literature search
l studies included
regardless of
publication type
l characteristics of
included studies
reported
l conflict of interest
statement reported
Wang et al. 2010110
(China) systematic
and meta-analysis
The Cochrane Library, MEDLINE,
EMBASE, CNKI, CBM, Chinese
Science and Technology Periodical
Database (VIP) from 1979 to 2009
Buvat et al. 2009,113
Kaufman et al. 2008,116
Pryor et al. 2006,118
Safarinejad 2006,85
Safarinejad 2008119
AMSTAR score, 2/11:
l characteristics of
included studies
reported
l study quality assessed
CBM, Chinese Biomedical Literature database; CNKI, China National Knowledge Infrastructure; NICE, National Institute for
Health and Care Excellence.
a Acronym not defined in original study.
AMSTAR review quality criteria: a priori design, duplicate study selection and data extraction; comprehensive literature
search of databases and other supplementary sources; studies included regardless of publication type; list of studies
(included and excluded); characteristics of included studies reported; study quality assessed; study quality used to informed
conclusions; appropriate methods used to pool data; publication bias assessed; and conflict of interest statement included.
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Assessment of effectiveness: dapoxetine – intravaginal ejaculatory latency
time outcomes
Intravaginal ejaculatory latency time data were reported for six RCTs85,113–115,118,170 identified from existing
reviews and the one further RCT120 identified for inclusion in this review. The report by Pryor et al.118
comprised an integrated analysis of two RCTs. Data from this study have been evaluated as a single trial in
this assessment report. Three trials were not included in the IELT analysis in this assessment report: one
Phase II RCT that evaluated doses of 20mg and 40mg dapoxetine,115 one Phase II RCT for which no
variance estimates or appropriate p-values were reported114 and one Phase III RCT for which no IELT data
were available.116
Intravaginal ejaculatory latency time: dapoxetine 30mg or 60mg compared with placebo
Meta-analysis of mean IELT (minutes) at 12 or 24 weeks’ follow-up, based on three RCT113,118,170 comparisons
of dapoxetine 30mg and placebo (n= 3036), displayed low heterogeneity (I2=28%). The pooled MD in
IELT was 1.16 minutes, significantly favouring dapoxetine 30mg [MD (fixed effect); 95% CI 0.94 to
1.39 minutes; p< 0.00001]. Meta-analysis of mean IELT (minutes) at 12 or 24 -weeks’ follow-up, based on
five RCT85,113,118,119,170 comparisons of dapoxetine 60mg compared with placebo (n= 3390), displayed low
heterogeneity (I2= 0%). The pooled MD in IELT was 1.66 minutes, significantly favouring dapoxetine 30mg
[MD (fixed effect); 95% CI 1.46 to 1.87 minutes; p< 0.00001]. The forest plot for this analysis is presented
in Figure 9. Summary results for these and all other meta-analyses are presented in Table 19.
Intravaginal ejaculatory latency time: dapoxetine 30mg compared with dapoxetine 60mg
Meta-analysis of mean IELT (minutes) at 12 or 24 weeks’ follow-up, based on three RCT113,117,118
comparisons (n= 3005) displayed low heterogeneity (I2= 0%). The pooled MD in IELT was 0.46 minutes,
significantly favouring dapoxetine 60mg [MD (fixed effect); 95% CI 0.19 to 0.74 minutes; p= 0.0009].
The forest plot for this analysis is presented in Figure 10.
Intravaginal ejaculatory latency time: dapoxetine 30mg plus mirodenafil compared with
dapoxetine 30mg plus placebo The between-group difference in mean IELT (minutes) at 4 weeks,
based on one RCT120 (n= 118), was 1.50 minutes (95% CI –0.55 to 3.55 minutes; p=0.15). The between-
group difference in mean IELT (minutes) at 12 weeks, based on one RCT120 (n= 118), was 2.20 minutes
(95% CI –0.89 to 5.29 minutes; p=0.16). The forest plot for this analysis is presented in Figure 11.
Assessment of effectiveness: dapoxetine – outcomes other than intravaginal
ejaculatory latency time
With the exception of the RCTs by Safarinejad85 and Safarinejad,119 all Phase III RCTs and the RCT by
Lee et al.120 reported outcomes other than IELT. These outcomes included control over ejaculation, sexual
satisfaction, global impression of change and a composite criterion for clinical benefit. However, the
reporting of these outcomes varied across the included RCTs and differed in how the outcome was
assessed (either as mean scores or as numbers of participants achieving a threshold). Results for
between-group comparisons undertaken using RevMan for this assessment report for all secondary outcomes
are presented in Table 19. All RCTs reporting these outcomes evaluated dapoxetine over 9–24 weeks.
Control over ejaculation: dapoxetine 30mg and 60mg Mean scores for this outcome were available
for two Phase III RCTs.116,118 High heterogeneity was observed for dapoxetine 60mg compared with
placebo (two RCTs,116,118 I2 = 86%, meta-analysis not undertaken). Numbers of patients reporting a change
in this outcome were available for two Phase III RCTs.113,116 High heterogeneity was observed for
dapoxetine 60mg compared with placebo (two RCTs,113,116 I2= 76%, meta-analysis not undertaken).
Between-group comparisons from individual RCTs estimated in RevMan for this assessment report
(see Table 19) suggested that both dapoxetine 30mg and dapoxetine 60mg are significantly more
effective then placebo on this outcome (MD, p< 0.0001 and p< 0.0001; RR, p< 0.0001 and p< 0.0001)
and dapoxetine 60mg is significantly more effective than dapoxetine 30mg (MD, p= 0.0002; RR, p= 0.0008).
DOI: 10.3310/hta19210 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 21
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Cooper et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
75
St
u
d
y 
o
r 
su
b
g
ro
u
p
D
ap
o
xe
ti
n
e 
30
 m
g
 v
s.
 p
la
ce
b
o
 –
 e
n
d
 o
f 
st
u
d
y 
va
lu
es
, m
in
u
te
s
D
ap
o
xe
ti
n
e 
60
 m
g
 v
s.
 p
la
ce
b
o
 –
 e
n
d
 o
f 
st
u
d
y 
va
lu
es
, m
in
u
te
s
B
u
va
t 
20
09
11
3  
30
 m
g
 2
4 
w
ee
ks
M
cM
ah
o
n
 2
01
01
68
 3
0 
m
g
 1
2 
w
ee
ks
Pr
yo
r 
20
06
11
8  
30
 m
g
 1
2 
w
ee
ks
Su
b
to
ta
l (
95
%
 C
l)
1.
9
2.
4
1.
75
2.
89
2.
05
2.
21
33
9
34
2
78
7
14
68
14
.8
%
22
.6
%
62
.6
%
10
0.
0%
1.
20
 (
0.
61
 t
o
 1
.7
9)
1.
50
 (
1.
02
 t
o
 1
.9
8)
1.
03
 (
0.
74
 t
o
 1
.3
2)
1.
16
 (
0.
94
 t
o
 1
.3
9)
36
3
33
3
80
1
14
97
4.
88
3.
94
3.
48
3.
1
3.
9
2.
78
B
u
va
t 
20
09
11
3  
60
 m
g
 2
4 
w
ee
ks
M
cM
ah
o
n
 2
01
01
68
 6
0 
m
g
 1
2 
w
ee
ks
Pr
yo
r 
20
06
11
8  
60
 m
g
 1
2 
w
ee
ks
Sa
fa
ri
n
ej
ad
85
 2
00
6 
60
 m
g
 1
2 
w
ee
ks
Sa
fa
ri
n
ej
ad
11
9  
20
08
 6
0 
m
g
 1
2 
w
ee
ks
Su
b
to
ta
l (
95
%
 C
l)
1.
9
2.
4
1.
75
0.
92 2
2.
89
2.
05
2.
21
0.
67
1.
63
33
9
34
2
78
7
10
0 96
16
64
16
.7
%
18
.2
%
45
.5
%
10
.8
%
8.
8%
10
0.
0%
1.
60
 (
1.
10
 t
o
 2
.1
0)
1.
80
 (
1.
32
 t
o
 2
.2
8)
1.
57
 (
1.
27
 t
o
 1
.8
7)
2.
06
 (
1.
44
 t
o
 2
.6
8)
1.
50
 (
0.
81
 t
o
 2
.1
9)
1.
66
 (
1.
46
 t
o
 1
.8
7)
35
5
33
1
76
3
10
4 96
16
46
3.
8
3.
97
3.
68
3.
16 3
3.
5
4.
2
3.
32
2.
98 3.
5
–  2
– 1
Fa
vo
u
rs
p
la
ce
b
o
Fa
vo
u
rs
d
ap
o
xe
ti
n
e
0
1
2
M
ea
n
SD
To
ta
l
W
ei
g
h
t
Pl
ac
eb
o
M
ea
n
SD
To
ta
l
D
ap
o
xe
ti
n
e
M
D
IV
, fi
xe
d
, 9
5%
 C
l
M
D
IV
, fi
xe
d
, 9
5%
 C
l
H
et
er
o
g
en
ei
ty
: χ
2  =
 2
.5
2,
 d
f =
 4
 (
p
 =
 0
.6
4)
; I
 2  
=
 0
%
Te
st
 f
o
r 
o
ve
ra
ll 
ef
fe
ct
: z
 =
 1
5.
94
 (
p
 <
 0
.0
00
01
)
H
et
er
o
g
en
ei
ty
: χ
2  =
 2
.7
7,
 d
f =
 2
 (
p
 =
 0
.2
5)
; I
 2  
=
 2
8%
Te
st
 f
o
r 
o
ve
ra
ll 
ef
fe
ct
: z
 =
 1
0.
06
 (
p
 <
 0
.0
00
01
)
Te
st
 f
o
r 
su
b
g
ro
u
p
 d
if
fe
re
n
ce
s:
 χ
2  =
 1
0.
41
, d
f =
 1
 (
p
 =
 0
.0
01
),
 I 
2  =
 9
0.
4%
FI
G
U
R
E
9
D
ap
o
xe
ti
n
e
30
m
g
o
r
60
m
g
co
m
p
ar
ed
w
it
h
p
la
ce
b
o
:f
o
re
st
p
lo
t
o
f
IE
LT
o
u
tc
o
m
es
.
d
f,
d
eg
re
es
o
f
fr
ee
d
o
m
;
IV
,i
n
ve
rs
e
va
ri
an
ce
;
SD
,s
ta
n
d
ar
d
d
ev
ia
ti
o
n
.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
76
TA
B
LE
19
Se
le
ct
iv
e
se
ro
to
n
in
re
u
p
ta
ke
in
h
ib
it
o
rs
lic
en
se
d
fo
r
PE
(d
ap
o
xe
ti
n
e)
:
re
su
lt
s
su
m
m
ar
y
C
o
m
p
ar
is
o
n
O
u
tc
o
m
e
St
u
d
y
d
u
ra
ti
o
n
N
o
.o
f
R
C
Ts
N
o
.o
f
p
ar
ti
ci
p
an
ts
I2
M
et
a-
an
al
ys
is
(m
o
d
el
)
Ef
fe
ct
es
ti
m
at
e
(9
5%
C
I)
Fa
vo
u
rs
p
-v
al
u
e
IE
LT
D
ap
ox
et
in
e
30
m
g
vs
.
pl
ac
eb
o
IE
LT
(m
in
ut
es
)
–
fin
al
va
lu
es
12
–
24
w
ee
ks
31
13
,1
17
,1
18
30
36
28
%
Y
es
(f
ix
ed
)
M
D
1.
16
(0
.9
4
to
1.
39
)
D
ap
ox
et
in
e
30
m
g
<
0.
00
00
1
D
ap
ox
et
in
e
60
m
g
vs
.
pl
ac
eb
o
IE
LT
(m
in
ut
es
)
–
fin
al
va
lu
es
12
–
24
w
ee
ks
58
5
,1
13
,1
17
–
11
9
33
90
0%
Y
es
(f
ix
ed
)
M
D
1.
66
(1
.4
6
to
1.
87
)
D
ap
ox
et
in
e
60
m
g
<
0.
00
00
1
D
ap
ox
et
in
e
60
m
g
vs
.
da
po
xe
tin
e
30
m
g
IE
LT
(m
in
ut
es
)
–
fin
al
va
lu
es
12
–
24
w
ee
ks
31
13
,1
17
,1
18
30
05
0%
Y
es
(f
ix
ed
)
M
D
0.
46
(0
.1
9
to
0.
74
)
D
ap
ox
et
in
e
60
m
g
0.
00
09
30
m
g
+
m
iro
de
na
fil
vs
.
30
m
g
+
pl
ac
eb
o
IE
LT
(m
in
ut
es
)
–
fin
al
va
lu
es
12
w
ee
ks
11
20
12
0
N
/A
N
/A
M
D
2.
20
(–
0.
89
to
5.
29
)
N
S
0.
16
C
o
n
tr
o
l
o
ve
r
ej
ac
u
la
ti
o
n
–
m
ea
n
sc
o
re
s
D
ap
ox
et
in
e
30
m
g
vs
.
pl
ac
eb
o
C
on
tr
ol
ov
er
ej
ac
ul
at
io
n:
m
ea
n
sc
or
es
12
w
ee
ks
11
18
15
88
N
/A
N
/A
M
D
0.
60
(0
.5
0
to
0.
70
)
D
ap
ox
et
in
e
30
m
g
<
0.
00
00
1
D
ap
ox
et
in
e
60
m
g
vs
.
pl
ac
eb
o
C
on
tr
ol
ov
er
ej
ac
ul
at
io
n:
m
ea
n
sc
or
es
9–
12
w
ee
ks
21
16
,1
18
22
02
86
%
D
at
a
no
t
po
ol
ed
M
D
0.
77
(0
.6
7
to
0.
87
)
D
ap
ox
et
in
e
60
m
g
<
0.
00
00
1
M
D
0.
50
(0
.3
3
to
0.
67
)
<
0.
00
00
1
D
ap
ox
et
in
e
30
m
g
vs
.
da
po
xe
tin
e
60
m
g
C
on
tr
ol
ov
er
ej
ac
ul
at
io
n
m
ea
n
sc
or
es
12
w
ee
ks
11
18
15
64
N
/A
N
/A
M
D
–
0.
17
(–
0.
28
to
–
0.
06
)
D
ap
ox
et
in
e
60
m
g
0.
00
02
C
o
n
tr
o
l
o
ve
r
ej
ac
u
la
ti
o
n
–
p
at
ie
n
ts
re
p
o
rt
in
g
ch
an
g
e
D
ap
ox
et
in
e
30
m
g
vs
.
pl
ac
eb
o
C
on
tr
ol
ov
er
ej
ac
ul
at
io
n:
pa
tie
nt
s
re
po
rt
in
g
ch
an
ge
24
w
ee
ks
11
13
72
3
N
/A
N
/A
RR
2.
05
(1
.4
8
to
2.
84
)
D
ap
ox
et
in
e
30
m
g
<
0.
00
00
1
D
ap
ox
et
in
e
60
m
g
vs
.
pl
ac
eb
o
C
on
tr
ol
ov
er
ej
ac
ul
at
io
n:
pa
tie
nt
s
re
po
rt
in
g
ch
an
ge
9–
24
w
ee
ks
21
13
,1
16
13
69
76
%
D
at
a
no
t
po
ol
ed
RR
3.
00
(2
.2
1
to
4.
07
)
D
ap
ox
et
in
e
60
m
g
<
0.
00
00
1
RR
1.
95
(1
.4
6
to
2.
59
)
<
0.
00
00
1
D
ap
ox
et
in
e
30
m
g
vs
.
da
po
xe
tin
e
60
m
g
C
on
tr
ol
ov
er
ej
ac
ul
at
io
n:
pa
tie
nt
s
re
po
rt
in
g
ch
an
ge
24
w
ee
ks
11
13
71
2
N
/A
N
/A
RR
0.
68
(0
.5
5
to
0.
85
)
D
ap
ox
et
in
e
60
m
g
0.
00
08
co
nt
in
ue
d
DOI: 10.3310/hta19210 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 21
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Cooper et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
77
TA
B
LE
19
Se
le
ct
iv
e
se
ro
to
n
in
re
u
p
ta
ke
in
h
ib
it
o
rs
lic
en
se
d
fo
r
PE
(d
ap
o
xe
ti
n
e)
:
re
su
lt
s
su
m
m
ar
y
(c
o
n
ti
n
u
ed
)
C
o
m
p
ar
is
o
n
O
u
tc
o
m
e
St
u
d
y
d
u
ra
ti
o
n
N
o
.o
f
R
C
Ts
N
o
.o
f
p
ar
ti
ci
p
an
ts
I2
M
et
a-
an
al
ys
is
(m
o
d
el
)
Ef
fe
ct
es
ti
m
at
e
(9
5%
C
I)
Fa
vo
u
rs
p
-v
al
u
e
Se
xu
al
sa
ti
sf
ac
ti
o
n
–
m
ea
n
sc
o
re
s
D
ap
ox
et
in
e
30
m
g
vs
.
pl
ac
eb
o
Se
xu
al
sa
tis
fa
ct
io
n:
m
ea
n
sc
or
es
12
w
ee
ks
11
18
15
88
N
/A
N
/A
M
D
0.
51
(0
.4
1
to
0.
61
)
D
ap
ox
et
in
e
30
m
g
<
0.
00
00
1
D
ap
ox
et
in
e
60
m
g
vs
.
pl
ac
eb
o
Se
xu
al
sa
tis
fa
ct
io
n:
m
ea
n
sc
or
es
9–
12
w
ee
ks
21
16
,1
18
22
02
99
%
D
at
a
no
t
po
ol
ed
M
D
0.
61
(0
.5
0
to
0.
72
)
D
ap
ox
et
in
e
60
m
g
<
0.
00
00
1
M
D
0.
50
(0
.3
3
to
0.
67
)
<
0.
00
00
1
D
ap
ox
et
in
e
60
m
g
vs
.
da
po
xe
tin
e
30
m
g
Se
xu
al
sa
tis
fa
ct
io
n:
m
ea
n
sc
or
es
12
w
ee
ks
11
18
15
64
N
/A
N
/A
M
D
0.
10
(0
.0
0
to
0.
20
)
N
S
0.
06
Se
xu
al
sa
ti
sf
ac
ti
o
n
–
p
at
ie
n
ts
re
p
o
rt
in
g
ch
an
g
e
D
ap
ox
et
in
e
30
m
g
vs
.
pl
ac
eb
o
Se
xu
al
sa
tis
fa
ct
io
n:
pa
tie
nt
s
re
po
rt
in
g
ch
an
ge
24
w
ee
ks
11
13
29
8
N
/A
N
/A
RR
1.
36
(1
.1
4
to
1.
62
)
D
ap
ox
et
in
e
30
m
g
0.
00
07
D
ap
ox
et
in
e
60
m
g
vs
.
pl
ac
eb
o
Se
xu
al
sa
tis
fa
ct
io
n:
pa
tie
nt
s
re
po
rt
in
g
ch
an
ge
9–
24
w
ee
ks
48
5
,1
13
,1
16
,1
19
17
45
89
%
D
at
a
no
t
po
ol
ed
RR
1.
56
(1
.3
2
to
1.
80
)
D
ap
ox
et
in
e
60
m
g
<
0.
00
00
1
RR
1.
61
(1
.3
2
to
1.
98
)
<
0.
00
00
1
RR
4.
15
(2
.5
9
to
6.
63
)
<
0.
00
00
1
RR
4.
19
(2
.6
8
to
6.
55
)
<
0.
00
00
1
D
ap
ox
et
in
e
30
m
g
vs
.
da
po
xe
tin
e
60
m
g
Se
xu
al
sa
tis
fa
ct
io
n:
pa
tie
nt
s
re
po
rt
in
g
ch
an
ge
24
w
ee
ks
11
13
71
2
N
/A
N
/A
RR
0.
87
(0
.7
5
to
1.
00
)
D
ap
ox
et
in
e
60
m
g
0.
05
G
lo
b
al
im
p
re
ss
io
n
o
f
ch
an
g
e
–
p
at
ie
n
ts
re
p
o
rt
in
g
ch
an
g
e
D
ap
ox
et
in
e
30
m
g
vs
.
pl
ac
eb
o
G
lo
ba
li
m
pr
es
si
on
of
ch
an
ge
:
pa
tie
nt
s
re
po
rt
ch
an
ge
12
–
24
w
ee
ks
31
13
,1
17
,1
18
29
50
48
%
Y
es
(r
an
do
m
)
RR
2.
01
(1
.6
9
to
2.
38
)
D
ap
ox
et
in
e
30
m
g
<
0.
00
00
1
D
ap
ox
et
in
e
60
m
g
vs
.
pl
ac
eb
o
G
lo
ba
li
m
pr
es
si
on
of
ch
an
ge
:
pa
tie
nt
s
re
po
rt
ch
an
ge
9–
24
w
ee
ks
41
13
,1
16
–
11
8
35
66
57
%
Y
es
(r
an
do
m
)
RR
2.
26
(1
.9
1
to
2.
67
)
D
ap
ox
et
in
e
60
m
g
<
0.
00
00
1
D
ap
ox
et
in
e
30
m
g
vs
.
da
po
xe
tin
e
60
m
g
G
lo
ba
li
m
pr
es
si
on
of
ch
an
ge
:
pa
tie
nt
s
re
po
rt
ch
an
ge
12
–
24
w
ee
ks
31
13
,1
17
,1
18
29
50
0%
Y
es
(f
ix
ed
)
RR
0.
86
(0
.8
0
to
0.
90
)
D
ap
ox
et
in
e
60
m
g
<
0.
00
01
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
78
C
o
m
p
ar
is
o
n
O
u
tc
o
m
e
St
u
d
y
d
u
ra
ti
o
n
N
o
.o
f
R
C
Ts
N
o
.o
f
p
ar
ti
ci
p
an
ts
I2
M
et
a-
an
al
ys
is
(m
o
d
el
)
Ef
fe
ct
es
ti
m
at
e
(9
5%
C
I)
Fa
vo
u
rs
p
-v
al
u
e
C
o
m
p
o
si
te
cr
it
er
ia
fo
r
cl
in
ic
al
b
en
ef
it
–
p
at
ie
n
ts
re
p
o
rt
in
g
ch
an
g
e
D
ap
ox
et
in
e
30
m
g
vs
.
pl
ac
eb
o
C
om
po
si
te
cr
ite
ria
fo
r
cl
in
ic
al
be
ne
fit
:
pa
tie
nt
s
re
po
rt
in
g
ch
an
ge
12
–
24
w
ee
ks
21
13
,1
17
13
76
0%
Y
es
(f
ix
ed
)
RR
1.
71
(1
.4
0
to
2.
08
)
D
ap
ox
et
in
e
30
m
g
<
0.
00
00
1
D
ap
ox
et
in
e
60
m
g
vs
.
pl
ac
eb
o
C
om
po
si
te
cr
ite
ria
fo
r
cl
in
ic
al
be
ne
fit
:
pa
tie
nt
s
re
po
rt
in
g
ch
an
ge
9–
24
w
ee
ks
31
13
,1
16
,1
17
20
29
66
%
Y
es
(r
an
do
m
)
RR
2.
15
(1
.6
4
to
2.
82
)
D
ap
ox
et
in
e
60
m
g
<
0.
00
00
1
D
ap
ox
et
in
e
30
m
g
vs
.
da
po
xe
tin
e
60
m
g
C
om
po
si
te
cr
ite
ria
fo
r
cl
in
ic
al
be
ne
fit
:
pa
tie
nt
s
re
po
rt
in
g
ch
an
ge
12
–
24
w
ee
ks
21
13
,1
17
13
75
76
%
N
o
RR
0.
68
(0
.5
4
to
0.
85
)
D
ap
ox
et
in
e
60
m
g
0.
00
08
RR
0.
93
(0
.7
6
to
1.
14
)
N
S
0.
51
N
/A
,
no
t
ap
pl
ic
ab
le
;
N
S,
no
t
si
gn
ifi
ca
nt
.
DOI: 10.3310/hta19210 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 21
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Cooper et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
79
St
u
d
y 
o
r 
su
b
g
ro
u
p
B
u
va
t 
20
09
11
3  
24
 w
ee
ks
M
cM
ah
o
n
 2
01
01
68
 1
2 
w
ee
ks
Pr
yo
r 
20
06
11
8  
12
 w
ee
ks
19
.8
%
20
.7
%
59
.4
%
0.
40
 (
–0
.2
2 
to
 1
.0
2)
0.
30
 (
–0
.3
0 
to
 0
.9
0)
0.
54
 (
0.
18
 t
o
 0
.9
0)
38
9
33
1
76
3
To
ta
l (
95
%
 C
l)
15
22
10
0.
0%
0.
46
 (
0.
19
 t
o
 0
.7
4)
14
83
3.
8
3.
97
3.
68
3.
5
4.
2
3.
32
– 2
– 1
Fa
vo
u
rs
d
ap
o
xe
ti
n
e 
30
 m
g
Fa
vo
u
rs
d
ap
o
xe
ti
n
e 
60
 m
g
0
1
2
W
ei
g
h
t
M
ea
n
SD
To
ta
l
D
ap
o
xe
ti
n
e 
60
 m
g
38
8
33
3
80
1
4.
88
3.
94
3.
48
3.
1
3.
9
2.
78
M
ea
n
SD
To
ta
l
D
ap
o
xe
ti
n
e 
30
 m
g
M
D
IV
, fi
xe
d
, 9
5%
 C
l
M
D
IV
, fi
xe
d
, 9
5%
 C
l
H
et
er
o
g
en
ei
ty
: χ
2  =
 0
.5
0,
 d
f =
 2
 (
p
 =
 0
.7
8)
; I
 2  
=
 0
%
Te
st
 f
o
r 
o
ve
ra
ll 
ef
fe
ct
: z
 =
 3
.3
1 
(p
 =
 0
.0
00
9)
FI
G
U
R
E
10
D
ap
o
xe
ti
n
e
30
m
g
co
m
p
ar
ed
w
it
h
60
m
g
:f
o
re
st
p
lo
t
o
f
IE
LT
o
u
tc
o
m
es
.
d
f,
d
eg
re
es
o
f
fr
ee
d
o
m
;I
V
,i
n
ve
rs
e
va
ri
an
ce
;S
D
,s
ta
n
d
ar
d
d
ev
ia
ti
o
n
.
St
u
d
y 
o
r 
su
b
g
ro
u
p
Le
e 
20
12
12
0
Su
b
to
ta
l (
95
%
 C
l)
10
0.
0%
10
0.
0%
1.
50
 (
–0
.5
5 
to
 3
.5
5)
1.
50
 (
–0
.5
5 
to
 3
.5
5)
62 62
4-
w
ee
k 
fo
llo
w
-u
p
 v
al
u
es
 –
 m
in
u
te
s
6.
68
8.
2
–  4
– 2
D
ap
o
xe
ti
n
e 
+
p
la
ce
b
o
D
ap
o
xe
ti
n
e 
+
m
ir
o
d
en
af
il
0
2
4
W
ei
g
h
t
M
ea
n
SD
To
ta
l
D
ap
o
xe
ti
n
e  
+
 m
ir
o
d
en
afi
l
56 56
4.
55
6.
7
M
ea
n
SD
To
ta
l
D
ap
o
xe
ti
n
e 
+
 p
la
ce
b
o
M
D
IV
, fi
xe
d
, 9
5%
 C
l
M
D
IV
, fi
xe
d
, 9
5%
 C
l
Te
st
 f
o
r 
su
b
g
ro
u
p
 d
if
fe
re
n
ce
s:
 χ
2  =
 0
.1
4,
 d
f =
 1
 (
p
 =
 0
.7
1)
, I
 2  
=
 0
%
H
et
er
o
g
en
ei
ty
: n
o
t 
ap
p
lic
ab
le
Te
st
 f
o
r 
o
ve
ra
ll 
ef
fe
ct
: z
 =
 1
.4
4 
(p
 =
 0
.1
5)
Le
e 
20
12
12
0
Su
b
to
ta
l (
95
%
 C
l)
10
0.
0%
10
0.
0%
2.
20
 (
–0
.8
9 
to
 5
.2
9)
2.
20
 (
–0
.8
9 
to
 5
.2
9)
62 62
En
d
 o
f 
tr
ea
tm
en
t 
(1
2 
w
ee
k)
 v
al
u
es
 –
 m
in
u
te
s
8.
92
11
.3
56 56
8.
18
9.
1
H
et
er
o
g
en
ei
ty
: n
o
t 
ap
p
lic
ab
le
Te
st
 f
o
r 
o
ve
ra
ll 
ef
fe
ct
: z
 =
 1
.4
0 
(p
 =
 0
.1
6)
FI
G
U
R
E
11
D
ap
o
xe
ti
n
e
+
m
ir
o
d
en
af
il
co
m
p
ar
ed
w
it
h
d
ap
o
xe
ti
n
e
+
p
la
ce
b
o
:f
o
re
st
p
lo
t
o
f
IE
LT
o
u
tc
o
m
es
.
d
f,
d
eg
re
es
o
f
fr
ee
d
o
m
;I
V
,i
n
ve
rs
e
va
ri
an
ce
;S
D
,s
ta
n
d
ar
d
d
ev
ia
ti
o
n
.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
80
Sexual satisfaction ejaculation: dapoxetine 30mg and 60mg Mean scores for this outcome were
available for two Phase III RCTs.116,118 A high level of heterogeneity was observed for dapoxetine 60mg
compared with placebo (two RCTs,116,118 I2= 99%, meta-analysis not undertaken). The number of patients
reporting a change in this outcome was available for four Phase III RCTs.85,113,116,119 High heterogeneity was
observed for dapoxetine 60mg compared with placebo (four RCTs,85,113,116,119 I2= 89%, meta-analysis not
undertaken). Between-group comparisons from individual RCTs in RevMan for this assessment report
(see Table 19) suggested that both dapoxetine 30mg and dapoxetine 60mg are significantly more
effective than placebo on this outcome (MD, p< 0.0001 and p< 0.0001; RR, p= 0.0007 and p< 0.0001)
and that dapoxetine 60mg is significantly more effective than dapoxetine 30mg on the number of
patients reporting a change in this outcome (MD, p= 0.06; RR, p= 0.05) (see Table 19).
Global impression of change: dapoxetine 30mg and 60mg The numbers of patients reporting a
change in this outcome were available for four Phase III RCTs.113,116–118 Pooled effects across RCTs
suggested that both dapoxetine 30mg and dapoxetine 60mg were significantly more effective than
placebo (RR, p< 0.0001 and p< 0.0001) and that dapoxetine 60mg is significantly more effective than
dapoxetine 30mg (RR, p< 0.0001) (see Table 19).
Composite criteria for clinical benefit: dapoxetine 30mg and 60mg The numbers of patients
reporting a change in this outcome were available for three Phase III RCTs (Buvat et al., 2009,113 Kaufman
et al., 2009,116 McMahon et al., 2010117). Pooled effects across RCTs suggested that both dapoxetine
30mg and dapoxetine 60mg were significantly more effective than placebo (RR, p< 0.0001 and
p< 0.0001) (see Table 19). High heterogeneity was observed for dapoxetine 30mg compared with
dapoxetine 60mg (two RCTs, I2= 76%, meta-analysis not undertaken). Between-group comparisons from
individual RCTs estimated in RevMan for this assessment report for one RCT suggested that dapoxetine
30mg was significantly more effective than dapoxetine 60mg on this outcome (RR, p= 0.0008)
(see Table 19).
Other outcomes: dapoxetine plus phosphodiesterase-5 inhibitor The RCT by Lee et al.120 reported no
statistically significant between-group difference in time from foreplay to beginning intercourse between
dapoxetine plus mirodenafil and mirodenafil alone. Nor was any statistically significant between-group
difference evident in overall sexual act time (OSAT) at week 4 or 12. The authors reported statistically
significant between-group differences in favour of dapoxetine plus mirodenafil on the PEP domains of
perceived control over ejaculation (p= 0.019), interpersonal difficulty related to ejaculation (p= 0.013) and
the overall index score (p= 0.046).
Assessment of safety: dapoxetine – adverse events
Adverse event and withdrawal data for RCTs from reviews are summarised from the reports by McCarty
and Dinsmore,109 McMahon and Porst,68 Hutchinson et al.111 and Kendirci et al.112 in Table 20.
These reviewers concluded that, among the Phase II studies, the most commonly reported AEs were
nausea, diarrhoea, headache and dizziness, and that the incidence of most AEs appeared to be dose
dependent. Amongst the Phase III studies, the most common treatment-related AEs included nausea,
dizziness and headache.
Across the included RCTs, insufficient data for numbers of patients experiencing AEs were available for any
meaningful pooling in a meta-analysis.
Assessment of effectiveness: dapoxetine – evidence summary
The current evidence base for dapoxetine at 30mg and 60mg on demand (approved doses for the
treatment of PE in the UK24) in the treatment of PE comprises one Phase II RCT114 and six Phase III RCT
reports.85,113,116,118,119,170 These RCTs are captured in six systematic reviews of effectiveness which are of low
to moderate methodological quality.65,67,108–110,169 One further RCT120 evaluating the effects of dapoxetine
combined with a PDE5 inhibitor (mirodenafil) is at overall low risk of bias. The pooled evidence across
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TABLE 20 Selective serotonin reuptake inhibitors licensed for PE (dapoxetine): AEs and withdrawals
AEs (%)
Dapoxetine
30mg
Dapoxetine
60mg
Dapoxetine+
mirodenafil Placebo References
Nausea 16.5 30.6 2.9 Buvat et al. 2009113 (24 weeks)
5.8 0.7 Hellstrom et al. 2004114 (2 weeks)
15.3 1.6 Kaufman et al. 2009116 (9 weeks)
10.5 26.4 2.0 McMahon 2010117 (12 weeks)
8.7 20.1 1.9 Pryor et al. 2006118 (12 weeks)
5.4 1.0 Safarinejad 2008119 (12 weeks)
10.7 8.1 Lee et al. 2012120 (12 weeks)
Diarrhoea 3.9 11.3 1.6 Buvat et al. 2009113 (24 weeks)
5.0 0.7 Hellstrom et al. 2004114 (2 weeks)
6.1 2.0 Kaufman et al. 2009116 (9 weeks)
2.0 1.7 0.8 McMahon et al. 2010168 (12 weeks)
3.9 6.8 1.4 Pryor et al. 2006118 (12 weeks)
5.4 0.0 Safarinejad 2008119 (12 weeks)
3.6 4.8 Lee et al. 2012120 (12 weeks)
Headache 6.4 13.6 8.3 Buvat et al. 2009113 (24 weeks)
4.3 0.0 Hellstrom et al. 2004114 (2 weeks)
8.1 6.1 Kaufman et al. 2009116 (9 weeks)
3.4 4.8 2.0 McMahon 2010117 (12 weeks)
5.9 6.8 4.0 Pryor et al. 2006118 (12 weeks)
4.3 1.0 Safarinejad 2008119 (12 weeks)
5.4 12.9 Lee et al. 2012120 (12 weeks)
Dizziness 7.7 13.4 2.6 Buvat et al. 2009113 (24 weeks)
2.2 0.0 Hellstrom et al. 2004114 (2 weeks)
10.2 2.9 Kaufman et al. 2009116 (9 weeks)
10.5 18.8 3.9 McMahon et al. 2010168 (12 weeks)
3.0 6.2 0.8 Pryor et al. 2006118 (12 weeks)
3.2 0.0 Safarinejad 2008119 (12 weeks)
8.9 9.7 Lee et al. 2012120 (12 weeks)
Somnolence 3.9 7.2 1.0 Buvat et al. 2009113 (24 weeks)
2.9 0.7 Hellstrom et al. 2004114 (2 weeks)
3.7 0.8 Kaufman et al. 2009116 (9 weeks)
3.4 6.2 0.6 McMahon et al. 2010168 (12 weeks)
3.2 3.7 0.2 Pryor et al. 2006118 (12 weeks)
Vomiting 1.3 3.1 0.5 Buvat et al. 2009113 (24 weeks)
0.3 2.5 0.0 McMahon et al. 2010168 (12 weeks)
Palpitation 1.8 6.5 Lee et al. 2012120 (12 weeks)
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three RCTs113,117,118 including 3036 participants and across five RCTs85,113,117–119 comprising 3390 participants
suggests that both dapoxetine 30mg and dapoxetine 60mg increase IELT in men with PE to a significantly
greater extent than placebo (30mg: MD 1.16 minutes, 95% CI 0.94 to 1.39 minutes; p< 0.00001; 60mg:
MD 1.66 minutes, 95% CI 1.46 to 1.87 minutes; p< 0.00001). The pooled evidence across three
RCTs113,117,118 including 3005 participants suggests that dapoxetine 60mg is significantly more effective in
increasing IELT in men with PE when compared with dapoxetine 30mg (MD 0.46 minutes, 95% CI 0.19 to
0.74 minutes; p= 0.0009). Evidence from one RCT120 (120 participants) showed no statistically significant
difference in IELT between dapoxetine 30mg combined with mirodenafil and dapoxetine 30mg alone.
Among the Phase III trials, treatment duration ranged from 9 to 24 weeks. The effects of longer-term
treatment with dapoxetine for PE or the effects once treatment is withdrawn have not been evaluated in
the current evidence base.
Evidence from individual Phase III RCTs suggests that both dapoxetine 30mg and dapoxetine 60mg are
significantly more effective than placebo and that dapoxetine 60mg is significantly more effective than
dapoxetine 30mg, on outcomes of ejaculatory control, sexual satisfaction, global impression of change
and clinical benefit. However, the assessment and reporting of these outcomes is variable across trials.
High levels of heterogeneity were observed when trials were pooled. These findings should be interpreted
with caution given the observed levels of between-study heterogeneity.
The most commonly reported AEs with dapoxetine are nausea, diarrhoea, headache, dizziness and appear
to be dose dependent. From the current evidence base there are no data regarding possible long-term AEs
of dapoxetine in the treatment of PE.
The findings for dapoxetine are based on meta-analyses of RCT data extracted from existing reviews and
meta-analyses. From a review presenting withdrawal data from Phase III trials, it is apparent that previous
reviews have meta-analysed RCT data across per-protocol (patients completing) and intention-to-treat
populations.111 Thus, an attrition bias may be present. The results for dapoxetine in this assessment report
should therefore be interpreted with caution.
TABLE 20 Selective serotonin reuptake inhibitors licensed for PE (dapoxetine): AEs and withdrawals (continued )
AEs (%)
Dapoxetine
30mg
Dapoxetine
60mg
Dapoxetine+
mirodenafil Placebo References
Facial flushing 1.8 3.2 Lee et al. 2012120 (12 weeks)
Any AE 32.1 45.2 Lee et al. 2012120 (12 weeks)
Withdrawals
(owing to AE)
3.9 8.2 1.3 Buvat et al. 2009113 (24 weeks)
1.7 5.1 0.3 McMahon et al. 2010168 (12 weeks)
4.0 10.0 0.9 Pryor et al. 2006118 (12 weeks)
3.5 0.0 Safarinejad 200685 (12 weeks)
5.7 0.0 Safarinejad 2008119 (12 weeks)
Withdrawals
(overall)
42.8 46.8 50.9 Buvat et al. 2009113 (24 weeks)
28.5 31.2 17.4 McMahon et al. 2010168 (12 weeks)
22.7 29.7 22.8 Pryor et al. 2006118 (12 weeks)
8.7 8.9 Safarinejad 200685 (12 weeks)
12.3 9.4 Safarinejad 2008119 (12 weeks)
0.0 0.7 Hellstrom et al. 2004114 (2 weeks)
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Serotonin–noradrenaline reuptake inhibitors
Characteristics of included studies: serotonin–noradrenaline reuptake inhibitors
One RCT evaluating duloxetine was identified from one review.68 The review was undertaken in Australia
and was awarded an AMSTAR score of 2 out of 11 (see Table 11 in the Characteristics of included studies:
selective serotonin reuptake inhibitors section and Appendix 4). A further two RCTs were identified, both
of which evaluated venlafaxine compared with placebo.122,123
Randomised controlled trials included in reviews Duloxetine 80mg was compared with placebo in
one trial.121 The duration was 12 weeks and IELT was assessed using a stopwatch. This RCT was captured
by the search strategy for this assessment report.
Randomised controlled trials not included in reviews The trial by Kilic et al.122 was undertaken in
Turkey and was a randomised crossover design trial recruiting 31 patients. Patients were randomised to
venlafaxine extended-release 75mg per day or placebo: 2 weeks treatment, 1 week washout, 2 weeks
treatment. IELT was assessed using a stopwatch. The authors reported that 21 out of 31 (67.7%) patients
completed the trial. This trial was considered at overall high risk of bias. The RCT by Safarinejad123 was
conducted in the Islamic Republic of Iran. Two hundred and twenty patients were randomised to either
venlafaxine extended-release 75mg per day or placebo. IELT was assessed using a stopwatch. Treatment
duration was 12 weeks and the authors reported that 192 out of 222 (86%) patients completed the
intervention. This trial was considered to be at overall unclear risk of bias.
Details of these trials are presented in Table 21.
Assessment of effectiveness: serotonin–noradrenaline reuptake inhibitors –
intravaginal ejaculatory latency time outcomes
Intravaginal ejaculatory latency time: venlafaxine compared with placebo The crossover trial by
Kilic et al.122 reported that there was no statistically significant between-group difference in IELT post
treatment (p= 0.144) while no variance estimates were reported for the RCT by Safarinejad.123 The author
reported that, during the study (fortnightly assessment points), there was no significant differences
between venlafaxine and placebo (p= 0.10). After 12 weeks, IELT did not differ significantly between the
two groups (p= 0.10 for geometric mean fold increase).
Intravaginal ejaculatory latency time: duloxetine compared with placebo The between-group
difference in mean IELT for one RCT evaluating this comparison121 was 1.52 minutes [MD (fixed effect),
95% CI 0.08 to 2.24 minutes; p< 0.00001] in favour of duloxetine at 12 weeks (estimated for this
assessment report using RevMan; figure not presented and, therefore, there is no figure for this
comparison in the report).
Assessment of effectiveness: serotonin–noradrenaline reuptake inhibitors –
other outcomes
The RCT by Athanasios et al.121 assessed score on the Clinical Global Impression – Improvement (CGI-I)
scale. The trial by Kilic et al.122 assessed sexual satisfaction, but did not report the instrument used.
Safarinejad123 assessed IIEF intercourse satisfaction and number of coitus episodes weekly.
Clinical global impression: duloxetine compared with placebo The proportion of patients reported as
‘much improved’ and ‘very much improved’ on a subjective measure of clinical improvement was greater
with duloxetine than with placebo in one RCT.121
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Sexual satisfaction and weekly coitus: venlafaxine compared with placebo The trial by Kilic et al.122
reported no statistically significant between-group difference in patient or partner sexual satisfaction
between venlafaxine compared with placebo. Safarinejad123 also reported no significant between-group
difference in IIEF sexual satisfaction or number of episodes of coitus per week.
Details of these outcomes and AEs are presented in Table 22.
Assessment of safety: serotonin–noradrenaline reuptake inhibitors – adverse events
Dry mouth and nausea were reported in one RCT evaluating duloxetine;121 however, it was unclear whether
this was in the duloxetine or placebo group. The two trials that evaluated venlafaxine both reported
proportions of patient experiencing specific AEs of treatment.122,123 The trial by Kilic et al.122 reported that only
nausea was significantly higher with venlafaxine than with placebo. Safarinejad123 reported that significantly
more AEs were associated with venlafaxine.
Assessment of effectiveness: serotonin–noradrenaline reuptake inhibitors –
evidence summary
The current evidence base for SNRIs in the treatment of PE comprises three RCTs,121–123 one captured in a
low methodological quality systematic review121 and two further RCTs,122,123 one122 of which is at overall
high risk of bias and the other at overall unclear risk of bias.123
There is evidence from one RCT121 (20 participants) that duloxetine is significantly more effective than
placebo in increasing IELT (MD 1.52 minutes, 95% CI 0.08 to 2.24 minutes; p< 0.00001). Measures
of clinical improvement appear improved with duloxetine. Duloxetine-associated side effects are reported
to be dry mouth and nausea. Evidence from two RCTs122,123 suggests that venlafaxine is not effective at
increasing IELT in men with PE when compared with placebo. Venlafaxine is associated with significantly
more treatment-related side effects than placebo.
The long-term efficacy and side effects of these treatments along with patient acceptability are not
assessed in the current evidence base.
Tricyclic antidepressants
Characteristics of included studies: tricyclic antidepressants
Two single-arm randomised crossover RCTs39,76 were captured in several reviews (see Characteristics of
included studies: selective serotonin reuptake inhibitors, Table 11). Both evaluated oral clomipramine.
Eight further RCTs124–131 that also evaluated oral clomipramine were identified from three reviews of low
methodological quality.52,68,69 Full details of the AMSTAR assessment for these and all other included
reviews are presented in Appendix 4. A further three RCTs were identified from the literature
search,107,132,133 and the RCT by Tuncel et al.107 evaluated clomipramine, sertraline, terazosin and placebo.
The trials by Akilov et al.132 and Leaker et al.133 both evaluated nasally inhaled clomipramine. The trial by
Tuncel et al.107 is also evaluated in sections Phosphodiesterase-5 inhibitors and Alpha-blockers.
Randomised controlled trials included in reviews In total, 10 trials were identified from
reviews.39,76,124–131 Of the trials identified as having as crossover design, by Abdel-Hamid et al.,39 evaluated
clomipramine 25mg, sildenafil 50mg, paroxetine 20mg, sertraline 50mg and the squeeze technique over
five separate 4-week treatment phases. IELT was assessed using a stopwatch. Kim and Seo76 evaluated
clomipramine 50mg, fluoxetine 40mg, sertraline 100mg and placebo over 4-week treatment phases. The
method of IELT assessment was not reported. Of the other trials, Althof et al.124 evaluated clomipramine
25mg, clomipramine 50mg or placebo in 15 couples (unclear from existing reviews if crossover or pairwise
comparison) over 2–7 weeks. Girgis et al.,125 Goodman,126 Haensel et al.,127 Montorsi et al.,128 Porto,129
Segraves et al.130 and Strassberg et al.131 all evaluated clomipramine compared with placebo. The total
number of participants per trial ranged from 16 to 33; however, numbers by treatment group were not
reported and it was unclear from the reviews from which these trials were extracted which, if any, were
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crossover design trials. Duration across these trials ranged from 2 to 6 weeks. IELT was reported as being
assessed using subject report or questionnaire. All RCTs in reviews were captured by the search strategy
for this assessment report.
Details of these RCTs extracted from reviews are presented in Table 23.
Randomised controlled trials not included in reviews The RCT by Akilov et al.132 was conducted in
Uzbekistan and patients were randomised, 19 to a clomipramine 4mg nasal spray and 15 to a placebo
nasal spray. The authors reported that 33 out of 34 (97%) completed the 8-week follow-up. IELT was via
patient self-report. The RCT by Leaker et al.133 was conducted in the UK and inhaled clomipramine 1mg
or placebo (not described) before intercourse for a maximum of five occasions was compared with inhaled
clomipramine 2mg or placebo before intercourse for a maximum of five occasions in a randomised crossover
design study. Thirty-nine patients were reported as included in an intention-to-treat analysis. IELT was
assessed using a stopwatch and both RCTs were reported in abstract form only. The RCT by Tuncel et al.107
was undertaken in Turkey and 90 patients were randomised to receive clomipramine 25mg per day, sertraline
50mg, terazosin 5mg or placebo. Treatment was for 2 months and IELT was not assessed. The authors
reported that 90 out of 90 (100%) patients completed the trial. Treatment was for 2 months and IELT was
not assessed. All three RCTs were considered to be at overall unclear risk of bias.107,132,133
Details of the treatments evaluated, definition of PE, IELT assessment method, other outcomes assessed,
study duration, along with the study country for the further RCTs not in reviews, and the overall study
quality assessment (AMSTAR33 for reviews and Cochrane risk of bias assessment34 for the RCTs not
included by reviews) are presented in Table 23.
Assessment of effectiveness: tricyclic antidepressants – intravaginal ejaculatory latency
time outcomes
Intravaginal ejaculatory latency time outcomes were reported by the two crossover RCTs39,76 identified from
existing reviews and the two further RCTs132,133 evaluating nasal administration identified for inclusion in
this review. IELT data with variance estimates or p-values were not available for the remaining RCTs
identified from reviews; however, the review summaries of data for TCAs are reported in the next section,
Intravaginal ejaculatory latency time: clomipramine compared with placebo – summary data from
existing reviews.
Intravaginal ejaculatory latency time: clomipramine compared with placebo – summary data from
existing reviews When IELT data post treatment were reported for the RCT by Althof et al.,124 a latency
increase of 3.37 minutes with clomipramine 25mg and of 6.98 minutes with clomipramine 50mg was
reported. p-values or variance estimates were not reported. Placebo was reported as not significantly
different from baseline; however, no data were reported. For the RCT by Haensel et al.,127 an increase in
latency from 2 to 8 minutes was reported (p-value not reported). For the RCT by Strassberg et al.,131
post-treatment IELT was 3.82 minutes with clomipramine, compared with 0.87 minutes with placebo
(p-value not reported).
When IELT was summarised across trials by reviews, Waldinger et al.52 reported that, across RCTs,
non-RCTs and single-arm studies, the mean percentage increase in delaying ejaculation was 512%
(95% CI 234% to 1122%) with clomipramine. The reviewers reported a p-value compared with placebo
of p< 0.001. Richardson et al.69 estimated the mean increase in latency over baseline or placebo,
combining data from different trials weighted by sample size. The latency increase was 3.66 minutes with
clomipramine 25mg and 5.31 minutes with clomipramine 50mg. The reviewers reported a significant
increase in latency for active treatment compared with baseline or placebo (p-values not reported).
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Intravaginal ejaculatory latency time: clomipramine compared with phosphodiesterase-5
inhibitors or selective serotonin reuptake inhibitors The between-group difference in mean IELT
change (minutes) following a 4-week randomised crossover comparison39 was 10.00 minutes in favour of
sildenafil compared with clomipramine [MD (fixed effect); 95% CI 6.32 to 13.68 minutes; p< 0.00001].
Comparisons of clomipramine 25mg with sertraline, paroxetine or the squeeze technique were not
statistically significant (Figure 12). A paired analysis could not be undertaken for approximation purposes
for this study. Data from this trial were not pooled with other RCTs in any meta-analysis in this assessment
report. Summary results for these and all other meta-analyses are presented in Table 24.
Intravaginal ejaculatory latency time: clomipramine compared with selective serotonin reuptake
inhibitors or placebo The crossover trial by Kim and Seo76 reported that mean [standard deviation (SD)]
post-treatment IELT (minutes) was 2.30 minutes (SD 2.08 minutes) with fluoxetine 40mg, 4.27 minutes
(SD 5.68 minutes) with sertraline 100mg, 5.75 minutes (SD 6.68 minutes) with clomipramine 50mg and
2.27 minutes (SD 3.78 minutes) with placebo, and that IELT was significantly increased in all treatment
phases (p< 0.001). The between-group comparisons from this study estimated in RevMan for this
assessment report are presented in Figure 13. The between-group difference in mean IELT (minutes) was
3.45 minutes in favour of clomipramine 100mg compared with fluoxetine [MD (fixed effect); 95% CI 1.65
to 5.75 minutes; p= 0.003] and 3.48 minutes in favour of clomipramine 100mg compared with placebo
[MD (fixed effect); 95% CI 0.97 to 5.99 minutes; p= 0.007]. The comparison of clomipramine with
sertraline was not statistically significant (Figure 13). A paired analysis could not be undertaken for
approximation purposes for this study. Data from this trial were not pooled with other RCTs in any
meta-analysis in this assessment report.
Intravaginal ejaculatory latency time: clomipramine nasal spray compared with placebo The
between-group difference in mean IELT (minutes) post treatment, based on one RCT132 (n= 34), was
1.68 minutes [MD (fixed effect) 95% CI 1.06 to 2.29 minutes; p< 0.00001] in favour of the clomipramine
spray (figure not presented). The RCT by Leaker et al.133 reported end of study IELT values without variance
estimates. The authors reported a p-value of p= 0.0108 for the comparison of inhaled clomipramine 2mg
compared with placebo and that the comparison of inhaled clomipramine 1mg with placebo was not
statistically significant (p-value not reported).
Assessment of effectiveness: tricyclic antidepressants – other outcomes
With the exception of the RCTs that were reported only in the review by Waldinger et al.,52 all of the
included trials reported one or more outcomes in addition to IELT. However, these outcomes were diverse
across the include trials and were often not reported in sufficient detail to permit any pooling across trials
(Table 25).
Other outcomes: clomipramine compared with phosphodiesterase-5 inhibitors, selective serotonin
reuptake inhibitors, alpha-blockers or placebo In the crossover study by Abdel-Hamid et al.,39 Erectile
Dysfunction Inventory of Treatment Satisfaction (EDIT) scores appeared lower with clomipramine than
with sildenafil or paroxetine. Kim and Seo76 reported that a sexual satisfaction rating was greater with
clomipramine than other therapies; however, no data for clomipramine or p-value were reported.
Tuncel et al.107 reported that clomipramine, sertraline and terazosin were all significantly better than
placebo on ejaculation control, but that there was no significant difference between the active treatments
on this outcome.
Other outcomes: clomipramine nasal spray compared with placebo Akilov et al.132 reported that CIPE
scores improved significantly with nasal clomipramine; however, there was no significant change in the
five-item version of the IIEF scores. Leaker et al.133 assessed IELT sexual satisfaction but did not report any
outcome data. The between-group difference in ejaculatory control between inhaled clomipramine and
placebo was statistically significant in favour of clomipramine 2mg spray, but not 1mg spray.
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Assessment of safety: tricyclic antidepressants – adverse events
Adverse events: clomipramine compared with placebo Althof et al.124 reported the proportion of
patients receiving clomipramine 25mg or 50mg who experienced dry mouth, feeling ‘different’ and
constipation (number not reported). The proportions were noticeably higher in the 50mg group than in
the 25mg group (see Table 25). Proportions for the placebo group were not reported. Tuncel et al.107
reported that there were no significant differences between clomipramine, sertraline and terazosin in the
number of patients reporting AEs of headache, hypotension, drowsiness and ejaculation disorder.
Adverse events: clomipramine compared with phosphodieterase-5 inhibitors or selective serotonin
reuptake inhibitor Abdel-Hamid et al.39 reported that the incidence of side effects was similar among
groups, but the types of side effects associated with clomipramine were not reported. A greater proportion
of patients receiving clomipramine experienced AEs than when receiving fluoxetine, sertraline or placebo in
the crossover trial by Kim and Seo.76 The authors reported that the between-group difference compared
with placebo was significant. No other statistical comparison between groups was reported.
Adverse events: clomipramine nasal spray compared with placebo Akilov et al.132 reported that
the most common side effect with nasal clomipramine was nasal irritation. Leaker et al.133 reported
that the incidence of AEs of local irritation cough, sore throat and respiratory tract infection was dose
related (1mg or 2mg).
Assessment of effectiveness: tricyclic antidepressants – evidence summary
The current evidence base for clomipramine in the treatment of PE comprises 13 RCTs, 10 captured in low
to moderate methodological quality systematic reviews39,76,107,124–133 and three further RCTs which are at
overall unclear risk of bias.39,76,124–131 Both oral and nasal administration of clomipramine is evaluated in the
evidence base. The quality of reporting in some reviews does not facilitate data extrapolation of IELT and
other data from RCTs therein.
Evidence from one crossover trial suggests that oral sildenafil is more effective than oral clomipramine in
increasing IELT in men with PE.39 Evidence from another crossover trial suggests that oral clomipramine is
more effective than fluoxetine at increasing IELT.76 There is evidence from one RCT (39 participants)132 that
clomipramine administered nasally (spray) at 4mg is significantly effective when compared with placebo at
increasing IELT [1.68 minutes (95% CI 1.06 to 2.29 minutes); p< 0.00001)]. Evidence from a further
crossover trial (39 participants) suggests that inhaled clomipramine at 2mg is also significantly effective
compared with placebo.133 No significant effects are evident at 1 mg. Summary evidence from one review52
that estimated a weighted mean increase in IELT across included studies and one review that estimated
a mean percentage increase in IELT across RCTs, non-RCTs, and from single-arm studies, suggests that
oral clomipramine may be more effective than placebo on this outcome.69
Various assessment methods in terms of treatment satisfaction, sexual satisfaction and ejaculation
control have been used across RCTs to measure the effectiveness of clomipramine. Evidence from one
crossover trial suggests that treatment satisfaction is greater with oral sildenafil and paroxetine than with
oral clomipramine.39 Evidence from one crossover trial suggests that sexual satisfaction is greater with oral
clomipramine than with SSRIs (fluoxetine and sertraline).39 Evidence from one RCT suggests that there is no
difference between oral clomipramine, sertraline and terazosin in effect on ejaculatory control.107 Evidence
from one RCT suggests that ejaculatory control is better with inhaled clomipramine at 2mg than 1mg.133
Evidence from one crossover trial suggests that clomipramine is associated with a greater incidence of AEs
than fluoxetine or sertraline; however, the nature of the AEs is unknown.76 Evidence from one RCT
suggests that there is no significant difference between oral clomipramine, sertraline and terazosin in the
number of patients reporting AEs of headache, hypotension, drowsiness and ejaculation disorder.107
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Nasal clomipramine is associated with nasal, throat and respiratory tract irritation, with greater incidence at
2mg than 1mg application.133
Clomipramine appears to be more effective than fluoxetine or paroxetine but not as effective as sildenafil
in the treatment of PE. However, these findings should be interpreted with caution given that they are
extrapolated from poorly reported crossover observations with low patient numbers. Inhaled clomipramine
appears effective at increasing IELT but efficacy appears to be dose dependent, as do treatment-related
side effects of application-associated irritation. The current evidence base for oral administration in the
treatment of PE in terms of both efficacy and safety of clomipramine along with patient acceptability
is limited.
Phosphodiesterase-5 inhibitors
Characteristics of included studies: phosphodiesterase-5 inhibitors
Phosphodiesterase-5 inhibitors were evaluated by five systematic reviews,37,134–137 one of which pooled data
in a meta-analysis.134 Two further RCTs evaluating PDE5 inhibitors were identified.101,120
Reviews Two of the systematic reviews were conducted in Italy,134,135 one review was conducted in
Australia,136 one in Israel137 and one in the USA.37 Details of the review type, the databases searched and
dates, included RCTs and the AMSTAR quality assessment for these reviews of effectiveness are presented in
Table 26. The overall AMSTAR quality score was 2 out of 11 in three of the reviews,134,136,137 3 out of 11 in
one review135 and 4 out of 11 in one review.37 However, the review by Asimakopoulos et al.134 was the most
comprehensive in terms of included studies. Full details of the AMSTAR assessment for these and all other
included reviews are presented in Appendix 4. The search methodology and inclusion criteria for studies were
varied across these reviews. In the review by Asimakopoulos et al.,134 which included a meta-analysis, the
authors pooled IELT effect estimates across studies using a standardised MD. These authors also pooled data
across different study types (observation studies and RCTs) in the same meta-analysis.
Randomised controlled trials included in reviews The reviews above varied in terms of which RCTs
they included. In total, 10 RCTs39,55,138–145 (total 795 participants) were included in the review by
Asimakopoulos et al.134 The other reviews included different subsets of these RCTS. Seven RCTs assessed
sildenafil.39,55,139,142–145 Among these trials the dose was 50mg or greater, administered a few hours
preintercourse. Sildenafil was combined with fluoxetine in one trial139 and with behavioural therapy in
another,143 i.e. there was no sildenafil-only arm in these two trials. One RCT assessed tadalafil 20mg one to
36 hours preintercourse141 and two RCTs assessed vardenafil.138,140 The vardenafil doses for these RCTs
were not available from any reviews.
Intravaginal ejaculatory latency time was reported as being measured using a stopwatch in all but one
RCT.55 When reported, duration of the RCTs included in the reviews ranged from 4 weeks to 4 months.
Comparators to PDE5 inhibitors within these RCTs were SSRIs (various), clomipramine, behavioural therapy
(squeeze technique), CBT, topical anaesthetics (EMLA cream) and placebo. Details of the RCTs extracted
from these reviews are presented in Table 27. All RCTs in reviews were captured by the search strategy for
this assessment report.
Randomised controlled trials not included in reviews The RCT by Culba et al.101 was undertaken in
Turkey and patients were randomised to fluoxetine 20mg per day plus tadalafil 20mg twice weekly,
fluoxetine 20mg per day alone, or placebo. The authors reported that 158 out of 180 (88%) completed the
10-week follow-up. This study was reported in abstract form only and outcome data were not presented by
the treatments evaluated. This trial was considered to be at overall unclear risk of bias. The RCT by Lee
et al.120 was undertaken in the Republic of Korea and patients were randomised to dapoxetine 30mg plus
mirodenafil 50mg or dapoxetine 30mg plus placebo. All agents were taken 1–3 hours preintercourse. IELT
was assessed using a stopwatch. In each group, 98% of patients were analysed. This trial was considered to
be at overall low risk of bias and is also evaluated in the section Selective serotonin reuptake inhibitors
licensed for premature ejaculation (dapoxetine).
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TABLE 26 Phosphodiesterase-5 inhibitors: details of reviews and AMSTAR quality score
Author (country),
review type
Databases searched and
dates
Included RCTs relevant to this
section
AMSTAR review
quality assessment
Asimakopoulos et al.
2012134 (Italy), systematic
review and meta-analysis
PubMed January 1990 and
June 2011
Abdel-Hamid et al. 2001,39
Atan et al. 2006,55 Aversa et al.
2009,138 Hosseini and
Yarmohammadi 2007,139
Mathers et al. 2009,140 Mattos et al.
2008,141 McMahon et al. 2005142
Tang et al. 2004,143 Wang et al.
2007,144 Zhang et al. 2005145
AMSTAR score, 2/11:
l characteristics of
included
studies reported
l conflict of interest
statement reported
Aversa et al. 2011135
(Italy), systematic review
MEDLINE up to a May
2010. No start date
Abdel-Hamid et al. 2001,39
Aversa et al. 2009,138 Hosseini et al.
2007,139 Mathers et al. 2009,140
Mattos et al. 2008,141
McMahon et al. 2005,142
Wang et al. 2007144
AMSTAR score, 3/11:
l duplicate study
selection extraction
l characteristics of
included
studies reported
l conflict of interest
statement reported
Burton and Liday 2011136
(Australia), systematic
review
MEDLINE (January
1980–April 2011) and
International
Pharmaceutical Abstracts
(January 1970–April 2011)
Hosseini and Yarmohammadi
2007,139 Mattos et al. 2008,141
AMSTAR score, 2/11:
l characteristics of
included
studies reported
l conflict of interest
statement reported
Chen et al. 2007137
(Israel), systematic review
MEDLINE 1 January 1990
to 28 February 2007
Abdel-Hamid et al. 2001,39
Atan et al. 2006,55
McMahon et al. 2005142
AMSTAR score, 2/11:
l characteristics of
included
studies reported
l conflict of interest
statement reported
McMahon et al. 200637
(USA), systematic review
MEDLINE, Web of Science,
PICAa and EMBASE
between 1998 and 2005
Abdel-Hamid et al. 2001,39
Atan et al. 2006,55
McMahon et al. 2005,142
Tang et al. 2004,143 Zhang et al.
2005145
AMSTAR score, 4/11:
l comprehensive
literature search
l studies included
regardless of
publication type
l characteristics of
included
studies reported
l conflict of interest
statement reported
a Acronym not defined in original study.
AMSTAR review quality criteria: a priori design, duplicate study selection and data extraction; comprehensive literature
search of databases and other supplementary sources; studies included regardless of publication type; list of studies
(included and excluded); characteristics of included studies reported; study quality assessed; study quality used to informed
conclusions; appropriate methods used to pool data; publication bias assessed; and conflict of interest statement included.
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Details of the treatments evaluated, definition of PE, IELT assessment method, other outcomes assessed,
study duration, along with the study country for the further RCTs not in reviews, and the overall study
quality assessment (AMSTAR33 for reviews and Cochrane risk of bias assessment34 for the RCTs not
included by reviews) are presented in Table 27.
Assessment of effectiveness: phosphodiesterase-5 inhibitors – intravaginal ejaculatory
latency time outcomes
For three RCTs, IELT data suitable for meta-analysis were not available. One RCT55 that evaluated sildenafil
and EMLA cream did not assess IELT. Post-treatment IELT data were available for one RCT assessing
sildenafil and fluoxetine;139 however, no variance estimates or p-values were reported. In one RCT
assessing tadalafil and fluoxetine,101 no IELT data were reported. These trials were therefore not included in
any IELT meta-analysis in this assessment report.
Evidence synthesis intravaginal ejaculatory latency time
Phosphodiesterase-5 inhibitors compared with placebo The between-group difference in mean
increase in IELT (minutes) was 2.59 minutes in favour of tadalafil compared with placebo at 8 weeks
[MD (fixed effect); 95% CI 1.28 to 3.90 minutes; p= 0.0001]. However, the between-group difference at
12 weeks between sildenafil and placebo was not significant [MD (fixed effect) 1.03 minutes; 95% CI
–0.39 to 2.45 minutes; p= 0.16]. The pooled effect estimate across these RCTs (I2= 59.9%, random
effects) was 1.84 minutes (95% CI 0.31 to 3.36 minutes; p= 0.02). The between-group difference in
geometric mean increase in IELT from one RCT138 was 3.80 minutes in favour of vardenafil compared with
placebo [MD (fixed effect); 95% CI 3.30 to 4.30 minutes; p< 0.00001]. The forest plot for this analysis is
presented in Figure 14. Results for this and all other meta-analyses are presented in Table 28.
Intravaginal ejaculatory latency time: phosphodiesterase-5 inhibitors compared with selective
serotonin reuptake inhibitors or tricyclic antidepressants The between-group difference in mean IELT
change (minutes) following a 4-week randomised crossover comparison39 was 12.00 minutes in favour
of sildenafil compared with sertraline [MD (fixed effect); 95% CI 7.70 to 16.30 minutes; p< 0.00001],
11.00 minutes in favour of sildenafil compared with paroxetine [MD (fixed effect); 95% CI 6.70 to
15.30 minutes; p< 0.00001] and 10.00 minutes in favour of sildenafil compared with clomipramine [MD
(fixed effect) 95% CI 6.32 to 13.68 minutes; p< 0.00001]. A paired analysis could not be undertaken for
approximation purposes for this study. Data from this trial were not pooled with other RCTs in any
meta-analysis in this assessment report. This trial is also evaluated in the Behavioural interventions,
Selective serotonin reuptake inhibitors not currently licensed for premature ejaculation, Selective serotonin
reuptake inhibitors licensed for premature ejaculation and Tricyclic antidepressants sections.
The between-group difference in mean increase in IELT was 1.26 minutes in favour of sildenafil compared
with paroxetine (duration unclear) [MD (fixed effect); 95% CI 0.81 to 1.71 minutes; p< 0.00001]. The
between-group difference in mean increase in IELT (minutes) between tadalafil and fluoxetine at 12 weeks
was –0.06 minutes [MD (fixed effect); 95% CI –1.56 to 1.44 minutes; p= 0.94].
The between-group difference in mean increase in IELT was 1.89 minutes in favour of behavioural therapy
followed by vardenafil compared with behavioural therapy followed by sertraline (duration unclear) [MD
(fixed effect); 95% CI, 0.54 to 3.24 minutes; p= 0.006]. A moderate level of heterogeneity was observed
across the non-crossover RCTs comparing PDE5 inhibitors with SSRIs (I2= 47%). The between-group
difference in mean increase in IELT across these RCTs (random effects) was 1.14 minutes [95% CI 0.31 to
1.96 minutes; p= 0.007].
The forest plot for these comparisons is presented in Figure 15.
DOI: 10.3310/hta19210 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 21
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Cooper et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
107
St
u
d
y 
o
r 
su
b
g
ro
u
p
V
ar
d
en
afi
l v
s.
 p
la
ce
b
o
 –
 g
eo
m
et
ri
c 
m
ea
n
 c
h
an
g
e 
fr
o
m
 b
as
el
in
e 
(m
in
u
te
s)
Si
ld
en
afi
l v
s.
 p
la
ce
b
o
 –
 c
h
an
g
e 
fr
o
m
 b
as
el
in
e 
(m
in
u
te
s)
Ta
d
al
afi
l v
s.
 p
la
ce
b
o
 –
 c
h
an
g
e 
fr
o
m
 b
as
el
in
e 
(m
in
u
te
s)
A
ve
rs
a 
20
09
13
8
Su
b
to
ta
l (
95
%
 C
l)
0.
2
0.
7
11 11
10
0.
0%
10
0.
0%
3.
80
 (
3.
30
 t
o
 4
.3
0)
3.
80
 (
3.
30
 t
o
 4
.3
0)
31 31
0.
8
4
M
cM
ah
o
n
 2
00
51
42
 8
 w
ee
ks
Su
b
to
ta
l (
95
%
 C
l)
0.
61
2.
07
79 79
10
0.
0%
10
0.
0%
1.
03
 (
–0
.3
9 
to
 2
.4
5)
1.
03
 (
–0
.3
9 
to
 2
.4
5)
78 78
6.
08
1.
64
M
at
to
s 
20
08
14
1  
12
 w
ee
ks
Su
b
to
ta
l (
95
%
 C
l)
0.
3
0.
53
15 15
10
0.
0%
10
0.
0%
2.
59
 (
1.
28
 t
o
 3
.9
0)
2.
59
 (
1.
28
 t
o
 3
.9
0)
15 15
2.
54
2.
89
–  4
– 2
Fa
vo
u
rs
p
la
ce
b
o
Fa
vo
u
rs
PD
E5
 in
h
ib
it
o
r
0
2
4
M
ea
n
SD
To
ta
l
W
ei
g
h
t
Pl
ac
eb
o
M
ea
n
SD
To
ta
l
PD
E5
M
D
IV
, fi
xe
d
, 9
5%
 C
l
M
D
IV
, fi
xe
d
, 9
5%
 C
l
H
et
er
o
g
en
ei
ty
: n
o
t 
ap
p
lic
ab
le
Te
st
 f
o
r 
o
ve
ra
ll 
ef
fe
ct
: z
 =
 1
4.
88
 (
p
 <
 0
.0
00
01
)
H
et
er
o
g
en
ei
ty
: n
o
t 
ap
p
lic
ab
le
Te
st
 f
o
r 
o
ve
ra
ll 
ef
fe
ct
: z
 =
 1
.4
2 
(p
 =
 0
.1
6)
H
et
er
o
g
en
ei
ty
: n
o
t 
ap
p
lic
ab
le
Te
st
 f
o
r 
o
ve
ra
ll 
ef
fe
ct
: z
 =
 3
.8
7 
(p
 =
 0
.0
00
1)
Te
st
 f
o
r 
su
b
g
ro
u
p
 d
if
fe
re
n
ce
s:
 χ
2  =
 1
4.
55
, d
f =
 2
 (
p
 =
 0
.0
00
7)
, I
 2  
=
 8
6.
3%
FI
G
U
R
E
14
Ph
o
sp
h
o
d
ie
st
er
as
e-
5
in
h
ib
it
o
rs
co
m
p
ar
ed
w
it
h
p
la
ce
b
o
:f
o
re
st
p
lo
t
o
f
IE
LT
o
u
tc
o
m
es
.
d
f,
d
eg
re
es
o
f
fr
ee
d
o
m
;
IV
,i
n
ve
rs
e
va
ri
an
ce
.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
108
TA
B
LE
28
Ph
o
sp
h
o
d
ie
st
er
as
e-
5
in
h
ib
it
o
rs
:
re
su
lt
s
su
m
m
ar
y
C
o
m
p
ar
is
o
n
O
u
tc
o
m
e
n
R
C
Ts
a
Pa
rt
ic
ip
an
ts
M
o
d
el
M
D
ef
fe
ct
es
ti
m
at
e
(9
5%
C
I)
Fa
vo
u
rs
p
-v
al
u
e
V
ar
de
na
fil
vs
.
pl
ac
eb
o
IE
LT
(m
in
ut
es
)
–
ge
om
et
ric
m
ea
n
ch
an
ge
fr
om
ba
se
lin
e
11
38
42
N
/A
3.
80
(3
.3
0
to
4.
30
)
V
ar
de
na
fil
<
0.
00
00
1
Si
ld
en
af
il
vs
.
pl
ac
eb
o
IE
LT
(m
in
ut
es
)
–
en
d
of
st
ud
y
va
lu
es
11
42
15
7
N
/A
1.
03
(–
0.
39
to
2.
45
)
N
S
0.
16
Ta
da
la
fil
vs
.
pl
ac
eb
o
IE
LT
(m
in
ut
es
)
–
ch
an
ge
fr
om
ba
se
lin
e
11
41
30
N
/A
2.
59
(1
.2
8
to
3.
90
)
Ta
da
la
fil
0.
00
01
Si
ld
en
af
il
vs
.
se
rt
ra
lin
e
IE
LT
(m
in
ut
es
)
–
si
ng
le
-a
rm
,
ra
nd
om
is
ed
cr
os
so
ve
r
13
9
cr
os
so
ve
r
31
N
/A
12
.0
0
(7
.7
0
to
16
.3
0)
Si
ld
en
af
il
<
0.
00
00
1
Si
ld
en
af
il
vs
.
pa
ro
xe
tin
e
IE
LT
(m
in
ut
es
)
–
si
ng
le
-a
rm
,
ra
nd
om
is
ed
cr
os
so
ve
r
13
9
cr
os
so
ve
r
31
N
/A
11
.0
0
(6
.7
0
to
15
.3
0)
Si
ld
en
af
il
<
0.
00
00
1
Si
ld
en
af
il
vs
.
pa
ro
xe
tin
e
IE
LT
(m
in
ut
es
)
–
ch
an
ge
fr
om
ba
se
lin
e
11
44
12
0
N
/A
1.
26
(0
.8
1
to
1.
71
)
Si
ld
en
af
il
<
0.
00
00
1
Ta
da
la
fil
vs
.
flu
ox
et
in
e
IE
LT
(m
in
ut
es
)
–
ch
an
ge
fr
om
ba
se
lin
e
11
45
30
N
/A
–
0.
06
(–
1.
56
to
1.
44
)
N
S
0.
94
BT
th
en
va
rd
en
af
il
vs
.
BT
th
en
se
rt
ra
lin
e
IE
LT
(m
in
ut
es
)
–
ch
an
ge
fr
om
ba
se
lin
e
11
40
72
N
/A
1.
89
(0
.5
4
to
3.
24
)
V
ar
de
na
fil
0.
00
6
Si
ld
en
af
il
vs
.
cl
om
ip
ra
m
in
e
IE
LT
(m
in
ut
es
)
–
si
ng
le
-a
rm
,
ra
nd
om
is
ed
cr
os
so
ve
r
13
9
cr
os
so
ve
r
31
N
/A
10
.0
0
(6
.3
2
to
13
.6
8)
Si
ld
en
af
il
<
0.
00
00
1
PD
E5
in
hi
bi
to
rs
+
SS
RI
s
vs
.
SS
RI
s
IE
LT
(m
in
ut
es
)
31
20
,1
41
,1
45
22
2
Fi
xe
d
ef
fe
ct
I2
=
0%
1.
70
(1
.6
4
to
1.
76
)
PD
E5
+
SS
RI
<
0.
00
00
1
Si
ld
en
af
il
vs
.
sq
ue
ez
e
te
ch
ni
qu
e
IE
LT
(m
in
ut
es
)
–
si
ng
le
-a
rm
,
ra
nd
om
is
ed
cr
os
so
ve
r
13
9
cr
os
so
ve
r
31
N
/A
12
.0
0
(8
.0
6
to
15
.9
4)
Si
ld
en
af
il
<
0.
00
00
1
Si
ld
en
af
il
vs
.
sq
ue
ez
e
te
ch
ni
qu
e
IE
LT
(m
in
ut
es
)
–
ch
an
ge
fr
om
ba
se
lin
e
11
44
12
0
N
/A
3.
56
(3
.1
6
to
3.
96
)
Si
ld
en
af
il
<
0.
00
00
1
Si
ld
en
af
il
+
BT
vs
.
BT
IE
LT
(m
in
ut
es
)
–
en
d
of
st
ud
y
va
lu
es
11
43
60
N
/A
1.
81
(1
.5
3
to
2.
09
)
Si
ld
en
af
il
<
0.
00
00
1
BT
,
be
ha
vi
ou
ra
lt
he
ra
py
;
N
/A
,
no
t
ap
pl
ic
ab
le
;
N
S,
no
t
si
gn
ifi
ca
nt
.
a
C
ro
ss
ov
er
in
di
ca
te
s
th
at
th
e
es
tim
at
e
is
fr
om
a
cr
os
so
ve
r
RC
T.
DOI: 10.3310/hta19210 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 21
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Cooper et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
109
St
u
d
y 
o
r 
su
b
g
ro
u
p
Si
ld
en
afi
l v
s.
 s
er
tr
al
in
e 
– 
si
n
g
le
-a
rm
, r
an
d
o
m
is
ed
 c
ro
ss
o
ve
r
Si
ld
en
afi
l v
s.
 p
ar
o
xe
ti
n
e 
– 
si
n
g
le
-a
rm
, r
an
d
o
m
is
ed
 c
ro
ss
o
ve
r
Si
ld
en
afi
l v
s.
 p
ar
o
xe
ti
n
e 
– 
ch
an
g
e 
fr
o
m
 b
as
el
in
e 
(m
in
u
te
s)
Ta
d
al
afi
l v
s.
 fl
u
o
xe
ti
n
e 
– 
ch
an
g
e 
fr
o
m
 b
as
el
in
e 
(m
in
u
te
s)
B
eh
av
io
u
ra
l t
h
er
ap
y 
th
en
 v
ar
d
en
afi
l v
s.
 b
eh
av
io
u
ra
l t
h
er
ap
y 
th
en
 s
er
tr
al
in
e 
– 
ch
an
g
e 
fr
o
m
 b
as
el
in
e 
(m
in
u
te
s)
Si
ld
en
afi
l v
s.
 c
lo
m
ip
ra
m
in
e 
– 
si
n
g
le
-a
rm
, r
an
d
o
m
is
ed
 c
ro
ss
o
ve
r
A
b
d
el
-H
am
id
 2
00
13
9  
cr
o
ss
o
ve
r
Su
b
to
ta
l (
95
%
 C
l)
2
7
31 31
10
0.
0%
10
0.
0%
12
.0
0 
(7
.7
0 
to
 1
6.
30
)
12
.0
0 
(7
.7
0 
to
 1
6.
30
)
31 31
10
14
A
b
d
el
-H
am
id
 2
00
13
9  
cr
o
ss
o
ve
r
Su
b
to
ta
l (
95
%
 C
l)
3
7
31 31
10
0.
0%
10
0.
0%
11
.0
0 
(6
.7
0 
to
 1
5.
30
)
11
.0
0 
(6
.7
0 
to
 1
5.
30
)
31 31
10
14
W
an
g
 2
00
71
44
Su
b
to
ta
l (
95
%
 C
l)
3.
86
0.
88
60 60
10
0.
0%
10
0.
0%
1.
26
 (
0.
81
 t
o
 1
.7
1)
1.
26
 (
0.
81
 t
o
 1
.7
1)
60 60
1.
54
5.
12
M
at
to
s 
20
08
14
1  
12
 w
ee
ks
Su
b
to
ta
l (
95
%
 C
l)
2.
95
1.
52
15 15
10
0.
0%
10
0.
0%
–0
.0
6 
(–
1.
56
 t
o
 1
.4
4)
–0
.0
6 
(–
1.
56
 t
o
 1
.4
4)
15 15
2.
54
2.
89
M
at
h
er
s 
20
09
14
0
Su
b
to
ta
l (
95
%
 C
l)
3.
12
1.
89
36 36
10
0.
0%
10
0.
0%
1.
89
 (
0.
54
 t
o
 3
.2
4)
1.
89
 (
0.
54
 t
o
 3
.2
4)
36 36
3.
69
5.
01
A
b
d
el
-H
am
id
 2
00
13
9  
cr
o
ss
o
ve
r
Su
b
to
ta
l (
95
%
 C
l)
4
3
31 31
10
0.
0%
10
0.
0%
10
.0
0 
(6
.3
2 
to
 1
3.
68
)
10
.0
0 
(6
.3
2 
to
 1
3.
68
)
31 31
10
14
–  1
0
– 5
Fa
vo
u
rs
co
m
p
ar
at
o
r
Fa
vo
u
rs
PD
E5
 in
h
ib
it
o
r
0
5
10
M
ea
n
SD
To
ta
l
W
ei
g
h
t
C
o
m
p
ar
at
o
r
M
ea
n
SD
To
ta
l
PD
E5
 in
h
ib
it
o
r
M
D
IV
, fi
xe
d
, 9
5%
 C
l
M
D
IV
, fi
xe
d
, 9
5%
 C
l
H
et
er
o
g
en
ei
ty
: n
o
t 
ap
p
lic
ab
le
Te
st
 f
o
r 
o
ve
ra
ll 
ef
fe
ct
: z
 =
 5
.3
3 
(p
 <
 0
.0
00
01
)
H
et
er
o
g
en
ei
ty
: n
o
t 
ap
p
lic
ab
le
Te
st
 f
o
r 
o
ve
ra
ll 
ef
fe
ct
: z
 =
 2
.7
4 
(p
 =
 0
.0
06
)
H
et
er
o
g
en
ei
ty
: n
o
t 
ap
p
lic
ab
le
Te
st
 f
o
r 
o
ve
ra
ll 
ef
fe
ct
: z
 =
 0
.0
8 
(p
 =
 0
.9
4)
H
et
er
o
g
en
ei
ty
: n
o
t 
ap
p
lic
ab
le
Te
st
 f
o
r 
o
ve
ra
ll 
ef
fe
ct
: z
 =
 5
.5
0 
(p
 <
 0
.0
00
01
)
H
et
er
o
g
en
ei
ty
: n
o
t 
ap
p
lic
ab
le
Te
st
 f
o
r 
o
ve
ra
ll 
ef
fe
ct
: z
 =
 5
.0
2 
(p
 <
 0
.0
00
01
)
H
et
er
o
g
en
ei
ty
: n
o
t 
ap
p
lic
ab
le
Te
st
 f
o
r 
o
ve
ra
ll 
ef
fe
ct
: z
 =
 5
.4
7 
(p
 <
 0
.0
00
01
)
Te
st
 f
o
r 
su
b
g
ro
u
p
 d
if
fe
re
n
ce
s:
 χ
2  =
 6
7.
85
, d
f =
 5
 (
p
 <
 0
.0
00
01
),
 I 
2  =
 9
2.
6%
FI
G
U
R
E
15
Ph
o
sp
h
o
d
ie
st
er
as
e-
5
in
h
ib
it
o
rs
co
m
p
ar
ed
w
it
h
SS
R
Is
o
r
TC
A
s:
fo
re
st
p
lo
t
o
f
IE
LT
o
u
tc
o
m
es
.
d
f,
d
eg
re
es
o
f
fr
ee
d
o
m
;I
V
,
in
ve
rs
e
va
ri
an
ce
.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
110
Intravaginal ejaculatory latency time: phosphodiesterase-5 inhibitors plus selective serotonin
reuptake inhibitors compared with selective serotonin reuptake inhibitors Meta-analysis of mean
IELT (minutes) at 12 weeks, based on three RCT comparisons120,141,145 (222 participants), displayed low
heterogeneity (I2= 0%). The pooled MD in IELT in favour of PDE5 inhibitors plus SSRIs compared with
PDE5 inhibitors alone was 1.70 minutes [MD (fixed effect); 95% CI 1.64 to 1.76 minutes; p< 0.00001].
Of note, the trial evaluating sildenafil plus sertraline by Zhang et al.,145 which was highly significant, was
awarded 99.9% of the weight in the analysis. The forest plot for this analysis is presented in Figure 16.
Intravaginal ejaculatory latency time: phosphodiesterase-5 inhibitors compared with behavioural
interventions The between-group difference in mean IELT change (minutes) following a 4-week
randomised crossover comparison39 was 12.00 minutes in favour of sertraline compared with the squeeze
technique [MD (fixed effect); 95% CI 8.06 to 15.94 minutes; p< 0.00001]. A paired analysis could not
be undertaken for approximation purposes. Data from this trial were not pooled with other RCTs.
The between-group difference in mean IELT (minutes) post treatment (duration unclear) was 3.56 minutes
in favour of sildenafil compared with the squeeze technique [MD (fixed effect); 95% CI 3.16 to 3.96
minutes; p< 0.00001]. The between-group difference in mean IELT change (minutes) post treatment was
1.81 minutes in favour of sildenafil plus behavioural therapy compared with behavioural therapy (duration
4 weeks) [MD (fixed effect); 95% CI 1.53 to 2.09 minutes; p< 0.00001]. A high level of heterogeneity was
observed across the non-crossover RCTs comparing PDE5 inhibitors with behavioural interventions
(I2= 97%, meta-analysis not undertaken). The forest plot for this analysis is presented in Figure 17.
Assessment of effectiveness: phosphodiesterase-5 inhibitors – other outcomes
Outcomes other than IELT were reported across the RCTs that were captured in reviews using a diversity of
instruments (sometimes not reported which) and outcome data. In some instances it was unclear if the
metric was an end of study or change from baseline value, or if the value was a mean or median. In a
large proportion of the RCTs, a variance estimate for the outcome was not reported. Either p-values were
not available for the majority of the RCTs or, when they had been reported, it was unclear if this was for a
between- or across-group comparison (Table 29).
Where between-group differences were estimatable, sildenafil plus behavioural therapy appeared to be
more effective than behavioural therapy alone in the number of patients answering ‘satisfied’ on a patient/
partner sexual satisfaction Likert scale (p= 0.04). Sildenafil plus sertraline also appeared to be more
effective than sertraline alone on the IIEF sexual satisfaction and intercourse frequency domains (p< 0.001).
Across the RCTs, p-values for outcomes other than IELT either were not reported or, if they were, it was
unclear whether the comparison was between groups or from baseline. The available data suggest that,
in terms of secondary outcomes to IELT, PDE5 inhibitors are better than placebo and that PDE5 inhibitors
combined with another therapy (SSRI or behavioural therapy) are better than the other therapy alone.
Assessment of safety: phosphodiesterase-5 inhibitors – adverse events
Of all the included RCTs, AE data were available for only a subset of trials evaluating sildenafil,39,55,145 for
which it was reported that sildenafil was associated with a greater incidence of flushing and headache.
However, data from these trials were insufficient for any meaningful pooling to be undertaken.
Assessment of effectiveness: phosphodiesterase-5 inhibitors – evidence summary
The current evidence base for PDE5 inhibitors in the treatment of PE comprises 10 RCTs39,55,138–145 captured
in five systematic reviews37,134–137 of low to moderate methodological quality reviews and two further
RCTs,101,120 one of which is at overall low risk of bias and the other at overall unclear risk.
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Evidence from two RCTs138,141 suggests that vardenafil (42 participants) and tadalafil (30 participants) are
both significantly effective in increasing IELT in men with PE [MD 3.80 minutes (95% CI 3.30 to 4.30
minutes; p= 0.0001) and 2.59 minutes (95% CI 1.28 to 3.90 minutes; p< 0.00001), respectively] when
compared with placebo. Evidence from one RCT (157 participants) suggests that there is no statistically
significant difference between sildenafil and placebo.142
In comparison with SSRIs, sildenafil appears significantly more effective than paroxetine (one RCT,144 120
participants) [MD 1.26 minutes (95% CI 0.81 to 1.71 minutes)] and vardenafil (preceded by behavioural
therapy) appears significantly more effective than sertraline preceded by behavioural therapy (one RCT,140
72 participants) [MD 1.89 minutes (95% CI 0.54 to 3.24 minutes); p< 0.00001 and p= 0.006,
respectively]. No significant difference was evident between tadalafil and fluoxetine. A crossover RCT of
31 participants also suggests that sildenafil is more effective than paroxetine, sertraline or clomipramine.39
No significant difference was evident between tadalafil and fluoxetine from one RCT.145 Pooled effects
across three RCTs120,141,145 (222 participants) suggests that PDE5 inhibitors in combination with a SSRI are
significantly more effective than a SSRI alone with sildenafil plus sertraline demonstrating the greatest
significant effect [MD 1.70 minutes (95% CI 1.64 to 1.76 minutes); p< 0.0001].
In comparison with behavioural interventions, sildenafil appears to be significantly more effective than
the squeeze technique (one RCT144 with 120 participants and one crossover RCT39 with 31 participants)
[(data not pooled) and one RCT144 with 120 participants (MD 3.56 minutes, 95% CI 3.16 to 3.96 minutes)],
and sildenafil combined with behavioural therapy is significantly more effective than behavioural therapy
alone (one RCT,143 60 participants) [MD 1.81 minutes (95% CI 1.53 to 2.09 minutes)].
Various assessment methods have been used across RCTs to measure effectiveness in terms of patient/
partner sexual satisfaction, and other outcomes, although the between-group significance is often unclear
or not reported. Outcomes appear to favour PDE5 inhibitors in comparison with placebo and PDE5
inhibitors combined with another therapy (SSRI or behavioural therapy) compared with another therapy
(SSRI or behavioural therapy) alone. However, in the current evidence base, data are poorly reported and
do not permit any meaningful interpretation of the efficacy of PDE5 inhibiters on efficacy outcomes other
than IELT.
There is some evidence suggesting that both sildenafil and tadalafil are associated with a greater incidence
of flushing and headache, and that tadalafil is also associated with palpitations. However, these data are
difficult to extrapolate in order to estimate any between-group comparisons with other treatments.
In addition, AE data are limited across the current evidence base for other PDE5 inhibitors.
Certain PDE5 inhibitors have been evaluated against placebo, while others are evaluated against SSRIs or
behavioural therapy, or, in combination with a SSRI or behavioural therapy, have been evaluated against
SSRI monotherapy or behavioural monotherapy. This variability of treatment comparisons in RCTs assessing
PDE5 inhibitors limits definitive conclusions regarding an appropriate choice in terms of efficacy and safety
for the treatment of men with PE. In addition, the long-term effects of PDE5 inhibitors in the treatment
of PE are not evaluated in the current evidence base.
Alpha-blockers
Characteristics of included studies: alpha-blockers
Two RCTs were identified that evaluated alpha-blockers107,146 and both were captured by the search
strategy for this assessment report. The RCT by Cavallini146 was evaluated by two systematic reviews
evaluating pharmacotherapies.52,69 The overall AMSTAR quality score was 1 out of 11 for both of these
reviews (see Table 11). Full details of the AMSTAR assessment for these and all other included reviews are
presented in Appendix 4. The RCT by Tuncel et al.107 was identified by the literature search.
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Cavallini146 included men with primary PE with an IELT ≤ 1 minute on more than 50% of occasions.
Ninety-one patients were allocated to alfuzosin 6mg, terazosin 5mg or vitamin C 1mg in a crossover
design trial, 2 months per treatment phase. Ejaculatory control was assessed by patient self-report. The RCT
by Tuncel et al.107 was undertaken in Turkey and 90 patients were randomised to receive clomipramine 25mg
per day, sertraline 50mg, terazosin 5mg or placebo. Treatment duration was 2 months, but IELT was not
assessed. The authors reported that 90 out of 90 (100%) patients completed the trial. This trial considered to
be at overall unclear risk of bias. This trial is also evaluated in the SSRIs inhibitors and PDE5 inhibitors sections
of this report.
Details of these trials are presented in Table 30.
Assessment of effectiveness: alpha-blockers – intravaginal ejaculatory latency
time outcomes
An objective assessment of IELT was not reported by either of the two RCTs evaluating alpha-blockers
identified for inclusion in this assessment report.
Assessment of effectiveness – alpha-blockers: other outcomes
Details of outcome results other than IELT and AEs are presented in Table 31.
Other outcomes: terazosin compared with tricyclic antidepressants, selective serotonin reuptake
inhibitors or placebo Tuncel et al.107 reported that terazosin, clomipramine and sertraline were all
significantly better than placebo on ejaculation control, but that there was no significant difference
between the active treatments on this outcome.
Other outcomes: alfuzosin or terazosin compared with vitamin C A significant ejaculatory latency
increase was reported for the RCT by Cavallini.146 The proportion of patients by treatment group with a
‘positive’ result for this outcome was reported as 46.2% with alfuzosin, 53.7% with terazosin and 24.2%
with vitamin C. However, no p-values were reported and it was unclear whether the reported ‘significant
increase’ was across or between groups.
Assessment of safety: alpha-blockers – adverse events
Adverse events: clomipramine compared with placebo Tuncel et al.107 reported that there were no
significant differences between clomipramine, sertraline and terazosin in the number of patients reporting
AEs of headache, hypotension, drowsiness and ejaculation disorder.
Adverse events: alfuzosin or terazosin compared with vitamin C Adverse events were not reported
for the RCT by Cavallini.146
Assessment of effectiveness: alpha-blockers – evidence summary
The current evidence base for alpha-blockers in the treatment of PE comprises two RCTs,39,107 one captured
in low methodological quality systematic reviews39 and one further RCT which is at overall unclear risk of
bias.107 An assessment of IELT is not reported for either these trials.
Ejaculation control is reported by both RCTs assessing alpha-blockers. Evidence from one of these trials
suggests that terazosin, clomipramine and sertraline were all significantly better than placebo on the
outcome of ejaculation control,107 but that there is no significant difference between the active treatments
on this outcome. Other RCT evidence for this outcome is unclear.39
One RCT suggests that there is no significant difference between terazosin, clomipramine and sertraline
and in the number of patients reporting AEs of headache,107 hypotension, drowsiness and ejaculation
disorder. However, this observation should be interpreted with caution given the unclear methodological
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quality of the trial. The current evidence base for alpha-blockers in the treatment of PE in terms IELT and
other secondary outcomes is limited.
Opioid analgesics
Characteristics of included studies: opioid analgesics
Tramadol was evaluated by three systematic reviews,147–149 two of which pooled data in a meta-analysis.148,149
A further two RCTs were identified, one of which evaluated tramadol at 25mg, 50mg and 100mg per day
doses (no other comparator or placebo arm),154 while the other evaluated 25mg per day against placebo.155
Reviews The three systematic reviews were all conducted in China.147–149 The overall AMSTAR quality score was
1 out of 11 in one of the reviews,147 2 out of 11 in another148 and 6 out of 11 in the last.149 Details of the review
type, the databases searched and dates, relevant included RCTs and the AMSTAR points awarded to these
reviews, are presented in Table 32. Full details of the AMSTAR assessment for these and all other include
reviews are presented in Appendix 4. The search methodology and inclusion criteria varied across these reviews.
Of the two reviews including a meta-analysis, the review by Wu et al.148 pooled data across different study types
TABLE 31 Alpha-blockers: outcomes other than IELT and AEs
RCT duration Treatment
Outcome
measure Results
Between-group
difference
reported as
significant AEs
aCavallini 1995,146
2 months per
treatment
Alfuzosin 6mg Ejaculatory
control
Percentage of
‘positive’ results:
alfuzosin, 46.2%;
terazosin, 53.7%;
vitamin C, 24.2%
Unclear NR
Terazosin 5mg
Vitamin C 1mg
Total n= 91
Tuncel et al.
2008,107
treatment was
for 2 months
Sertraline
50mg/day
(n= 23)
Ejaculation
control,
self-assessed
Ejaculation control:
n/N (%) reporting
‘no change’,
‘improvement’,
‘under control’
Yes compared
with placebo
% AEs:
Clomipramine
25mg/day
(n= 20)
All three treatments
were ‘superior to
placebo’ – p= 0.001
Clomipramine – headache,
34.8%; hypotension, 4%;
drowsiness, 8.6%;
ejaculation disorder, 0%
No significant
difference in efficacy
between ‘medical
treatments’ –
p= 0.537
Sertraline – headache,
25%; hypotension, 0%;
drowsiness, 15%;
ejaculation disorder, 0%
Terazosin
5mg/day
(n= 25)
Terazosin – headache,
20%; hypotension, 12%;
drowsiness, 0%;
ejaculation disorder, 8%
Placebo (n= 22) Placebo – headache,
9.1%; hypotension, 0%;
drowsiness, 0%;
ejaculation disorder, 0%
No significant differences
between ‘medical
treatment groups’ –
p= 0.204
NR, not reported.
a Crossover study.
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(observational studies and RCTs) using a MD. The authors also included different dosing arms from studies
separately in the meta-analysis, but included the comparator arm (placebo) against each dosing arm in effect
counting participants twice in the analysis. Likewise, the authors also pooled together data from the same arm
at different time points (i.e. the same study group was counted twice in the analysis). In the review by Yang
et al.,149 the authors pooled IELT effect estimates across studies using a standardised MD.
Randomised controlled trials included in reviews The reviews above varied in terms of which RCTs
they included. In total, five RCTs46,150–153 (total n= 863) were included in at least one review. IELT was
reported as being assessed using a stopwatch in all five RCTs. Duration of the RCTs included in these
reviews ranged from 6 to 12 weeks and comparators to tramadol within the RCTs included in these review
were behavioural therapy, paroxetine, or placebo. Tramadol doses varied from 25mg to 89mg, taken as
needed, usually 2–3 hours preintercourse. Details of the RCTs extracted from these reviews are presented
in Table 33. All RCTs in reviews were captured by the search strategy for this assessment report.
Randomised controlled trials not included in reviews The RCT by Eassa and El-Shazly154 was conducted
in Egypt and patients were randomised 100 per group to tramadol at 25mg, 50mg and 100mg 2 to 3 hours
preintercourse. The authors reported that all patients completed the 24 week follow-up and IELT was
stopwatch assessed. Of note, the authors reported a mean baseline IELT of 2.82, 2.79 and 2.99 minutes for
each of the treatment groups, respectively. This was noticeably higher than any other RCT, for any treatment,
identified for inclusion in this assessment report. The RCT by Generali and Cada155 was conducted in the USA.
Patients were randomised to tramadol 50mg 2 hours before intercourse or placebo. Fifty-seven patients
TABLE 32 Opioid analgesics, tramadol: details of reviews and AMSTAR quality score
Author (country)
review type
Databases searched and
dates
Included RCTs relevant to this
section
AMSTAR review
quality assessment
Wong and Malde
2013147 (China)
systematic review
PubMed 2006 to March
2012
Alghobary et al. 2010,150 Bar-Or
et al. 2012,151 Kaynar et al. 2012,152
Safarinejad and Hosseini 2006153
AMSTAR score, 1/11:
l characteristics of
included studies
reported
Wu et al. 2012148 (China)
systematic review and
meta-analysis
The Cochrane Library,
MEDLINE, EMBASE, and
Science Citation Index
Expanded Until the end of
February 2012, with no
lower date limit
Alghobary et al. 2010,150 Bar-Or
et al. 2012,151 Kaynar et al. 2012,152
Safarinejad and Hosseini 2006,153
Xiong et al. 201146
AMSTAR score, 2/11:
l characteristics of
included studies
reported
l study quality
assessed
Yang et al. 2013149
(China) systematic review
and meta-analysis
PubMed, EMBASE, CCRT
and the Cochrane
Database of Systematic
Reviews 1980 to April
2012 all databases
Bar-Or et al. 2012,151 Kaynar et al.
2012,152 Safarinejad and Hosseini
2006,153 Xiong et al. 201146
AMSTAR score, 6/11:
l duplicate study
selection and
extraction
l comprehensive
literature search
l characteristics of
included studies
reported
l study quality
assessed
l appropriate
methods used to
pool data
l conflict of interest
statement reported
AMSTAR review quality criteria: a priori design, duplicate study selection and data extraction; comprehensive literature
search of databases and other supplementary sources; studies included regardless of publication type; list of studies
(included and excluded); characteristics of included studies reported; study quality assessed; study quality used to informed
conclusions; appropriate methods used to pool data; publication bias assessed; and conflict of interest statement included.
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completed the 8-week study and the IELT assessment method was not reported. Variance estimates for the
outcome data were not reported by the authors and were imputed for this assessment report using the
reported p-values employing methods detailed in the Cochrane Reviewer’s Handbook.31 Both of these trials
were considered to be at overall unclear risk of bias.
Details of the treatments evaluated, definition of PE, IELT assessment method, other outcomes assessed,
study duration, along with the study country for the further RCTs not in reviews, and the overall study
quality assessment (AMSTAR33 for reviews and Cochrane risk of bias assessment34 for the RCTs not
included by reviews) are presented in Table 33.
Assessment of effectiveness: opioid analgesics – intravaginal ejaculatory latency
time outcomes
Intravaginal ejaculatory latency time outcomes were reported for all of the RCTs identified from existing
reviews and the two further RCTs identified for inclusion in this review.
Intravaginal ejaculatory latency time: tramadol compared with placebo Meta-analysis of mean IELT
change (minutes) at 8- or 12-week follow-up, based on five RCT study group comparisons from four RCTs
(n= 776),151–153,155 displayed moderate heterogeneity (I2= 70%). The pooled MD in IELT was 1.35 minutes,
significantly favouring tramadol [MD (random effects) 95% CI 0.63 to 2.07 minutes; p= 0.0002]. The
forest plot for this analysis is presented in Figure 18. Summary results for these, and all other
meta-analyses, are presented in Table 33.
Intravaginal ejaculatory latency time: tramadol compared with paroxetine The between-group
difference in mean IELT change (minutes) at 6 weeks, based on one RCT150 (n= 70) was –0.83 minutes
(95% CI –1.80 to 0.14 minutes; p= 0.09). The forest plot for this analysis is presented in Figure 18.
Intravaginal ejaculatory latency time: tramadol with behavioural therapy compared with
behavioural therapy alone The between-group difference in mean IELT (minutes) at 12 weeks, based on
one RCT46 (n= 72) was 1.65 minutes, significantly favouring tramadol with behavioural therapy (95% CI
0.30 to 3.00 minutes; p= 0.02). The forest plot for this analysis is presented in Figure 18.
Intravaginal ejaculatory latency time: tramadol 25mg, 50mg or 100mg One RCT154 (n= 300)
evaluated three different doses of tramadol. The between-group differences in mean IELT (minutes) at
24 weeks were 10.65 minutes in favour of tramadol 50mg compared with 25mg (95% CI 9.76
to 10.76 minutes; p< 0.00001); 23.32 minutes in favour of tramadol 100mg compared with 25mg
(95% CI 22.59 to 24.05 minutes; p< 0.00001); and 13.06 minutes in favour of tramadol 100mg
compared with 50mg (95% CI 12.33 to 13.79 minutes; p< 0.00001). The forest plot for this analysis is
presented in Figure 19.
Assessment of effectiveness: opioid analgesics – other outcomes
With the exception of the RCT by Eassa and El-Shazly154 that did not report any outcomes other than IELT,
all of the included trials reported one or more other outcomes. However, these were diverse across the
include trials and were often not reported in sufficient detail to permit any pooling across trials (Table 34).
Other outcomes: tramadol compared with placebo Bar-Or et al.151 reported an improvement in 62-mg
and 89-mg tramadol dose groups compared with placebo on measures of the PEP (p< 0.05 for all). Generali
and Cada155 reported a change from baseline in the IIEF mean number of acts of coitus per week and mean
intercourse satisfaction associated with tramadol (p< 0.05). However, p-values were not reported for the
placebo group (data by group not reported). Kaynar et al.152 reported improvements on ability of ejaculation
control (AEC) (AEC score: placebo increased from 0.93 to 1.50; tramadol increased from 0.83 to 2.83) and
sexual satisfaction scores (placebo increased from 0.80 to 1.33) for tramadol over placebo (p< 0.001 for both),
although the instrument was not described. Safarinejad and Hosseini153 reported a between-group difference
of p< 0.05 on the IIEF intercourse satisfaction score (tramadol mean change 4, placebo –1).
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Other outcomes: tramadol plus behavioural therapy compared with behavioural therapy
Xiong et al.46 reported a significant between-group difference in IIEF intercourse satisfaction (p< 0.05) in
favour of tramadol plus behavioural therapy.
Other outcomes: tramadol compared with paroxetine Alghobary et al.150 was the only RCT to employ
the AIPE. The reviewers reported that paroxetine improved AIPE at 6 weeks (p< 0.05) and 12 weeks
(p< 0.05), whereas tramadol improved AIPE at 6 weeks but not at 12 weeks.
Other outcomes: tramadol with behavioural therapy compared with behavioural therapy
alone Xiong et al.46 reported a between-group difference at 8 weeks of p< 0.05 on the IIEF favouring the
tramadol group. This trial is also evaluated in the Behavioural therapies section.
Assessment of safety: opioid analgesics – adverse events
No AEs were reported for the RCT by Alghobary et al.150 When reported, AEs associated with tramadol
included erectile dysfunction, constipation, nausea, headache, somnolence, dry mouth, dizziness, pruritus
(itching) and vomiting. Numbers of patients by treatment groups experiencing AEs were reported by all
RCTs. The trial by Eassa and El-Shazly,154 which compared tramadol at different doses, reported that
all patients in the trial experienced one or more AEs (all experienced somnolence and pruritus).
Adverse events: tramadol compared with placebo Meta-analysis of numbers experiencing AEs at
8- or 12-week follow-up displayed low heterogeneity (I2= 0%). The pooled RR across trials was 2.14
experiencing AEs [RR (fixed effect) 95% CI 1.36 to 3.38; p= 0.001] in favour of placebo (lower risk).
The forest plot for this analysis is presented in Figure 20. Results for these, and all other meta-analyses,
are presented in Table 35.
Adverse events: tramadol with behavioural therapy compared with behavioural therapy
alone The between-group difference in RR at 12 weeks was 21.00 [RR (random effects) 95% CI 1.28 to
345.410; p= 0.03] in favour of behavioural therapy alone (lower risk). The forest plot for this analysis is
presented in Figure 20. An assessment of between study heterogeneity could not be undertaken for this
comparison as only one trial was included.
Assessment of effectiveness: opioid analgesics – evidence summary
The current evidence base for tramadol in the treatment of PE comprises seven RCTs,46,150–155 five46,150–153
captured in three low to moderate methodological quality systematic reviews and two further RCTs154,155
which are at overall unclear risk of bias. The pooled evidence across five RCT study groups151–153,155
(776 participants) suggests that tramadol is effective in increasing IELT in men with PE when compared
with placebo [MD 1.35 minutes (95% CI 0.63 to 2.07 minutes); p= 0.0002]. Evidence from one RCT46
(72 participants) suggests that tramadol combined with behavioural therapy is significantly more effective
than behavioural therapy alone in increasing IELT [MD 1.65 minutes (95% CI 0.30 to 3.00 minutes);
p= 0.02]. The evidence from one RCT150 (70 participants) suggests that there is no statistically significant
difference in IELT between tramadol and paroxetine.
Various assessment methods in terms of ejaculation control, patient/partners sexual satisfaction, anxiety
and other patient-reported outcomes have been used across RCTs to measure the effectiveness of
tramadol. Four46,151–153 out of five RCTs46,151–153,155 reported that tramadol was significantly more effective
than placebo for various patient-reported outcomes, while one RCT155 did not report any significant
between-group differences. Pooled evidence across trials151–153,155 (587 participants) suggests that tramadol
is associated with significantly more AEs including erectile dysfunction, constipation, nausea, headache,
somnolence, dry mouth, dizziness, pruritus (itching) and vomiting, than placebo or behavioural therapy
over 8–12 weeks of treatment. Addiction to tramadol by patients treated with this agent for PE is not
assessed in the current evidence base. Likewise, patient acceptability of treatment is not reported.
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Tramadol appears more effective than placebo or behavioural therapy in the treatment of PE. However,
these findings should be interpreted with caution given the observed levels of between-study
heterogeneity and the methodological quality of the available evidence. In addition, the variability across
placebo-controlled trials in terms of the tramadol dose evaluated and the treatment duration does not
permit any assessment of a safe and effective minimum daily dose. Furthermore, the long-term effects and
side effects of the treatment for men with PE have not been evaluated in the current evidence base.
Other therapies: acupuncture
Characteristics of included studies: acupuncture
No RCTs evaluating acupuncture were included in any of the systematic reviews identified for inclusion
in this assessment report. Two RCTs were identified through the literature searches, one of which
evaluated acupuncture compared with citalopram,156 while the other evaluated acupuncture compared
with sham acupuncture or paroxetine.157
Randomised controlled trials not included in reviews The RCT by Chen156 was conducted in China.
A total of 111 patients were randomised to daily acupuncture or citalopram (described as Sailete tablets)
20mg per day. The trial was reported in Chinese with an English-language abstract. Treatment duration
was 4 weeks and the authors reported that 111 out of 111 (100%) patients completed the trial, but the
assessment method of IELT was not reported. The RCT by Sunay et al.157 was conducted in Turkey
and 90 patients were recruited to the trial and were randomised to either acupuncture twice a week, sham
acupuncture twice a week or paroxetine 20mg per day. The authors reported that 90 out of 90 (100%)
patients completed the intervention. Both of these trials were considered to be at overall unclear risk of bias.
Details of the treatments evaluated, definition of PE, IELT assessment method, other outcomes assessed,
study duration, along with the study country for the further RCTs not in reviews and the overall study
quality assessment (Cochrane risk of bias assessment34) are presented in Table 36.
Assessment of effectiveness: acupuncture – intravaginal ejaculatory latency
time outcomes
The RCT by Chen156 employed the CIPE. The CIPE has 10 questions focusing on libido, erectile function,
ejaculatory latency, sexual satisfaction and difficulty in delaying ejaculation, self-confidence and depression.
However, the authors only reported an overall score (see Assessment of effectiveness: acupuncture – other
outcomes). Sunay et al.157 reported IELT outcomes as median and mean rank values post treatment and
change from baseline. The mean rank increase with paroxetine, acupuncture and sham acupuncture were
1.38 minutes, 1.10 minutes and 0.55 minutes, respectively. The authors reported that statistically
significant between-group differences were determined for mean rank IELTs for paroxetine compared with
sham acupuncture in favour of paroxetine (p= 0.001), acupuncture compared with sham acupuncture in
favour of acupuncture (p= 0.001) and paroxetine compared with acupuncture in favour of paroxetine
(p= 0.001) after treatment.
Assessment of effectiveness: acupuncture – other outcomes
Chen156 reported that the change from baseline in cumulative CIPE scores were statistically significant
with both acupuncture and with citalopram and that the between-group difference post treatment was
statistically significant in favour of acupuncture (Table 37). The RCT by Sunay et al.157 reported that median
PEDT scores were significantly improved from baseline in both the acupuncture and paroxetine groups,
but not in the sham acupuncture group. The authors also reported that both acupuncture and paroxetine
were significantly better than sham acupuncture on this outcome; however, that there was no statistically
significant between-group difference between acupuncture and paroxetine. Similarly, that no significant
differences were found between PEDT subscores (ejaculation control, frequency, minimal stimulation,
distress, interpersonal difficulty) for the paroxetine and acupuncture groups before and after treatment,
but significant differences were determined between the paroxetine and placebo groups and between the
acupuncture and placebo groups after treatment.
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Assessment of safety: acupuncture – adverse events
Adverse event data were not reported for the RCT by Chen.156 Sunay et al.157 reported that no
questionnaire was used to evaluate the side effects; however, no side effects were observed in any
of the patients.
Assessment of effectiveness: acupuncture – evidence summary
The current evidence base for acupuncture in the treatment of PE comprises two RCTs156,157 that compare
acupuncture with SSRIs (citalopram and paroxetine) that are at overall unclear risk of bias. Evidence from
one of these RCTs157 suggests that both acupuncture and paroxetine are both effective in increasing IELT in
men with PE when compared with sham acupuncture. However, that paroxetine is more effective than
acupuncture in increasing IELT.
Evidence from one RCT156 suggests that subjective measures of libido, erectile function, ejaculatory latency,
sexual satisfaction and difficulty in delaying ejaculation, self-confidence and depression are significantly
improved with both acupuncture and citalopram and that the difference is greater with acupuncture.
Conversely, evidence from one RCT157 suggests that there is no statistically significant difference in
subjective measures of ejaculation control, frequency, minimal stimulation, distress and interpersonal
difficulty, between acupuncture and paroxetine. Treatment-related AEs for acupuncture in the treatment
of PE are not well reported in the current literature.
Acupuncture appears more effective than citalopram but not paroxetine in the treatment of PE. The AEs
associated with acupuncture in the treatment of PE are unclear. However, these finding should be
interpreted with caution given the limited available evidence for this treatment.
TABLE 37 Acupuncture: outcomes other than IELT and AEs
RCT, duration Treatment Outcome measure Results
Between-group
difference reported
as significant AEs
Chen 2009,156
4 weeks
Acupuncture
daily (n= 56)
CIPE Change from baseline:
acupuncture, p< 0.01;
citalopram, p< 0.05
Yes NR
Citalopram
20mg per
day (n= 55)
Between group difference
in post-treatment scores,
p< 0.05 (favouring
acupuncture)
Sunay et al.
2011,157
4 weeks
Acupuncture
2 ×weekly
(n= 30)
PEDT Change from baseline:
paroxetine, p= 0.001;
acupuncture, p= 0.001
Yes for acupuncture
and paroxetine from
baseline and vs. sham
acupuncture
No AEs were
reported by
patients
Sham
acupuncture
2 ×week
(n= 30)
Sham acupuncture,
p= 0.314
Paroxetine
20mg per
day (n= 30)
Between-group differences:
paroxetine vs. acupuncture,
p=NS; paroxetine vs. sham
p= 0.001; acupuncture
vs. sham, p= 0.001
No between
acupuncture and
paroxetine
NR, not reported; NS, not significant.
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Other therapies: Chinese medicine
Characteristics of included studies: Chinese medicine
No RCTs evaluating Chinese medicine were included in any of the systematic reviews identified for
inclusion in this assessment report, but five RCTs158–162 were identified through the literature searches.
One compared Chinese medicine combined with sertraline and counselling with sertraline alone,158
one compared Chinese medicine with treatment as usual,159 one compared Chinese medicine with
fluoxetine,160 one compared Chinese medicine alone with Chinese medicine combined with trazodone
[a serotonin antagonist and reuptake inhibitor (SARI) antidepressant]161 and one compared Chinese
medicine adjuvant to behavioural therapy with behavioural therapy alone.162
Randomised controlled trials not included in reviews All five RCTs158–162 were undertaken in China
and three were reported in Chinese with an English-language abstract.158,160,161 Pei and Shi158 randomised
110 patients to Wu Bei Zi (Galla Chinensis) and Xi Xin (Asari Herba) combined with sertraline and
counselling or sertraline alone; no further treatment details were reported. The assessment method of IELT
was not reported. Treatment duration was 4 weeks and the authors reported that 110 out of 110 (100%)
patients completed the trial. In the trial by Song et al.,159 68 patients were randomised to Uighur medicine
(ingredients: Radix anacycli pyrethri, Mastiche, Fructus Cardamomi, Rhizoma Cyperi, Stigma Croci, Semen
Myristicae, Radix Curcumae, Folium Syringae oblatae, Radix et Rhizoma Nardostachyos, Fructus Tsaoko and
Flos Rosae rugosae), four tablets twice a day or treatment as usual (no tablets). IELT was assessed by a
questionnaire designed for the study and all patients were reported as completing the 15-day trial.
Sun et al.160 evaluated Yimusake (Arabian Olibanum, Moschus, Stigma Croci, Testis Et penis Bovis seu
Bubali, Ambra Grisea, Semen Myristicae, Rhizoma Alpiniae Officinarum, Flos Caryophylli, Salep, Semen
Strychni, Pericarpium Papaveris) 1.5 g per day, fluoxetine 20mg per day, and Yimusake 1.5 g combined
with fluoxetine 20mg per day. Thirty-eight patients were randomised to each of the three treatment
groups and all were reported as completing. The IELT assessment method was not reported, but duration
was 4 weeks. The RCT by Xu et al.161 compared Yimusake 50mg per day with Yimusake 50mg per day
combined with trazodone 50mg per day. The IELT assessment method was not reported, but duration
was 4 weeks. The authors reported that 68 out of 68 (100%) patients completed the trial. The RCT by
Zhang et al.162 randomised 28 patients to Xuanju compound (Formica fusca, Herba epimedii, Fructus cnidii
and Fructus lycii) with sensate focus and 24 patients to sensate focus alone. The IELT assessment method
was not reported, but treatment was for 4 weeks and all patients (100%) were reported as completing.
All five trials were at overall unclear risk of bias.
Details of treatments evaluated, definition of PE, IELT assessment method, other outcomes assessed, study
duration and country for the further RCTs not in reviews, and the overall study quality assessment
(Cochrane risk of bias assessment34) are presented in Table 38.
Assessment of effectiveness: Chinese medicine – intravaginal ejaculatory latency
time outcomes
With the exception of the RCTs by Pei and Shi158 and Zhang et al.,162 IELT outcomes were reported for all
of the included trials.
Intravaginal ejaculatory latency time: Chinese medicine (Uighur medicine) compared with
treatment as usual The between-group difference in mean IELT change (minutes) at 4 weeks, based on
one RCT (n= 68) was 1.57 minutes (95% CI 1.11 to 2.03 minutes; p< 0.00001) in favour of
Chinese medicine.159
Intravaginal ejaculatory latency time: Chinese medicine (Yimusake) compared with fluoxetine
The between-group difference in mean IELT change (minutes) after 15 days, based on one RCT (n= 76)
was 0.60 minutes (95% CI 0.19 to 1.01 minutes; p= 0.004) in favour of fluoxetine.160
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Intravaginal ejaculatory latency time: Chinese medicine (Yimusake) compared with Chinese
medicine combined with fluoxetine The between-group difference in mean IELT change (minutes) after
15 days, based on one RCT (n= 76) was 2.50 minutes (95% CI 2.08 to 2.92 minutes; p< 0.00001) in
favour of Chinese medicine combined with fluoxetine.160
Intravaginal ejaculatory latency time: Chinese medicine (Yimusake) combined with fluoxetine
compared with fluoxetine The between-group difference in mean IELT change (minutes) after 15 days,
based on one RCT (n= 76) was 1.90 minutes (95% CI 1.47 to 2.33 minutes; p< 0.00001) in favour of
Chinese medicine combined with fluoxetine.160
Intravaginal ejaculatory latency time: Chinese medicine (Yimusake) compared with Chinese
medicine combined with trazodone The between-group difference in mean IELT change (minutes)
at 4 weeks, based on one RCT (n= 68) was not significant (MD 0.08 minutes 95% CI –0.19 to
0.35 minutes; p= 0.56).161
The forest plot for these analyses is presented in Figure 21.
Assessment of effectiveness: Chinese medicine – other outcomes
A greater proportion of patients receiving Chinese medicine combined with sertraline and sexual
counselling than those receiving sertraline alone reported an effectiveness rating of ‘effective’ or ‘improved’
in the RCT by Pei and Shi.158 The between-group difference in the number of patients reporting ‘effective’
or ‘improved’ estimated using RevMan for this assessment reported was 1.21 in favour of Chinese medicine
combined with sertraline and sexual counselling compared with sertraline alone [RR (fixed effect), 95% CI
1.01 to 1.43; p= 0.03] (figure not presented).
Song et al.159 reported a statistically significant between-group difference in Chinese medicine compared
with care as usual in favour of Chinese medicine on sexual satisfaction and ejaculation control measures of
the Chinese index of sexual function for PE scale for PE-related items. Sun et al.160 reported that Chinese
medicine combined with fluoxetine was significantly better than fluoxetine alone or Chinese medicine
alone, on a measure of patient and partner intercourse satisfaction. Xu et al.161 reported the number of
patients as ‘total efficacious’ (assume ‘improved’ or ‘cured’). The between-group difference was not
significant (p= 0.27). In the RCT by Zhang et al.,162 a greater proportion of patients in the Chinese medicine
combined with behavioural therapy than those in the behavioural therapy alone group reported a ‘cure
rate’ of ‘cured’ or ‘improved’ on an overall ‘Cure rate and rate of sexual satisfaction improvement’ rating.
The between-group difference in the number of patients reporting ‘cured’ or ‘improved’ estimated using
RevMan for this assessment reported was 1.92 in favour of Chinese medicine combined with behavioural
therapy [RR (fixed effect), 95% CI 1.27 to 2.92; p< 0.00001] (figure not presented).
Details of outcomes other than IELT and AEs are presented in Table 39.
Assessment of safety: Chinese medicine – adverse events
Reporting of AEs was only available for one of the included RCTs160 for which it was reported that the
AEs observed with Chinese medicine combined with fluoxetine were not significantly different to those
observed with Chinese medicine alone or fluoxetine alone. However, no details of the AEs assessed or a
p-value for between-group differences were reported.
Assessment of effectiveness: Chinese medicine – evidence summary
The current evidence base for Chinese medicine in the treatment of PE comprises five RCTs all at unclear
risk of bias. One comparing Wu Bei Zi and Xi Xin combined with sertraline and counselling with sertraline
alone, one comparing Uighur medicine with treatment as usual, one comparing Yimusake with fluoxetine
or Yimusake combined with fluoxetine, one comparing Yimusake with Yimusake combined with trazodone,
and one comparing Xuanju compound plus sensate focus with sensate focus alone. No placebo-controlled
trials of any Chinese medicine have been identified from the current literature. Evidence from one RCT159
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suggests Chinese medicine is significantly more effective than treatment as usual (no tablet) in increasing
IELT in men with PE (1.57 minutes, 95% CI 1.11 to 2.03; p< 0.00001). One RCT160 suggests that fluoxetine
is better than Chinese medicine and that Chinese medicine combined with fluoxetine is significantly better
than Chinese medicine alone or fluoxetine alone in increasing IELT [(0.60 minutes, 95% CI 0.19 to 1.01;
2.50 minutes, 95% CI 2.08 to 2.92; and 1.90 minutes, 95% CI 1.47 to 2.33 minutes), p= 0.004,
p< 0.00001 and p< 0.00001, respectively]. One RCT159 suggests no significant difference in IELT between
Chinese medicine combined with trazodone and Chinese medicine alone.
Evidence from one RCT each suggests that CIPE-assessed sexual satisfaction and ejaculation control are
better with Chinese medicine than treatment as usual and that a subjective measure of intercourse
satisfaction is better with Chinese medicine combined with a SSRI than Chinese medicine or SSRI alone.
Treatment-related AEs for Chinese medicine in the treatment of PE are not well reported in the
current literature.
Limited evidence suggests that Chinese medicine may be effective in the treatment of PE and that greater
efficacy is evident when Chinese medicine is combined with a SSRI. However, AEs associated with Chinese
medicine, with or without these secondary agents, in the treatment of PE are unclear. The long-term
effects of Chinese medicine in the treatment of PE and patient acceptability of the treatment are not
evaluated in the current evidence base.
Other therapies: delay devices
Characteristics of included studies: delay devices
No studies evaluating delay devices were included in any of the systematic reviews identified for inclusion
in this assessment report. One RCT was identified through the literature searches which evaluated a novel
desensitising band.163
The study was undertaken in the UK and PE was defined by DSM-IV diagnosis.163 The numbers of
lifelong/acquired PE was not reported. The device evaluated was a desensitising ring comprising a
stretchable latex ring with stimulating ridged plate which was used three times per week combined with
the stop–start technique which was compared with CBT (six sessions with a trained therapist) combined
with the stop–start technique. Twenty-six patients were randomised to each treatment group. The trial was
reported in conference poster format and treatment duration was unclear (possibly eight weeks).
Assessment was at the end of therapy and three months post treatment. The authors assessed PE and
other subscales of the GRISS questionnaire. The authors reported that 52 out of 52 (100%) patients
completed the study. This trial was considered at overall unclear risk of bias.
Assessment of effectiveness: delay devices – intravaginal ejaculatory latency
time outcomes
Wise et al.163 reported that the mean latency for coitus at completion was 8.8 minutes in the desensitising
band group and 2.6 minutes in the CBT group and that the between-group difference favouring the
desensitising band was significant (p< 0.002). However, it was unclear how this outcome was assessed as
the authors reported that stopwatches were not used.
Wise et al.163 reported that 16 out of 26 (62%) patients in the desensitising band group reported an
improvement in latency, compared with 11 out of 26 (42%) in the CBT group. The between-group
difference estimated using RevMan for this assessment report was 1.60 [RR (fixed effect), 95% CI 0.90 to
2.84; p= 0.11] (figure not presented).
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
142
Assessment of effectiveness: delay devices – other outcomes
Wise et al.163 reported that the GRISS subscales showed no statistically significant differences between
groups except in the PE subscale. The GRISS mean rank score was reported as being significantly lower
(better) in the desensitising band group compared with the CBT group at 8 weeks (p≤ 0.05) and
3 months (p< 0.05).
Assessment of safety: delay devices – adverse events
Adverse events were not reported in the RCT by Wise et al.163 A case study (six patients) report from the
same research group171 reported that the only side effect associated with the desensitising band was slight
soreness with over-use which was resolved when used as instructed.
Assessment of effectiveness: delay devices – evidence summary
The current RCT evidence base for delay devices in the treatment of PE comprises one study that compares
a desensitising band combined with the stop–start technique compared with behavioural therapy combined
with the stop–start technique.163 The RCT is considered to be at overall unclear risk of bias. Evidence from this
study suggests that a desensitising band combined with the stop–start technique is more effective than
behavioural therapy combined with the stop–start technique in increasing IELT in men with PE.
Evidence from the same RCT suggests that GRISS questionnaire assessed IELT appears improved with the
desensitising band and is continued with use over 3 months. Evidence from one case series study suggests
that soreness is reported with over-use but appears resolved when the device is used as instructed.171
Evidence from one RCT,163 that is considered to be at unclear risk of bias, suggests that desensitising bands
combined with the stop–start technique appear effective in increasing IELT in men with PE. The effects
of desensitising bands alone on PE are not evaluated in the current evidence base. AEs appear minimal
when these devices are used as directed.
Other therapies: yoga
Characteristics of included studies: yoga
No RCTs evaluating yoga were included in any of the systematic reviews identified for inclusion in this
assessment report. One observational study (non-RCT) was identified through the literature searches which
evaluated yoga compared with fluoxetine.164 In the absence of any RCT evidence for the effects of yoga
in the treatment of PE, this study was included in this assessment report.
The study was undertaken in India and PE was defined by DSM-IV diagnosis.164 The number of patients
with lifelong/acquired PE was not reported. Yoga (14 active and passive postures for 1 hour each day) was
compared with fluoxetine, 20–60mg per day (single dose). Patients self-selected to treatment groups and
study duration was 12 weeks. IELT was assessed using a stopwatch and partner satisfaction (‘good’, ‘fair’,
‘poor’ responses) was also assessed. The authors reported that 68 out of 68 (100%) patients completed
the study. This trial was considered at overall high-risk of bias.
Assessment of effectiveness: yoga – intravaginal ejaculatory latency time outcomes
The observational study by Dhikav et al.164 reported that the mean post-treatment IELT at the 8-week
follow-up was 1.07 minutes (SD 0.49 minutes) in the yoga group compared with 1.88 minutes
(SD 0.59 minutes) in the fluoxetine groups. The authors reported that the change from baseline was
significant in both groups (p< 0.0001). The between-group difference estimated using RevMan for
this assessment report was 0.81 minutes in favour of fluoxetine [MD (fixed effect), 95% CI 0.55 to
1.08 minutes; p< 0.0001] (figure not presented).
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Assessment of effectiveness: yoga – other outcomes
Dhikav et al.164 reported that in the yoga group, partner satisfaction was rated as ‘good’ by 25 out of
38 (65.6%) patients, ‘fair’ by 13 out of 38 (34.2%) patients and ‘poor’ by 0 out of 38 (0.0%) patients.
No data were reported for the fluoxetine group.
Assessment of safety: yoga – adverse events
Dhikav et al.164 reported that there were no significant side effects or dropouts during course of treatment
with yoga; however, no data were reported. The authors reported numbers of patients experiencing AEs
in the fluoxetine group of: nausea 14 out of 30 (46.7%); vomiting, 4 out of 30 (13.3%); anxiety, 4 out of
30 (13.3%); and insomnia, 8/30 (26.7%).
Assessment of effectiveness: yoga – evidence summary
The current evidence base for yoga in the treatment of PE comprises one observational study that compares
yoga with fluoxetine. The study is considered to be at overall high risk of bias base on participants
self-selecting to treatment groups (selection bias).164 In this study, both yoga and fluoxetine were reported
as significantly effective at increasing IELT following treatment. However, the between-group estimate post
treatment for this study suggests that fluoxetine is more effective than yoga in increasing IELT in men with
PE. However, these results should be interpreted with caution given the possibility of selection bias in
this study.
Evidence from the same study suggests that a high proportion of partners report a satisfaction rating of
yoga of ‘good’. No data for fluoxetine are reported for this outcome. AEs associated with fluoxetine
include nausea, vomiting, anxiety and insomnia, and AEs associated with yoga are not reported.
Based on one observational study that is considered to be at high risk of selection bias, fluoxetine appears
more effective than yoga in the treatment of PE, but is associated with AEs. The long-term effects of yoga
in treating men with PE and patient acceptability compared with fluoxetine are not adequately assessed in
the current evidence base.
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Chapter 4 Discussion
The purpose of this report was to systematically review the evidence for interventions in the treatmentof PE in men and to summarise this in the form of a short report. The treatments evaluated were those
relevant to the UK setting. RCTs in adult men with PE that evaluated a treatment of interest compared
with other interventions, waiting list control, placebo or no treatment were eligible for inclusion.
When RCT evidence was not available, other study types were considered. RCTs were identified from
existing systematic reviews and through literature searching. Data for RCT publications reported in existing
systematic reviews were extrapolated from the review article (not from the original RCT publications).
Methodological quality of included reviews and additional RCTs was assessed. The primary outcome was
IELT; other outcomes included sexual satisfaction, control over ejaculation, relationship satisfaction,
self-esteem, quality of life, treatment acceptability and AEs. When possible, data were pooled across trials
in a meta-analysis.
Statement of principal findings
Behavioural interventions
The evidence for behavioural therapy was reported in 12 RCTs:39–50 nine39–47 captured in two low-quality
reviews and one moderate quality Cochrane review, plus three further RCTs48–50 of unclear methodological
quality. The quality of reporting and diversity of outcome data did not permit pooling of effect estimates.
Individual trial results suggest that behavioural therapies improved both IELT and sexual satisfaction
compared with waiting list control. Behavioural therapies combined with pharmacological therapies (PDE5
inhibitors, SSRIs, chlorpromazine, tramadol) were better than behavioural therapy alone or pharmacological
agents alone in improving IELT, sexual satisfaction, sexual anxiety and ejaculation control. No AEs specific
to behavioural therapies were reported.
Topical anaesthetics
The evidence for topical anaesthetics was reported in nine RCTs,55–63 seven55–61 captured in three low
methodological quality systematic reviews and two further RCTs62,63 of unclear methodological quality.
Pooled evidence across RCTs suggests that both EMLA cream and TEMPE spray are more effective
than placebo in increasing IELT [MD 6.44 minutes, 95% CI 6.01 to 6.87 minutes (p< 0.00001); and
3.30 minutes, 95% CI 1.33 to 5.27 minutes (p= 0.001), respectively]. AEs include loss of sensation and
irritation for both men and women. Application of topical anaesthetics for ≥ 20 minutes preintercourse
appears to be associated with erection loss.
Selective serotonin reuptake inhibitors currently not licensed for
premature ejaculation
The evidence for SSRIs other than dapoxetine was reported in 42 RCTs,39,41,70–107,141,166 2639,41,70–91,141,166
captured in seven52,64–69 low methodological quality systematic reviews and 16 further RCTs,92–107
1492–94,96–100,104–107 of unclear methodological quality and two95,103 at high risk of bias. Treatment duration
was 4–12 weeks. Evidence suggests that citalopram is significantly more effective in increasing IELT than
placebo (MD 4.08 minutes, 95% CI –3.40 to 4.76 minutes; MD 4.62 minutes, 95% CI 4.21 minutes to
5.03 minutes; both p< 0.00001). Citalopram is also significantly more effective than no treatment (MD
3.14 minutes, 95% CI 2.47 minutes to 4.35 minutes; p< 0.00001). Escitalopram significantly increased
IELT compared with placebo (MD 1.2 minutes, 95% CI 0.79 to 1.61 minutes; geometric mean 3.5 minutes,
95% CI 1.96 to 5.04 minutes; both p< 0.00001). Fluoxetine significantly increased IELT compared with
placebo (MD 2.41 minutes, 95% CI 2.10 to 2.73 minutes; p< 0.00001). There was no significant difference
in IELT between fluvoxamine and placebo. Paroxetine significantly increased IELT compared with placebo
(MD 5.34 minutes, 95% CI 3.79 to 6.89 minutes; p< 0.00001) and improved sexual satisfaction. Sertraline
significantly increased IELT compared with placebo (MD 2.72 minutes, 95% CI 1.77 to 3.67 minutes;
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p< 0.00001) and improved ejaculation control. AEs included nausea, headache, insomnia, dry mouth,
diarrhoea, drowsiness, dizziness, somnolence, decreased libido and anejaculation.
Selective serotonin reuptake inhibitors licensed for premature
ejaculation (dapoxetine)
The evidence for dapoxetine at 30mg or 60mg on demand (approved doses in the UK) came from eight
RCTs113–116,118–120,170 including one Phase II RCT114 and six Phase III RCT85,113,116,118,119,170 reports captured in
six systematic reviews65,67,68,108–110 of low to moderate quality, plus one further RCT of low quality. The
pooled evidence across RCTs suggests that dapoxetine 30mg (three RCTs113,118,170) and 60mg (five
RCTs85,113,118,119,170) both significantly increased IELT compared with placebo (MD 1.16 minutes, 95% CI
0.94 to 1.39 minutes; and 1.66 minutes, 95% CI 1.46 to 1.87 minutes; both p< 0.00001). Dapoxetine
60mg was significantly more effective than 30mg (MD 0.46 minutes, 95% CI 0.19 to 0.74 minutes;
p= 0.0009). Similar effects were evident for ejaculatory control, sexual satisfaction, global impression of
change and clinical benefit. There was no significant difference in IELT between dapoxetine 30mg
combined with mirodenafil (PDE5 inhibitor) and dapoxetine 30mg alone. AEs included nausea, diarrhoea,
headache and dizziness and appear to be dose dependent.
Serotonin–noradrenaline reuptake inhibitors
The evidence for SNRIs was reported in three RCTs,121–123 one121 captured in a low-quality systematic
review, plus two further RCTs,122,123 one123 of unclear quality and one122 at high risk of methodological bias.
Evidence from one RCT121 indicated that duloxetine was significantly better than placebo in increasing IELT
(MD 1.52 minutes, 95% CI 0.08 to 2.24 minutes; p< 0.00001). Evidence from two RCTs122,123 suggests
that venlafaxine is not effective at increasing IELT compared with placebo. Duloxetine-associated side
effects are reported as dry mouth and nausea, and venlafaxine caused more side effects than placebo.
Tricyclic antidepressants
The evidence for clomipramine was reported in 13 RCTs,39,76,107,124–133 1039,76,124–131 captured in
low-to-moderate methodological quality systematic reviews, plus three further RCTs107,132,133 of unclear
quality. Both oral and nasal administration of clomipramine is evaluated in these trials. Existing study
evidence summarised by reviews suggests that oral clomipramine might be better than placebo at
increasing IELT,52,69 but the reviews are of low methodological quality and report pooled estimates based
on RCT and observational data. Inhaled clomipramine 4mg appears effective at increasing IELT compared
with placebo (1.68 minutes, 95% CI 1.06 to 2.29 minutes; p< 0.00001). Crossover trial evidence suggests
efficacy with 1mg or 2mg appears to be dose dependent, as do treatment-related side effects of local
irritation associated with nasal administration.
Phosphodiesterase-5 inhibitors
The evidence for PDE5 inhibitors was reported in 12 RCTs,39,55,101,120,138–145 1039,55,138–145 captured in
five37,134–137 systematic reviews of low to moderate methodological quality and two further RCTs97,116 of low
and unclear quality. Based on one RCT each, vardenafil138 and tadalafil141 both significantly increased IELT
compared with placebo, (MD 3.80 minutes, 95% CI 3.30 to 4.30 minutes; and 2.59 minutes, 95% CI 1.28
to 3.90 minutes; p< 0.00001 and p= 0.0001, respectively). There was no significant difference in IELT
between sildenafil and placebo in one RCT.142 Sexual satisfaction favoured PDE5 inhibitors compared with
placebo. Combined therapy (sildenafil plus sertraline or behavioural therapy) was better than sildenafil
alone. Some RCTs provided evidence that PDE5 inhibitors increased IELT more than SSRIs; however, no
significant difference was evident for some RCTs. AEs included flushing, headache and palpitations.
Alpha-blockers
The evidence for alpha-blockers was reported in two RCTs,39,107 one39 captured in low methodological
quality systematic reviews and one further RCT107 of unclear quality. IELT was not reported for either trial.
Evidence from one RCT107 suggested that terazosin, clomipramine and sertraline are all significantly better
than placebo on ejaculation control, with no significant difference between active treatments. The same
RCT reported no significant difference between terazosin, clomipramine and sertraline in the number
of patients reporting AEs of headache, hypotension, drowsiness and ejaculation disorder.
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Opioid analgesics: tramadol
The evidence for tramadol was reported in seven RCTs,46,150–155 five46,150–153 captured in three147–149 low to
moderate methodological quality systematic reviews and two further RCTs154,155 of unclear methodological
quality. Pooled evidence suggested that tramadol significantly increased IELT compared with placebo
(MD 1.35 minutes, 95% CI 0.63 to 2.07 minutes; p= 0.0002) and improved sexual satisfaction. One RCT46
suggested that tramadol combined with behavioural therapy was significantly more effective than
behavioural therapy alone (MD 1.65 minutes, 95% CI 0.30 to 3.00 minutes; p= 0.02). One RCT150 found
no statistically significant difference in IELT between tramadol and paroxetine. Tramadol was associated
with significantly more AEs than placebo, including erectile dysfunction, constipation, nausea, headache,
somnolence, dry mouth, dizziness, pruritus (itching) and vomiting. Addiction to tramadol was not assessed.
Other therapies: acupuncture
The current evidence base for acupuncture comprises two RCTs156,157 of unclear methodological quality
comparing acupuncture with SSRIs (citalopram and paroxetine). Acupuncture appeared to be more
effective than sham acupuncture or citalopram but paroxetine appeared to be more effective than
acupuncture. The AEs associated with acupuncture are unclear and the evidence base for this treatment
is limited.
Other therapies: Chinese medicine
The current evidence base for Chinese medicine comprises five RCTs158–162 of unclear methodological
quality. None was placebo controlled. These trials suggest that Chinese medicine is more effective than
treatment as usual (1.57 minutes, 95% CI 1.11 to 2.03 minutes; p< 0.00001) but that fluoxetine is better
than Chinese medicine (0.60 minutes, 95% CI 0.19 to 1.01 minutes; p= 0.004) in increasing IELT.
AEs were not well reported. The lack of any placebo comparisons in PE trials coupled with limited
evidence-based information regarding the efficacy and safety of Chinese medicine compounds limits the
interpretation of results.
Other therapies: delay devices
The current evidence base for delay devices comprises one RCT163 of unclear methodological quality.
This trial indicated that a desensitising band combined with the stop–start technique increased IELT more
than behavioural therapy combined with the stop–start technique. Soreness is reported with overuse but
appears resolved when the device is used as instructed.
Other therapies: yoga
The current evidence base for yoga comprises one observational study (non-RCT)164 comparing yoga with
fluoxetine. This study reported that a high proportion of partners reported a satisfaction rating of yoga of
‘good’. However, the IELT data suggested that fluoxetine is more effective than yoga. AEs associated
with yoga were not reported. These findings are limited by non-randomised trial design and no RCTs
assessing yoga for the treatment of PE were identified.
Strengths and limitations of the assessment
Strengths
Methodological considerations
This report has systematically reviewed the evidence for a range of treatments for PE. RCT evidence reported
in existing reviews along with further identified RCTs was included. Our literature search covered all dates
(from database inception to August 2013) in order to capture any studies missed by existing reviews in
addition to those published more recently. The current evidence base includes several systematic reviews
of PE treatments, many of which do not report a meta-analysis. Where meta-analyses are undertaken,
methodological errors are evident. These include combining RCTs with observational studies (and not
reporting which are which), double-counting participants within the meta-analyses (including the control
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group from a RCT twice when different treatments are assessed), pooling data from crossover and pairwise
RCTs (double counting for crossover trials), pooling between-group comparisons on questionnaire domains
(subgroups) as an overall effect for the same trial (double counting), and applying a standardised MD to pool
IELT effects where a MD is statistically more appropriate. This assessment report has pooled data across RCTs,
when appropriate, in a meta-analysis using a MD to summarise IELT outcomes, has avoided double-counting
of participants in the analysis and has considered pairwise and crossover RCT data separately. Furthermore, a
formal assessment of methodological quality was undertaken. This was undertaken for both reviews from
which RCT data were extrapolated and for any further RCTs identified by the searches not included in reviews.
Range of interventions assessed
The treatments evaluated in this assessment report were those relevant to the UK setting. In addition to
treatments currently recommended in clinical practice, other treatments, including Chinese medicine,
acupuncture, yoga and delay devices, were also evaluated, as patients might access these outside clinical
practice. These treatments have not previously been reviewed in the management of PE.
Limitations
Methodological considerations
This assessment report summarises a wide range of interventions from a large volume of trial evidence
and was undertaken within a limited timeframe. While RCT publications not already included in a review
were obtained in full and data extracted (and checked by a second reviewer), data for RCTs reported in
reviews were extracted (and checked) from the review article and not the original RCT publication. While
data extraction from reviews was optimised when more than one review reported data for the same RCT,
the reliability of the data extraction within the reviews cannot be guaranteed by this assessment report.
The methodological quality of the majority of existing reviews was low. Only four reviews reported
independent double data extraction36,53,135,149 (see Appendix 4). Reported search strategies varied in terms
of the search dates and resources searched. The search strategy for this assessment report covered all
dates (from database inception to August 2013) in order to capture any studies missed by existing reviews.
Within this assessment report, although quality assessment was undertaken for RCTs not included in
reviews, the methodological quality of individual RCTs reported in existing reviews was not assessed.
Of the nine existing reviews that reported undertaking quality assessment,35,36,38,51,53,64,65,108,110 quality scores
were reported by only four,35,51,53,64 across which the assessment method was diverse, including use of
an assessment instrument not appropriate for RCTs53 (the Newcastle–Ottawa Scale for assessing the quality
of non-randomised studies in meta-analyses).
Although the search strategy for this assessment report was comprehensive, the possibility of a publication
bias cannot be discounted. Nonetheless, given the unclear methodological quality of the majority of
included RCTs, coupled with the variability of treatment effects on IELT, it could be considered unlikely
that any additional unpublished data would contribute significantly to the overall findings.
Nature of the available evidence
Most trials comprised men with primary PE without a concomitant condition and excluded those with
erectile dysfunction. When reported, men were mainly recruited from specialist sexual health settings.
For this reason, effectiveness of in men with secondary PE, PE concomitant to another condition, or not
attending specialised clinics, is less certain. Trials were undertaken in a variety of European Union (EU) and
non-EU countries. Variability in cultural attitudes towards PE and acceptability of the various treatments
in trial populations, coupled with variability in PE definitions and IELT entry criteria, also limits the
generalisability of the findings.
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Within the current evidence base, there are very few RCTs of robust methodological quality that compare
one treatment with another in pairwise comparisons. A network meta-analysis has not been undertaken to
date. It is therefore difficult to make comparisons of efficacy between treatments. The only treatment
licensed for PE in the UK is dapoxetine, which has demonstrated modest but statistically significant
improvements in IELT and other outcomes, but is associated with AEs similar to those of other SSRIs.
Although some other treatments (e.g. topical) have shown greater IELT improvements than dapoxetine,
other treatments have not been so extensively investigated.
Treatment duration within RCTs ranged from 2 to 24 weeks. No studies reported long-term follow-up
(> 6 months) of patients either continuing on or withdrawing from treatment; thus, there was no
assessment of long-term safety and efficacy, or effects of treatment withdrawal.
The majority of RCTs assessed IELT and, when reported, the assessment method was mainly by stopwatch.
The duration of treatment effects on IELT ranged from< 0.50 minutes to > 6.00 minutes. Many
interventions also demonstrated improvements in ejaculation control, sexual satisfaction and other
outcomes. However, these outcomes were often measured using different assessment scales and the
reporting of outcome data was often limited. IELT is reported to have a significant direct effect on
perceived control over ejaculation, but not a significant direct effect on ejaculation-related personal distress
or satisfaction with sexual intercourse.172 There is currently no published literature which identifies a
clinically significant threshold response to intervention.23 Although the observed increases in IELT were
statistically significant in favour of active treatments, it is difficult to quantify how acceptable and
meaningful these changes are for men with PE, without being able to evaluate the relationship between
IELT, ejaculation control and sexual satisfaction within the current RCT evidence base.
Adverse event reporting, both in reviews and in further RCTs, was limited. Although the nature of AEs
associated with specific treatments could be identified, evidence surrounding proportions of patients
withdrawing from treatment owing to AEs was either unclear or not reported. Furthermore, patient
adherence to and acceptability of PE treatments has not yet been fully evaluated in the current
evidence base.
Assessment of factors relevant to the NHS and other parties
Key considerations include the following:
l The treatment duration among RCTs ranged from 2 to 24 weeks (maximum of 12 weeks for many
treatments). Thus, there is limited evidence regarding long-term safety and effectiveness of treatments.
l The effects of many treatments may be expected to end when treatment is stopped. This may be of
particular concern following cessation of pharmacological agents. Behavioural modifications that are
acquired through counselling might also not endure long term without continued support.
l Some AE data were available from the included RCTs, but some key safety concerns were not assessed.
These include possible long-term effects of SSRIs8 and the addiction potential of tramadol.
l Different interventions have different modes of action and patients may have a preference, for example
a preference for non-pharmacological interventions, or for pharmacological agent that can be taken as
needed rather than every day. Having available a range of treatment options (to be used individually or
in combination) would be a useful approach to individual patient management.
l It is important to consider the balance between IELT and other effectiveness outcomes compared with
AEs and inconvenience. Some patients may consider small increases of a few minutes in IELT to
outweigh any treatment-related AEs, while others may not.
l In the UK, there are currently only a few specialised treatment centres for PE, and a general practitioner
(GP) referral to one of these may have long waiting times. A range of treatment options should be
available to GPs as a first-line approach for patients presenting with PE.
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Chapter 5 Conclusions
Implications for service provision
Several interventions provided statistically significant improvements of between 1 and 6 minutes in time to
ejaculation (IELT). These include pharmacological interventions (SSRIs and other antidepressants, PDE5
inhibitors, tramadol), topical anaesthetics and behavioural therapies. Many interventions also demonstrated
improvements in sexual satisfaction and other outcomes. Behavioural therapy combined with pharmacotherapy
was better than behavioural therapy or pharmacotherapy alone. Pharmacological and topical therapies are
associated with some AEs. Trial duration was a maximum of 12 weeks for most interventions (24 weeks for
dapoxetine and tramadol). Different interventions have different modes of action and individual patients may
have a preference for pharmacological or behavioural interventions, so maintaining a range of options (to be
used individually or in combination) may remain a useful approach in the treatment of PE.
Suggested research priorities
The suggested research priorities when evidence is most unclear are as follows.
Long-term safety and effectiveness
Assessment of long-term safety and effectiveness (> 6 months) is required to evaluate whether or not
initial treatment effects are maintained long term, whether or not dose escalation is required, how soon
treatment effects end following treatment cessation, and whether or not treatments can be stopped
and resumed at a later time. In addition, it is important to assess the AEs associated with long-term
treatment (e.g. long-term effects of SSRIs and the addiction potential of tramadol) and whether or not
different doses have differing AE profiles. These research questions might be addressed by reviewing the
literature surrounding the use of these treatments in other conditions (e.g. SSRIs in the management of
depression). Any evidence gaps could be addressed through longer-term studies in PE; this may include
observational studies or longer-term follow-up of RCT participants.
Comparison between treatments
The majority of treatments evaluated by this report provide improvements in IELT and other outcomes
compared with placebo or no treatment, but are associated with AEs. The current evidence base does not
include sufficient direct comparisons between treatments to inform any judgement regarding the ‘best
treatment’. Future research could consider a mixed treatment comparison/network meta-analysis approach
and/or further head-to-head trials, as well as assessment of cost-effectiveness of the different interventions.
Given that dapoxetine has been specifically developed for PE and has been extensively evaluated for this
indication, head-to-head comparisons between this and other treatments might be informative. The effect
of treatments used sequentially or in combination should also be further assessed. However, as patients
are likely to have preferences for different types of treatment (e.g. pharmacological or behavioural),
maintaining a range of options may remain a useful approach.
In terms of behavioural therapies, given the diversity of interventions in terms of technique, duration and
delivery, further research is required to establish the components and intensity of intervention that are
most effective. This could be addressed via further RCTs comparing different behavioural interventions in
a head-to-head manner.
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Clinical significance of outcomes and risk–benefit assessment
Future research should also consider an evaluation of the clinical significance of IELT increases, which
may include assessment of the relationship between increases in IELT, ejaculatory control and sexual
satisfaction, and whether or not increases of a few minutes in IELT are more meaningful to some patients
than others. The trade-off between improvements in IELT and other clinical effectiveness outcomes
compared with AEs and inconvenience should also be further assessed. Patient and partner acceptability
of the different types of treatment (systemic, topical, behavioural) should also be further evaluated.
CONCLUSIONS
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Appendix 1 Preferred Reporting Items for
Systematic Reviews and Meta-Analyses checklist
TITLE
Title 1 Identify the report as a systematic review, meta-analysis, or
both
i (title page)
ABSTRACT
Structured summary 2 Provide a structured summary including, as applicable:
background; objectives; data sources; study eligibility criteria,
participants, and interventions; study appraisal and synthesis
methods; results; limitations; conclusions and implications of
key findings; systematic review registration number
v–vi
INTRODUCTION
Rationale 3 Describe the rationale for the review in the context of what is
already known
3
Objectives 4 Provide an explicit statement of questions being addressed with
reference to participants, interventions, comparisons,
outcomes, and study design (PICOS)
3
METHODS
Protocol and
registration
5 Indicate if a review protocol exists, if and where it can be
accessed (e.g. web address), and, if available, provide
registration information including registration number
vi
Eligibility criteria 6 Specify study characteristics (e.g. PICOS, length of follow-up)
and report characteristics (e.g. years considered, language,
publication status) used as criteria for eligibility, giving rationale
5–7
Information sources 7 Describe all information sources (e.g. databases with dates of
coverage, contact with study authors to identify additional
studies) in the search and date last searched
5
Search 8 Present full electronic search strategy for at least one database,
including any limits used, such that it could be repeated
169
Study selection 9 State the process for selecting studies (i.e. screening, eligibility,
included in systematic review, and, if applicable, included in
the meta-analysis)
8
Data collection
process
10 Describe method of data extraction from reports (e.g. piloted
forms, independently, in duplicate) and any processes for
obtaining and confirming data from investigators
8
Data items 11 List and define all variables for which data were sought
(e.g. PICOS, funding sources) and any assumptions and
simplifications made
7
Risk of bias in
individual studies
12 Describe methods used for assessing risk of bias of individual
studies (including specification of whether this was done at the
study or outcome level), and how this information is to be used
in any data synthesis
8
Summary measures 13 State the principal summary measures (e.g. RR, difference
in means)
8
Synthesis of results 14 Describe the methods of handling data and combining results
of studies, if done, including measures of consistency (e.g. I2)
for each meta-analysis
8
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TITLE
Risk of bias across
studies
15 Specify any assessment of risk of bias that may affect the
cumulative evidence (e.g. publication bias, selective reporting
within studies)
N/A
Additional analyses 16 Describe methods of additional analyses (e.g. sensitivity or
subgroup analyses, meta-regression), if done, indicating which
were pre-specified
N/A
RESULTS
Study selection 17 Give numbers of studies screened, assessed for eligibility, and
included in the review, with reasons for exclusions at each
stage, ideally with a flow diagram
9
Study characteristics 18 For each study, present characteristics for which data were
extracted (e.g. study size, PICOS, follow-up period) and provide
the citations
13, 29, 42, 71, 84, 86,
102, 118, 121, 133,
136, 142 and 143
Risk of bias within
studies
19 Present data on risk of bias of each study and, if available, any
outcome level assessment (see item 12)
174
Results of individual
studies
20 For all outcomes considered (benefits or harms), present, for
each study: (a) simple summary data for each intervention
group (b) effect estimates and CIs, ideally with a forest plot
18, 31, 44, 75, 84, 89,
107, 119, 125, 134,
138, 143 and 144
Synthesis of results 21 Present results of each meta-analysis done, including CIs and
measures of consistency
23, 35, 54, 76, 97, 108,
126 and 139
Risk of bias across
studies
22 Present results of any assessment of risk of bias across studies
(see Item 15)
N/A
Additional analysis 23 Give results of additional analyses, if done (e.g. sensitivity or
subgroup analyses, meta-regression [see Item 16])
N/A
DISCUSSION
Summary of evidence 24 Summarise the main findings including the strength of
evidence for each main outcome; consider their relevance to
key groups (e.g. healthcare providers, users, and policy makers)
145
Limitations 25 Discuss limitations at study and outcome level (e.g. risk of bias),
and at review-level (e.g. incomplete retrieval of identified
research, reporting bias)
147
Conclusions 26 Provide a general interpretation of the results in the context of
other evidence, and implications for future research
149
FUNDING
Funding 27 Describe sources of funding for the systematic review and
other support (e.g. supply of data); role of funders for the
systematic review
vi and xxiii
Checklist from www.prisma-statement.org173 (under the terms of the Creative Commons Attribution Licence, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited) and
has been used in other studies.25
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Appendix 2 Literature search strategies
MEDLINE
The following strategy was developed for use in MEDLINE. This strategy was subsequently translated in
accordance with the other databases searched.
MEDLINE search strategy
1. exp Ejaculation/
2. exp Premature Ejaculation/
3. (premature$ adj3 ejaculat$).ti,ab.
4. (early adj3 ejaculat$).ti,ab.
5. (rapid adj3 ejaculat$).ti,ab.
6. (rapid adj3 climax$).ti,ab.
7. (premature$ adj3 climax$).ti,ab.
8. (ejaculat$ adj3 pr?ecox).ti,ab.
9. or/1-8
Filter 1: randomised controlled trials
10. Randomized Controlled Trials as Topic/
11. randomized controlled trial/
12. Random Allocation/
13. Double Blind Method/
14. Single Blind Method/
15. clinical trial/
16. clinical trial, phase i.pt.
17. clinical trial, phase ii.pt.
18. clinical trial, phase iii.pt.
19. clinical trial, phase iv.pt.
20. controlled clinical trial.pt.
21. randomized controlled trial.pt.
22. multicenter study.pt.
23. clinical trial.pt.
24. exp Clinical Trials as topic/
25. or/10-24
26. (clinical adj trial$).tw.
27. ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw.
28. PLACEBOS/
29. placebo$.tw.
30. randomly allocated.tw.
31. (allocated adj2 random$).tw.
32. 26 or 27 or 28 or 29 or 30 or 31
33. 25 or 32
34. case report.tw.
35. letter/
36. historical article/
37. 34 or 35 or 36
38. 33 not 37
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Filter 2: reviews
10. review.ab.
11. review.pt.
12. meta-analysis.ab.
13. meta-analysis.pt.
14. meta-analysis.ti.
15. or/10-14
16. letter.pt.
17. comment.pt.
18. editorial.pt.
19. or/16-18
20. 15 not 19
Filter 3: guidelines
10. guideline.pt.
11. practice guideline.pt.
12. exp Guideline/
13. health planning guidelines/
14. 10 or 11 or 12 or 13
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Appendix 3 Table of excluded studies
with rationale
Author and Year Reason for exclusion
Abdallah H, Abdelnasser T, Hosny H, Selim O, Al-Ahwany A, Shamloul R. Treatment
of premature ejaculation by glans penis augmentation using hyaluronic acid gel:
a pilot study. Andrologia 2012;44(Suppl. 1):650–3
Treatment not relevant to UK
setting
Abdel-Hamid IA. Pharmacologic treatment of rapid ejaculation: levels of
evidence-based review. Curr Clin Pharmacol 2006;1:243–54
Non-systematic review/treatment
overview
Bandolier. Premature ejaculation treatments reviewed. Bandolier 2004;11:3 Non-systematic review/treatment
overview
Basar MM, Yilmaz E, Ferhat M, Basar H, Batislam E. Terazosin in the treatment of
premature ejaculation: a short-term follow-up. Int Urol Nephrol 2005;37:773–7
Treatment not relevant to UK
setting
Burner M, Tahrat A. Double blind trial of atrium 300 in the treatment of sexual
disorders. Psychol Med 1978;10:1165–71
Treatment not relevant to UK
setting
Demirta A, Hali F, Ekmekciogl O. The effects of sildenafil, vardenafil and tadalafil on
ejaculation latency time in premature ejaculators: a double blind, randomized,
placebo controlled laboratory setting study. J Sex Med 2009;6:93–4
Laboratory study
Dresser MJ, Desai D, Gidwani S, Seftel AD, Modi NB. Dapoxetine, a novel treatment
for premature ejaculation, does not have pharmacokinetic interactions with
phosphodiesterase-5 inhibitors. Int J Impot Res 2006;18:104–10
Pharmacokinetic study
Dogan S, Dogan M. Premature ejaculation, treatment of the premature ejaculation
and efficacy of selective serotonin reuptake inhibitors in the treatment of premature
ejaculation. Klinik Psikofarmakoloji Bulteni 2007;17:87–99
Non-systematic review/treatment
overview
El-Seweifi A. Partial penile neurectomy for management of ejaculatio praecox.
J Mens Health 2010;7:282–3
Treatment not relevant to UK
setting
Feige AM, Pinsky MR, Hellstrom WJG. Dapoxetine for premature ejaculation.
Clin Pharmacol Ther 2011;89:125–8
Non-systematic review/treatment
overview
Ginsberg DL. Gabapentin treatment of premature ejaculation. Prim Psychiatry
2004;11:20–1
Treatment not relevant to UK
setting
Giuliano F, Patrick DL, Porst H, La Pera G, Kokoszka A, Merchant S, et al. Premature
ejaculation: results from a five-country European observational study. Eur Urol
2008;53:1048–57
Non-systematic review/treatment
overview
Gokce A, Halis F, Demirtas A, Ekmekcioglu O. The effects of three phosphodiesterase
type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators:
a double-blind laboratory setting study. BJU Int 2011;107:1274–7
Laboratory study
Greco E, Polonio-Balbi P, Speranza JC. Levosulpiride: a new solution for premature
ejaculation? Int J Impot Res 2002;14:308–9
Treatment not relevant to UK
setting
Guan ZC, Shi BT, Wang R. Resiniferatoxin for treatment of premature ejaculation:
a new medical therapy. J Sex Med 2010;7:177
Treatment not relevant to UK
setting
Gurkan L, Oommen M, Hellstrom WJG. Premature ejaculation: current and future
treatments. Asian J Androl 2008;10:102–9
Non-systematic review/treatment
overview
Hakobyan AE, Nersisyan NR, Azatyan RE, Azizian A, Grigoryan AD. New approach to
premature ejaculation treatment. J Sex Med 2011;8:175–6
Treatment not relevant to UK
setting
Hoy SM, Scott LJ. Dapoxetine: in premature ejaculation. Drugs 2010;70:1433–43 Non-systematic review/treatment
overview
Modi NB, Dresser MJ, Simon M, Lin D, Desai D, Gupta S. Single- and multiple-dose
pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of
premature ejaculation. J Clin Pharmacol 2006;46:301–9
Pharmacokinetic study
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Author and Year Reason for exclusion
Morales A, Black A, Clark-Pereira J, Emerson L. A novel approach to premature
ejaculation: extracorporeal functional magnetic stimulation. Can J Urol
2009;16:4458–62
Treatment not relevant to UK
setting
Porst H. An overview of pharmacotherapy in premature ejaculation. J Sex Med
2011;8(Suppl. 4):335–41
Non-systematic review/treatment
overview
Riley AJ, Riley EJ. Amitriptyline-perphenazine and the squeeze technique in premature
ejaculation. J Pharmacother 1979;2:136–40
Treatment not relevant to UK
setting
Safarinejad MR. Safety and efficacy of venlafaxine in the treatment of premature
ejaculation: a double-blind, placebo-controlled, fixed-dose, randomised study.
Andrologia 2008;40:49–55
Treatment not relevant to UK
setting
Zhang GX, Yu LP, Bai WJ, Wang XF. Selective resection of dorsal nerves of penis for
premature ejaculation. Int J Androl 2012;35:873–9
Treatment not relevant to UK
setting
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